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ABSTRACT  1 
1 Abstract 
The importance of elucidating mechanisms of cardiac regulatory networks during cardiogenesis 
is underscored by the re-activation of fetal gene expression in the diseased adult heart. To 
further understand this phenomenon, the insulin-like growth factor binding protein 5 (IGFBP5), 
an extracellular binding protein for IGF, possessing IGF-independent functions, was 
investigated. In this study, analysis of murine cardiac tissue at different developmental stages 
showed a progressive decrease in Igfbp5 expression with heart maturation, remaining 
significantly low in the adult heart. Moreover, sustained IGFBP5 expression in human 
embryonic stem cells arrested cardiomyocyte differentiation subsequent to progenitor 
specification. In line with these results, expression analysis in different cell populations of the 
adult murine heart showed very low Igfbp5 expression in cardiomyocytes in contrast to high 
levels expressed in Sca1-positive cardiac progenitor cells. Additionally, re-expression of 
IGFBP5 was found in the transition to heart failure in murine and human hearts consequent to 
pressure overload and aortic stenosis, respectively. Furthermore, IGFBP5 expression detected 
in mice upon preserved cardiac function post-TAC, was at physiological levels. In the failing 
heart, cardiomyocytes were shown to express and secrete IGFBP5, which could also be detected 
in the blood serum. In turn, cardiac fibroblasts showed uptake of exogenous IGFBP5, whereas 
IGFBP5 overexpression in these cells regulated cardiac gene expression and influenced 
engineered heart muscle physiology. In vivo, AAV9-mediated cardiomyocyte specific 
overexpression of Igfbp5 in the adult healthy heart led to an atrophy-like phenotype with 
reduced heart size. Transcriptome analysis revealed a decrease in extra-cellular matrix and 
sarcomeric gene expression as well as a reduced junction and ion channel expression, indicating 
altered cardiac cell integrity. Key regulators of fibrotic processes were downregulated, while a 
positive effect on fatty acid metabolism could be observed. Notably, this study revealed that 
IGFBP5 has nuclear functions in cardiac cells including the occupancy of its own promoter and 
the repression of the TNNT2 promoter by antagonizing NKX2.5-mediated TNNT2 promoter 
activation. In conclusion, this study demonstrates that IGFBP5 has an important role to play in 
cardiac progenitor cell commitment and in the transition to heart failure, as a part of the fetal 
gene re-activation program. Additionally, it furnishes evidence to support an IGFBP5 mediated 
cardiomyocyte-fibroblast crosstalk, where IGFBP5 may alter gene expression via its 
transcriptional co-factor function.  
INTRODUCTION  2 
2 Introduction 
2.1 Heart failure 
2.1.1 Cardiovascular disease and heart failure 
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality worldwide, 
claiming 17.7 million lives every year: one third of all global deaths (according to the WHO 
2017). CVDs encompass multiple, heterogeneous disorders with multi-factorial 
pathophysiology, with heart failure (HF) being a final manifestation of many CVDs [2]. HF is 
a clinical syndrome caused by structural and functional cardiac abnormalities that lead to 
elevated intracardiac pressures and/or reduced cardiac output. HF symptoms include dyspnoea, 
fatigue, poor exercise tolerance, and fluid retention and can be clinically confirmed by a rise in 
jugular venous pressure, pulmonary crackles, and peripheral oedema. Finally, low cardiac 
output can lead to an imbalance in oxygen delivery and demand in tissues. Since the metabolic 
requirements of the cells cannot be maintained, decompensation of cardiac function is the 
consequence. HF is caused by many conditions that damage the heart muscle, including 
myocardial infarction, pressure overload (aortic stenosis, hypertension), inflammatory heart 
muscle disease (myocarditis), volume overload (valvular regurgitation) or idiopathic dilated 
cardiomyopathy. Before the onset of HF, the heart tries to compensate lost cardiomyocytes and 
counteracts an insufficient pump function by a process termed cardiac remodelling. 
2.1.2 Cardiac remodelling and fetal gene re-activation 
Cardiac remodelling constitutes molecular, cellular and interstitial changes and manifests itself 
as changes in size, shape, geometry (together termed hypertrophy) and function of the heart [3]. 
On a molecular level, hypertrophy, is the result of the activation of several signalling pathways 
and target genes which differ between physiological and pathological hypertrophy [4]. 
Mechanical stress in cardiomyocytes leads to oxidative stress [5], changes in local 
norepinephrine (NE) activity [6] and in increased angiotensin II (Ang II) [7] and endothelin [8] 
release. These neurohormonal factors, in turn, activate other signalling cascades and mediators 
like mitogen-activated protein kinases (MAPK), insulin-like growth factors 1 (IGF-1), 
phosphatidylinositol-3-kinase/protein kinase B (PI3K/PKB), histone deacetylases (HDACs) 
and calcineurin-mediated pathways, leading to an altered transcription and protein synthesis 
which mediates the hypertrophic response [9, 10]. These molecular and morphological changes 
essentially represent an adaptation of the injured heart. Adaptive compensatory hypertrophy, 
the remodelling that occurs at the outset, is largely beneficial and appears to be at least partially 
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reversible in some experimental and/or clinical models [11]. Sustained remodelling can lead to 
maladaptive decompensated hypertrophy, characterized by cardiomyocyte apoptosis, 
inflammation and fibrosis [12]. Collectively these factors lead to a reduction of cardiac force, 
tissue stiffening, wall stress, dilation and disturbed electrical conduction, culminating in HF 
[13]. Pathways and genes that are implicated in fetal heart development are shown to be 
expressed during cardiac remodelling following insult or injury. [10, 14]. Additionally, upon 
remodelling, cardiomyocytes show signs of dedifferentiation including disorganised sarcomeric 
structures [15], upregulation of the fetal actin isoform alpha skeletal actin [16] and the fetal 
myosin isoform myosin heavy chain beta (MYH7) [17]. However, the pathophysiology of fetal-
gene re-activation remains largely speculative. One example is the metabolic switch of the 
diseased heart. A potential hypothesis posits that the switch to fetal metabolism is an adaptation 
due to a changed energy/oxygen demand. Since fatty acid transport is impaired during cardiac 
hypertrophy and the oxygen supply is limited, a switch from fatty acid to glucose as a primary 
substrate allows the generation of greater energy (ATP) per molecule of oxygen. This reversal 
to the fetal program allows for greater efficiency in cellular energy production, thus averting 
cell death [18, 19]. Emerging data indicates that evolutionarily conserved regulatory networks 
that drive cardiogenesis and maturation might also control aspects of heart regeneration [20]. 
Little is known about the signals that trigger differentiation of committed cardiac progenitor 
cells (CPCs) into cardiomyocytes, but fetal genes which are involved in cardiogenesis might 
have a role to play. Further investigations are essential to reveal the mechanisms that stimulate 
the proliferation and differentiation of residual cardiac progenitor cells as well as those that 
control cardiomyocyte dedifferentiation [20]. Understanding these mechanisms could point the 
way toward a therapeutic strategy that enhances cardiac repair and prevents HF progression via 
the re-activation of regenerative pathways [21, 22]. 
2.1.3 Regenerative capacity of the heart  
The postnatal mouse heart retains its regenerative potential for a few days after birth and fully 
regenerates in a model of neonatal myocardial infarction unlike its adult counterpart [15, 23]. 
Intriguingly, similar to neonatal mice, new-born humans and infants seem to harbour a potent 
cardiac regenerative capacity as reported by Fratz et al. and Haubner et al. [24, 25]. While adult 
cardiomyocytes are cell cycle arrested (post-mitotic), cardiomyocytes of neonatal mice are 
capable of entering a proliferative state through dedifferentiation [15] in a process that has been 
studied extensively in the adult zebrafish [26]. Besides the neonatal regenerative potential via 
dedifferentiation, these studies assume that 30% of the regenerated cardiomyocytes are derived 
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from unidentified stem or progenitor cell populations [27]. Even though the adult mammalian 
heart lacks a potent regenerative capacity, Bergmann et al. reported the approximate 
cardiomyocyte turnover in humans. The authors calculated that about 1% of cardiomyocytes 
are renewed per year, suggesting that fewer than 50% of cardiomyocytes are exchanged during 
a lifetime [28]. As discussed by Murry and Lee, this calculation has its pitfalls, but even though 
cardiomyocyte turnover is low, the fact that it occurs, suggests that it can potentially be 
therapeutically exploited, since it represents a potential endogenous sources for cell 
replacement [29]. There is still an ongoing debate whether cardiomyocyte turnover and cardiac 
regeneration are to be attributed to dedifferentiation and proliferation of cardiomyocytes [30] 
or to the differentiation of cardiac stem or progenitor cells [31, 32]. 
2.1.4 Cardiogenic potential of cardiac progenitor cells 
The presence of cardiac progenitor cells (CPCs) in the fetal, as well as the adult heart has been 
described extensively in humans, as reviewed by Lee and Chong et al. [33]. In contrast to stem 
cells, CPCs are multipotent, but their division is limited. Cardiac side population cells (cSPCs), 
c-kit+ and Sca-1+ cardiac cells are the different cell populations of the heart which are classified 
as CPCs according to criteria described by Mauretti et al. [32]. These populations can be 
identified by their different phenotypes and the expression of different surface markers. Even 
when CPC populations in the adult heart are rare, their application for cardiac regeneration is 
promising due to their capacity for differentiation [34, 35] and their ability to produce and 
remodel ECM proteins [36]. Interestingly, CPCs were found to proliferate and differentiate into 
the cardiac lineages upon myocardial infarction, indicating that these cells contribute to the 
limited regenerative capacity of the adult heart [30]. However, these authors went on to show 
that CPCs possess decreased telomerase activity in chronic infarcts with concomitant impaired 
cell division and cellular senescence, as well as increased CPC apoptosis which could point to 
why CPCs have such a limited regenerative capacity [30]. Other studies suggest that the hostile 
CPC microenvironment created by the MI is the cause of CPC senescence and apoptosis [32]. 
Taken together, insights into the mechanisms that control progenitor cell fate could open the 
door to new therapeutic approaches including activating these cells to enhance cardiac 
regeneration and potentially delaying HF progression [10]. 
2.1.5 Current therapies  
To date, numerous drugs and implants can temporarily maintain cardiac function but these 
approaches are transient and only delay HF progression instead of reversing it. Cardiac 
transplantation remains the only feasible means to replace lost cardiac tissue and besides the 
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lack of universal access, the procedure is not without its own pitfalls [37]. Current HF 
medications include diuretics, angiotensin-converting-enzyme inhibitors (ACE-I), β-blockers, 
Ang II receptor blockers (ARBs), hydralazine, and nitrates [38]. In first line, these drugs aim to 
reduce blood pressure, thus minimizing cardiac pressure overload and increase cardiac output. 
Pharmacological interventions cannot, however, compensate for the irreversible loss of 
cardiomyocytes. It follows that the future challenge of cardiovascular therapies lies in the 
functional regeneration of myocardial contractility through novel approaches which can include 
cell based therapy (e.g. transplantation of stem cells or differentiated cardiomyocytes), tissue 
engineering or the reprogramming of scar fibroblasts [39]. It is questionable whether the use of 
locally applied xenografts is useful in the event of HF, since cardiac dilation affects the heart 
globally and cannot be located to a specific spot like myocardial infarction does initially. 
Moreover, xenotransplantation harbours the risk of immune rejection and the reprogramming 
of cells can give rise to uncontrollable cell proliferation. In contrast, the stimulation of 
endogenous myocardial regeneration could offer a mechanism to improve HF regression while 
lowering the risk of severe side effects. 
2.2 The insulin-like growth factor binding protein 5 
2.2.1 Insulin-like growth factor binding proteins 
The IGF (insulin-like growth factor) axis plays a crucial role in regulating cellular growth, 
differentiation and apoptosis which underscores the vital role it has to play in the development 
and regulation of many tissues [40]. The insulin-like growth factor binding protein (IGFBPs) 
family comprises six different IGF carrier proteins that form high-affinity complexes with both, 
IGF-I and IGF-II to modulate their functions [41]. More than 95% of IGFs in serum and other 
biological fluids are bound to IGFBPs. IGFs have a higher affinity for IGFBPs than to their 
own receptors [42] and this preference is controlled by phosphorylation, glycosylation, 
adherence to either cell-surface proteins or the extracellular matrix and, most importantly, by 
specific proteolysis [43]. Besides prolonging the half-life of the IGFs in circulation and 
inhibiting their metabolic effects by preventing them from binding  their receptors [44], IGFBPs 
regulate cell activity in other ways [45]. IGFBPs which are strongly evolutionarily linked 
multifunctional proteins, share about 50% homology with each other [46]. The cysteine-rich N- 
and C-terminal domains are highly conserved within the IGFBP family, while the central 
domain varies both within the family and across species. Different subdomains, or functional 
motifs, within each domain are presumed to contribute to their diverse roles. The precursor 
forms of all six IGFBPs have secretory signal peptides and the mature proteins are mostly found 
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extracellularly [47]. IGFBPs are secreted in a tissue and developmental stage specific manner 
and are present in different concentrations in different organs [48, 49]. Functionally, IGFBPs 
are known to affect cell motility and adhesion, apoptosis and survival, and the cell cycle [50]. 
Largely independent of their IGF-binding activity, IGFBPs can modulate cell functions via 
interactions with other cell-surface proteins, like integrins, [51] and with nuclear receptors [52]. 
A classical bipartite nuclear localization signals (NLS), which shares homology with the DNA-
binding domains of several transcription factors, was formerly only described for IGFBP3 and 
IGFBP5 [53, 54]. More recent work also showed NLS sequences that bear limited homology to 
those found in IGFBP3 and IGFBP5 in IGFBP6 [55] and IGFBP2 [56]. Apart from the nuclear 
activity of some IGFBPs, it is known that these proteins may participate in their own signalling 
pathways [50] and interact with many others [57].  
2.2.2 The insulin-like growth factor binding protein 5 
The insulin-like growth factor binding protein 5 (IGFBP5) is the most conserved IGFBP. It is 
present in all vertebrates and its amino acid sequence is more than 97% identical between 
human, mouse and rat [58]. The conserved N-terminal domain of IGFBP5 contains a 
hydrophobic patch which is the primary binding site for IGFs [59] while the C-terminal domain 
seems to be essential for a stable, high affinity IGF interaction [60]. The observation that both, 
the C-terminal and the N-terminal domains contain residues important for IGF binding implies 
the existence of an IGF-binding pocket involving both domains. Together with an acid-labile 
subunit (ALS), IGFBP5 can form ternary complexes with IGF-I or IGF-II and regulate the 
effects of these proteins [61]. Moreover, several proteolytic cleavage sites generate fragments 
which have reduced affinity for IGFs [62], while plasma proteolysis of IGFBP5 preferentially 
generates different C-terminal fragments, possibly acting in an IGF-dependent manner and 
bearing intrinsic biological functions [63]. The C-terminal domain also contains a consensus 
nuclear localisation signal [64] which is responsible for the nuclear translocation of IGFBP5 
[65]. A basic residue rich region within the C-terminal domain is responsible for binding to the 
extracellular matrix components [66] and multiple extracellular proteins like heparin and 
heparan sulphate [67], serum glycoprotein ALS [68], plasminogen activator inhibitor-1 [69] 
and many more [50]. The central domain of IGFBP5 shows no structural conservation and is 
important for post-translational modifications, like serine/threonine phosphorylation [70], 
which is essential for its physiological role. IGFBP5 was found upregulated during the 
differentiation of neural [71], osteoblast [72] and myoblast [58] lineages and was identified as 
an essential regulator of physiological processes in bone, kidney and mammary glands [73]. 
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Moreover, Igfbp5 is upregulated in several different types of cancer [42] and is suggested to be 
indicative of a poor prognosis [74]. Other investigators reported that IGFBP5 has tumour 
suppressor functions [75–77]. Transgenic mice with ubiquitous overexpression (OE) of Igfbp5 
exhibited a significant increase in neonatal mortality, reduced female fertility, whole body 
growth inhibition, and retarded muscle development, whereas other Igfbp OE models show only 
modest changes or lack of a phenotype. The more severe phenotype observed in Igfbp5 
overexpression mice compared to Igf-null mice suggests a dual function for IGFBP5: Both, as 
a modulator of IGF activity and as an IGF-independent signalling protein [78]. However, Igfbp5 
knockout (KO) mice are not substantially different from normal mice with regard to whole-
body growth, selected organ weights and body composition, presumably as a result of 
substantial compensation by the remaining members of the IGFBP family [79]. Several studies 
demonstrate an increase in body size and mild glucose intolerance mostly in Igfbp5 KO mice 
due to IGF-dependent effects [80]. IGFBP5 is known to regulate cell proliferation [81, 82], 
migration [83], and apoptosis/survival [84] in an IGF-independent manner. However, the 
IGFBP5-dependent regulation of these processes is cell and context specific, mediated by both 
IGF-dependent and independent mechanisms and can be both stimulating or repressing in 
nature [42]. The mechanistic basis of the ligand-independent actions of IGFBP5 are not well 
defined. A putative IGFBP5-receptor, which was reported but could not be cloned successfully 
may hold the key [57]. Considering the ability of IGFBP5 to enter cell nuclei via its nuclear 
localisation sequence, it can be inferred that IGFBP5 might have a transcriptional regulation 
function [65]. Consistent with this theory, the interaction of IGFBP5 with the transcriptional 
co-activator protein four-and-a-half LIM domain 2 (FHL2) [85], as well as its interaction with 
the histone-DNA complex in the nucleus of vascular smooth-muscle cells [86] were recently 
reported. These observations demonstrate that IGFBP5 might possesses both, an extracellular 
growth factor function as binding partner to IGF as well as a nuclear function as a potential 
transcriptional co-factor.  
2.2.3 IGFBP5 and the heart 
Regarding the embryonic heart, Igfbp5 is expressed in the early cardiac crescent in mouse 
embryos [87]. Several studies reported a link between sustained Igfbp5 expression and impaired 
cardiomyocyte differentiation, while enhanced cardiomyocyte differentiation correlated with 
decreasing Igfbp5 expression [87–89]. In rat neonatal cardiomyocytes, IGFBP5 was shown to 
mediate methamphetamine-induced apoptosis [90], whereas in rat neonatal fibroblasts IGFBP5 
was revealed to be mediating high glucose induced profibrotic effects [91]. Thus far, there has 
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been neither in vitro nor in vivo data available regarding the role of IGFBP5 in the cells of the 
healthy or diseased adult heart.  
Previous work showed an upregulated expression of Igfbp5 in a mouse model with inducible, 
cardiac specific β-catenin stabilization (β-Cat GOF) leading to experimentally induced cardiac 
hypertrophy with increased heart sizes, cardiac mass, myocyte cross-sectional area, fibrosis and 
high mortality [92, 93]. Apart from cardiac dysfunction, these mice displayed a limited 
cardiogenic differentiation potential of the undifferentiated cell pool [94]. Consistent with this 
result, Igfbp5 was upregulated in murine embryonic stem cells (mESCs) overexpressing Fhl2, 
which showed arrested cardiac differentiation in an early cardiogenic mesodermal progenitor 
state. Interestingly, Igfbp5 was found downregulated upon mESC differentiation to 
cardiomyocytes [89].  
In preliminary unpublished work, analysis of murine cardiac tissue at different developmental 
stages showed a decreasing Igfbp5 expression with progressing heart maturation (Figure 2-1, 
n=3). In the adult murine heart, Igfbp5 maintained higher expression levels in Sca-1+ progenitor 
cells in comparison to cardiomyocytes and fibroblasts (Figure 2-2, n=3). While investigating a 
mouse model with pressure-overload induced HF, upregulated Igfbp5 mRNA levels were found 
in mice upon TAC (transverse aortic constriction) operation when compared to sham operated 
mice (Figure 2-3, n=8/12, P<0.05). Together, these observations suggest a role for IGFBP5 in 
cardiogenesis, in cardiac progenitor cells and in the adult diseased heart. 
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Figure 2-1: Igfbp5 expression during cardiogenesis in vivo 
qPCR analysis of temporal changes in cardiac Igfbp5 expression in the developing and postnatal heart in vivo. Tpt1 
(Tumor protein translationally-controlled 1) was used for normalization, n=3.  
 
 
 
Figure 2-2: Igfbp5 expression in different cell populations of the adult murine heart  
qPCR analysis of Igfbp5 in isolated adult cardiomyocytes [CM], fibroblasts and Sca-1+ positive progenitor cells [non-
CM]. Gapdh was used for normalization, n=3.  
 
 
 
Figure 2-3: Igfbp5 expression in mice upon TAC operation 
qPCR analysis of Igfbp5 expression in mice two weeks after transverse aortic constriction (TAC) and sham operation. 
Tpt1 (Tumor protein translationally-controlled 1) was used for normalization, n=8/12, data are mean ± SEM; t-test, * 
P<0.05.  
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2.3 Project aim 
The main focus of this project was to investigate the role of IGFBP5 during cardiogenesis and 
in HF as a part of the fetal gene re-activation program. 
This study tested the following specific hypotheses: 
- Igfbp5 is regulated in the event of cardiac remodelling and HF 
- IGFBP5 is critical for cardiac progenitor cell homeostasis  
- Downregulation of Igfbp5 is necessary for cardiomyocyte maturation 
- IGFBP5 functions as a transcriptional co-factor 
The hypotheses were investigated using different transgenic mouse models and various cardiac 
disease models to study Igfbp5 expression in the heart and also in different cell populations. 
Additionally, a mouse model with a cardiac specific OE of Igfbp5 was used to study the gene´s 
direct influence on the heart. To investigate the impact of IGFBP5 on cardiomyocyte 
differentiation in vitro, a gain-of function mutation was implemented in human stem cell. 
Different in vitro experiments were employed to investigate the responsiveness of cardiac cells 
to hypertrophic stimuli and IGFBP5. Moreover, chromatin immunoprecipitation (ChIP) 
experiments with subsequent promoter assays were used to investigate the transcriptional co-
factor role of IGFBP5. 
 
 
 
Figure 2-4: Project hypothesis 
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3 Material and Methods 
3.1 Material 
3.1.1 Consumables 
Material Type Manufacturer 
96-well  flat bottom Sarstedt 
384-well 
MicroAmp Optical 384-Well 
Reaction Plate 
Thermo Scientific 
384-well adhesive film MicroAmp Optical adhesive film  Thermo Scientific 
Bradford reagent Rotiquant Carl Roth 
DNA/RNA stain MidoriGreen Nippon Genetics 
Canules / B.Braun 
Cell culture plates  96-, 48-, 24-, 12-, 6-well,  
Thermo Scientific (Nunc), 
Greiner, Sarstedt 
Cell culture flasks 25 cm2, 75 cm2, 175 cm2 
Thermo Scientific (Nunc), 
Greiner, Sarstedt 
Cell scraper 16 mm Sarstedt 
Chromatography paper 3 mm Whatman 
Cryo-vials 1.8 ml Nunc, Greiner 
Falcon tubes  15 ml, 50 ml Greiner 
Filter tips, sterile 0,5-10 µl, 2-200 µl, 1000 µl Labsolute 
Lentiviral Titer Test Takara Clontech LentiGo stick 
Glass cover slips 12 mm Thermo Scientific 
Hoechst 10 mg/ml Invitrogen/BD 
Object slides Menzel-Gläser Superfrost Thermo Scientific 
Pipet tips  0,5-10 µl, 2-200 µl, 1000 µl Greiner 
Pipets, serological  5 ml, 10 ml, 25 ml Sarstedt 
Plates 
384 well Applied Biosystems 
96 well Sarstedt 
PVDF membrane Roti®-PVDF, 0.45 µm Roth 
Reaction tubes  0.5 ml, 1.5 ml, 2 ml Eppendorf 
Sterile filter  0,2 and 0,45 µm Sartorius 
Syringe  1,2,5,10,20 and 50 ml Henke-Sass, Wolf,Braun 
Western blot substrate Supersignal West Femto Pierce Thermo Scientific 
Whatman Blotting Paper / Whatman 
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3.1.2 Devices 
Device Type Manufacturer 
Agarose gel casting system and 
electrophoresis unit 
/ Generic 
Blot imager VersaDocTM Imaging System BioRad 
CASY cell counter Model TT Roche Innovatis AG 
Centrifuges 
Centrifuge 5417C 
Eppendorf Centrifuge 5417R 
Centrifuge 5810R 
Centrifuge Megafuge 1.0R Thermo Scientific 
Centrifuge MIKRO 22R Hettich GmbH & Co. KG 
Biofuge pico Heraeus 
CombiSpin FVL-2400L Peqlab Biotechnology GmbH 
Clean bench HERAGUARD Thermo Scientific 
Electrophoresis chamber 
PerfectBlue™Maxi L Peqlab 
Mini Protean Tetra System Biorad 
Semi dry blotter unit Scie Plas 
Electroporator Nucleofector™ 2b Device Lonza 
FACS LSRII flow cytometer BD 
Freezer  
Freezer (-20°C) Liebherr 
Freezer (-80°C) Heraeus, Thermo Scientific 
Freezer (-152°C) Heraeus, Thermo Scientific 
Fridge / Liebherr 
Gel imager 
GelDocTM 
Imaging System 
BioRad 
Heating block / Eppendorf 
Isometric force measurement 
apparatus 
/ Customized 
Low Voltage Power Supply Power Pack P25 Biometra 
Incubator 
Hera Cell 150 Heraeus, Thermo Scientific 
Sanyo Incubator FCC free Sanyo 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Luminometer GLOMAXTM 96 Microplate Promega 
Magnet stirrer MR3001 Heidolph Instruments GmbH  
Microscopes 
Axiovert 200 Carl Zeiss 
Leica M80 Leica 
LSM 710 Carl Zeiss 
SteReo Discovery.V8 Carl Zeiss 
Multi-Mode Microplate Reader FlexStation 3 Molecular Devices 
PCR device T Gradient Biometra 
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Device Type Manufacturer 
Veriti® 96-Well  
Thermal Cycler 
Applied Biosystems 
pH meter / Sartorius 
Pipets 
0,1-2.5μL; 2-20μL; 20-200μL; 
100-1000μL 
Eppendorf/Sartorius/Gilson 
Power supply unit Powerpack P25T Biometra 
qRT-PCR device 
7900 HT Fast Real-Time PCR 
System 
Applied Biosystems 
Shaking devices 
innova 4300 Incubator Shaker New Brunswick Scientific 
“Rocky“ Schütt Labortechnik 
Rocking Platform Biometra 
Spectrophotometer NanoDrop 1000 Peqlab 
Sonicator Biorupter Diagenode 
Thermomixer Thermomixer Compact Eppendorf 
Tissue dissociator gentleMACS™ Dissociator Miltenyi Biotec 
UV Transilluminators TI1 Biometra 
Tissue Lyser TissueLyser II Quiagen 
Vortexer 
Biovortexer MHX (E) Xenox 
VF2 Janke&Kunkel IKA-Labortechnik 
Peq Twist PeqLab 
3.1.3 Software 
Type Company 
AxioVision Carl Zeiss 
FACS DIVA BD 
Gentle V1.9.4 Magnus Manske, Köln 
GLOWMAX 1.9.2 Promega 
GraphPad Prism 6 GraphPad Software 
Image Lab Bio Rad 
Microsoft Office Microsoft 
ND-1000 V3.8.1 NanoDrop Technologies 
SDS 2.4 Applied Biosystems 
Soft Max Pro5.4 Molecular Devices 
Quantity One 4.6.7 Bio Rad 
ZEN 2011 (blue version) Carl Zeiss 
Zotero Open source/freeware 
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3.1.4 Databases 
Type Manufacturer 
BLAST National Library of Medicine 
Ensembl WTSI / EBI 
OligoCalc Northwestern University Chicago 
3.1.5 Cell culture media and supplements 
3.1.5.1 Supplements 
Type Cat # Manufacturer 
β-Mercaptoethanol 31350-010 Sigma 
Bromodeoxyuridine (BrDU) B5002 Sigma 
Collagen (Rat tail) / In-house made 
Dulbecco’s Modified Eagle Medium 
(DMEM) (Glutamax) 
61965-059 Life technologies/Gibco 
DMEM for TSA cells 42430-082 Life technologies/Gibco 
DMSO D2650 Sigma 
RPMI 1640 without glucose, without 
HEPES  
11879020 Life technologies/Gibco 
RPMI 1640 (Glutamax) 61870-044 Life technologies/Gibco 
B27 supplement 17504-044 Life technologies/Gibco 
TrypLE 12604 Life technologies/Gibco 
StemPro® Accutase® Cell Dissociation 
Reagent 
A11105-01 Life technologies/Gibco  
EDTA 0.5 mmol/L, 2 mmol/L / In-house made 
Polybrene  107689 Sigma 
Accutase Solution  SCR005, Milipore 
Trypsin   Life technologies/Gibco 
Non-essential amino acids (NEAA) 100X 
(10 mmol/L) 
11140050 Life technologies/Gibco 
Fetal bovine serum (FBS) 11573397 Life technologies/Gibco 
L-Glutamine, 100X (200 mmol/L) 35050061 Life technologies/Gibco 
100X penicillin/streptomycin (10.000 U/ml) 15140 Life technologies/Gibco 
100X sodium pyruvate (NaP) (100 mmol/L) 11360 Life technologies/Gibco 
BD Matrigel Basement Membrane Matrix 
Growth Factor Reduced  
354230 BD 
Activin A 338-AC R&D systems 
CHIR 04-0004 Stemgent 
bFGF 130-093-841 Stemgent 
Laminin-521 (100 µg/ml)  LN521-03 Biolamina 
Retinoic acid  R2625 Sigma 
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IWP4 04-0036 Stemgent 
IGF AF-100-11 Peprotech 
FGF AF-100-18B Peprotech 
VEGF AF-100-20 Peprotech 
TGFβ AF-100-21C Peprotech 
L-ascorbic acid  A8960 Sigma 
Rock inhibitor Y27632 (ROCKi) 04-0012-10 Stemolecule 
Matrigel Basement Membrane Matrix 
Growth Factor Reduced 
354230 BD 
DNaseI 3750 Calbiochem 
TeSR™-E8™ Kit 05940 Stem Cell Technologies 
Transfection reagent, Turbofect R0532 Thermo Scientific 
Trypsin-EDTA (0.05%), phenol red 25300054 Thermo Scientific 
FBM CC-3131 Lonza 
FGM-3 SingleQuots CC-4525 Lonza 
Polybrene - Hexadimethrine bromide H9268 Sigma 
Puromycin A1113803 Life technologies/Gibco 
3.1.5.2 Cell culture media 
Medium for Ingredient Ingredient volume 
hCFB medium (FGM3) 
FBM medium  500 ml 
FGM3 bullet kit Total aliquot 
hES medium  
TeSR™-E8 medium 500 ml 
supplements Total aliquot 
Cardiomyocyte (hCM)  
basal medium 
RPMI 1640 with Glutamax 500 ml 
Penicillin/streptomycin 100 U/ml 
sodium pyruvate 1 mmol/l  
B27 supplement 2 %  
L-AAP 200 µmol/L 
(hCM) Mesodermal induction 
medium 
CM basal medium 500 ml 
CHIR 1 µmol/L  
BMP4 10 ng/ml  
Activin A 9 ng/ml  
bFGF 5 ng/ml 
(CM) Cardiac specification 
medium 
CM basal medium  500 ml 
IWP4 5 µmol/L 
(hCM) Lactate selection medium 
RPMI without Glucose  500 ml 
Penicillin/streptomycin 100 U/ml 
Natrium lactate 2.2 mmol/L  
2-mercaptoethanol 0.1 mmol/L 
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Medium for Ingredient Ingredient volume 
Murine adult cardiomyocytes 
MEM phenol red 48 ml 
FBS  0.5 ml (1% final) 
Penicillin/Streptomycin 100x 0.5 ml 
L-Glutamin 0.5 ml (1% final) 
ITS-X 0.5 ml (1% final) 
L-Carnitine 19.766 mg (2 mM final) 
Creatine 32.785 mg (5 mM final) 
Taurine 31.285 mg (5 mM final) 
BSA  100 mg (2 mg/ml final) 
Murine neonatal cardiomyocytes 
DMEM (Biochrom), 1.0 g/l D-
glucose, with 3.7 g/l NaHCO3, 
without L-glutamine 
450 ml 
FBS 10% 
Pen-Strep (100x) 1% 
BrDU 100 µM 
Non-essential amino acids 1% 
Murine adult/neonatal fibroblast  
DMEM 500 ml 
FBS 50 ml (10% final) 
Penicillin-Streptomycin 100x 5.5 ml 
Non-essential amino acids 5.5 ml (1% final) 
TSA 
DMEM 450 ml 
FBS 50 ml (19% final) 
Penicillin-Streptomycin 100x 5 ml 
Cell-freezing-liquid 
FBS 90/80% 
DMSO 10/20% 
3.1.6 Buffers and compositions 
3.1.6.1 Buffers 
Buffer Ingredient Amount 
Agarose gel electrophoresis 
TAE buffer (50x) Tris base 242.2 g/L 
EDTA  18.6 g/L 
Acetic acid 57.1 g/L 
Cell lysis 
Bäuerle buffer  
HEPES 2.38 g 
NaCl 10.2 g 
Glycerol 100 ml 
MgCl2 102 g 
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Buffer Ingredient Amount 
EDTA 93 mg 
EGTA 19 mg 
NP-40 5 ml 
→ Fill to 500 ml with ddH2O 
Hypertonic buffer  
HEPES 2.98 g  
KCl 0.93 g 
NaCl 4.38 g 
EDTA 0.009 g 
DTT 0.039 g 
Glycerol 25 ml 
→ Fill to 250 ml with ddH2O 
Hypotonic buffer  
HEPES 0.596 g  
KCl 0.186 g 
MgCl2 0.102 g 
EDTA 0.009 g 
DTT 0.039 g 
→ Fill to 250 ml with ddH2O 
Lysis buffer  
Bäuerle buffer 750 µl 
Proteinase inhibitor (10x) 150 µl  
Phosphatase inhibitor (10x) 100 µl 
Chromatin immunoprecipitation 
ChIP Wash buffer 
LiCl 8 M 15.625 ml 
EDTA pH 8.0, 0.5 M 10 ml 
Tris HCl pH 8.5, 1 M 25 ml 
NP-40 10% 25 ml 
NaF 0.5 M  10 ml 
Sodium deoxycholate 10% 25 ml 
→ Fill to 250 ml with ddH2O 
Dilution buffer 
NaCl 5 M 7.5 ml 
EDTA pH 8.0, 0.5 M 10 ml 
Tris HCl pH 8, 1 M 12.5 ml 
NP-40 10% 25 ml 
NaF 0.5 M  10 ml 
Sodium deoxycholate 10% 12.5 ml 
→ Fill to 250 ml with ddH2O 
IP buffer 
NaCl 5 M 7.5 ml 
EDTA pH 8.0, 0.5 M 10 ml 
Tris HCl pH 8, 1 M 12.5 ml 
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Buffer Ingredient Amount 
NP-40 10% 25 ml 
NaF 0.5 M  10 ml 
Sodium deoxycholate 10% 12.5 ml 
SDS 10% 2.5 ml 
→ Fill to 250 ml with ddH2O 
Nuclear preparation buffer 
NaCl 5 M 3 ml 
EDTA pH 8.0, 0.5 M 4 ml 
Tris pH 7.5, 1 M 5 ml 
NP-40 10% 5 ml 
Triton-X-100 10% 10 ml 
NaF 0.5 M 4 ml 
→ Fill to 100 ml with ddH2O 
Sonication buffer-1 
EDTA pH 8.0, 0.5 M 0.1 ml 
Tris HCl pH 8, 1 M 0.25 ml 
SDS 10% 0.5 ml 
→ Fill to 5 ml with ddH2O 
Sonication buffer-2 
NaCl 5 M 6 ml 
EDTA pH 8.0, 0.5 M 8 ml 
Tris HCl pH 8, 1 M 10 ml 
NP-40 10% 20 ml 
NaF 0.5 M 8 ml 
→ Fill to 100 ml with ddH2O 
TE buffer 
Tris HCl pH 8.0, 1 M 2.5 ml 
EDTA pH 8.0, 0.5 M 0.5 ml 
→ Fill to 250 ml with ddH2O 
FACS buffer 
Blocking buffer  
BSA 5-10% 
→ Dissolved in PBS 
Nuclear staining buffer 
Hoechst 5 µg/ml 
→ Dissolved in blocking buffer 
Immunofluorescence staining 
Permeabilization buffer BSA 0.2% 
Triton X 100 0.3% 
→ Dissolved in PBS 
Blocking solution BSA 5% 
Triton X 100 0.1% 
→ Dissolved in PBS 
Antibody solution BSA 2% 
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Buffer Ingredient Amount 
Triton X 100 0.1% 
→ Dissolved in PBS 
Phosphate buffered saline (PBS),  
pH 7.4 
KH2PO4  0,15 mmol/L 
Na2HPO4 X 2 H2O 0,81 mmol/L 
KCl 0,27 mmol/L 
NaCl 24 mmol/L 
Nuclear staining buffer Hoechst (1 mg/ml) 1:1000 
→ Dissolved in antibody solution 
Lagendorff perfusion 
10x Perfusion Buffer (Stock) 
NaCl 120.4 mM 70.3 g 
KCl 14.7 mM 11 g 
KH2PO4  0.6 mM 0.82 g 
Na2HPO4 – 2 H2O 0.6 mM 1.1 g 
MgSO4 – 7 H2O 1.2 mM 3 g 
HEPES 10 mM 23.83 g 
→ Add ddH20 to 1 L 
1x Perfusion Buffer 
NaHCO3 4.6 mM 0.195 g 
Taurin 30 mM 1.875 g 
Butanediome monoxime  10 mM 0.5 g 
Glucose 5.5 mM 0.5 g 
10x Perfusion Buffer  50 ml 
→ Add ddH20 to 500 ml 
Digestion Buffer 
Collagenase B  2 mg /ml 0.1 g (1 vial) 
CaCl2 40 µM 20 µl 
→Add to 50 ml with 1x Perfusion Buffer 
Stopping Buffer 
FBS 10 % 5 ml 
CaCl2 12.5 (100/400/900) µM 6.25 µl (+50/+200/+450 µl) 
→Add to 50 ml with 1x Perfusion Buffer 
Polyacrylamide gel electrophoresis 
Separating gel (12%, 2x) 
ddH2O 3.3 ml 
Acrylamide 30% 4.0 ml 
Tris 1.5 M, pH 8.8 2.5 ml 
SDS 10% 0.1 ml 
APS 10% 0.1 ml 
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Buffer Ingredient Amount 
TEMED 0.004 ml 
Stacking gel (6%, 2x) 
ddH2O 2.8 ml 
Acrylamide 30% 0.85 ml 
Tris 0.5 M, pH 6.8 1.25 ml 
SDS 10% 0.05 ml 
APS 10% 0.05 ml 
TEMED 0.005 ml 
Running buffer (10x) 
Tris base 30.3 g 
Glycine 144 g 
SDS 10 g 
→ Fill to 1L with ddH2O 
Protein quantification 
Bradford reagent 
RotiQuant 53.3 l 
Sterile water 146.7 l 
Western blot 
Ponceau S solution 
Ponceau S  0.1% 
acetic acid 0.5% 
Blocking solution 
Milk, non-fatty dried 5% 
→ Dissolved in TBST 
Laemmli buffer (6x) 
Tris pH 6.8 0.35 mol/L 
Glycerol 30% 
SDS 10% 
Dithiotreit (DTT) 9.3% 
Bromphenol blue 0.02% 
Transfer buffer (10x) 
Tris base 75.6 g 
Glycine 74.4 g 
SDS 15 g 
→ Fill to 1 L with ddH2O 
Transfer buffer (1x) 
Transfer buffer (10x) 10 ml 
Methanol 20 ml 
→ Fill to 100 ml with ddH2O 
TBST  
Tris/HCl 1 M, pH 7.6 20 ml  
NaCl 5 M 33 ml 
Tween 20  
→ Fill to 1 L with ddH2O 
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3.1.7 Inhibitors 
Inhibitor Concentration / Dilution Manufacturer 
ChIP 
Aprotinin / leupeptin 1 µg/mL (1:1000) Roche 
β-glycerophosphate 10 mM (1:100) Roth 
Indole acetamide 10 µM (1:10000) Sigma 
N-Ethyl Maleimide 1 mM (1:100) Sigma 
NiCl2 x 6H2O 1 mM (1:1000) Roth 
Pefablock 1 mM (1:100) Roth 
Protein lysis 
PhosSTOP Phosphatase Inhibitor 
Cocktail 
1 tablet / 1 ml (1:10) Roche 
Protease Inhibitor Cocktail, 
Complete Mini EDTA free 
1 tablet / 1.5 ml (1:10) Roche 
3.1.8 Kits 
Method Kit type Manufacturer 
DNA isolation NucleoSpin® Tissue Macherey-Nagel 
Electroporation Amaxa® Nucleofector® Technology Lonza 
ELISA kit 
Human IGFBP-5 ELISA Kit Sigma 
Mouse IGFBP-5 ELISA Kit Sigma 
Gel extraction & PCR clean-up NucleoSpin® Gel and PCR Clean-up Macherey-Nagel 
Lentivirus isolation 
Vivapure™ LentiSELECT 40 Purification 
and Concentration Kit 
Sartorius 
Luciferase assay Dual-Luciferase® Reporter Assay System Promega 
Nonatal cell isolation Neonatal Heart Dissociation Kit mouse&rat Miltenyi Biotec 
Plasmid isolation (Mini) NucleoSpin® Plasmid (NoLid) Macherey-Nagel 
Plasmid isolation (Midi) NucleoBond® Xtra Midi Macherey-Nagel 
RNA isolation NucleoSpin® RNA Macherey-Nagel 
3.1.9 Enzymes and supplemented buffers 
Method Substance / Enzyme Manufacturer 
Dephosphorylation 
Fast AP Thermosensitive Alkaline Phosphatase 
1 U/µL Thermo Scientific 
10x reaction buffer for AP 
DNAse 20 000 units Thermo Scientific 
Ligation 
T4 DNA Ligase 5 U/µL 
Thermo Scientific 
10x T4 DNA Ligase buffer 
PCR 
Phusion DNA Polymerase 2U/µL 
Thermo Scientific 
5x Phusion HF buffer  
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AmpliTaq 
Applied Biosystems 10X PCR Buffer 
MgCl2 Solution 
qPCR 
GoTaq® qPCR MasterMix 2x  
Promega 
CXR Reference Dye 
Restriction digest 
Fast Digest Enzymes 
Thermo Scientific 
10x Fast Digest Green buffer 
Reverse transcription 
M-MLV RT 5x Buffer 
Promega 
M-MLV Reverse Transcriptase 200 U/µL 
3.1.10 Ladder 
Ladder type Type Manufacturer 
DNA ladder 
GeneRuler 100 bp DNA Ladder 
Thermo Scientific 
GeneRuler 1 kb DNA Ladder 
MassRuler DNA Ladder Mix 
6x Loading Dye 
Protein ladder Spectra Multicolor Broad Range Protein Ladder Thermo Scientific 
3.1.11 Antibodies 
Antibody target Species Company 
Dilution 
WB IF ChIP FACS 
anti-α-Actinin ms Sigma - 1:500 - - 
anti-α-Smooth muscle actin ms Sigma - 1:500 - - 
anti-α-Tubulin ms Sigma 1:3000 - - - 
anti-cardiac troponin T ms Abcam 1:1000 1:200 - - 
anti-Connexin43 rb Sigma - 1:200 - - 
anti-FLAG M2 ms Sigma 1:1000 1:200 - - 
anti-FLAG rb Sigma 1:1000 - 2 µg - 
anti-IGFBP5 rb Sigma / 
customized 
1:500 1:50 2 µg - 
anti-Ncadherin rb Santa Cruz - 1:100 - - 
anti-NKX2.5 ms abcam 1:1000 - - - 
anti-OCT3/4  
(Alexa Fluor 647) 
ms BD 
Biosiences 
- - - 1:100 
anti-TBX5 rb Millipore 1:1000 1:20 - - 
anti-TRA-1-60 
(Alexa Fluor 647) 
ms BD 
Biosiences 
- - - 1:100 
anti-TPT1 ms Sigma 1:1000 - - - 
normal mouse IgG1 ms Santa Cruz - 1:200 - - 
normal rabbit IgG rb Santa Cruz - 1:500 2 µg - 
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Secondary Antibodies 
anti-ms-Alexa Fluor 488 goat Invitrogen - 1:200 - 
anti-ms-Alexa Fluor 494 goat Invitrogen - 1:200 - 
anti-rb-Alexa Fluor 488 goat Invitrogen - 1:200 - 
anti-rb-Alexa Fluor 494 goat Invitrogen - 1:200 - 
HRP conjug. anti-mouse-IgG rb Dako 1:10000 - - 
HRP conjug. anti-rabbit-IgG goat Dako 1:5000 - - 
3.1.12 Plasmids 
Name Insert / utilization Source 
pcDNA3.1 puromycin resistance own production 
pcDNA3.1-hIGFBP5-FLAG-Puro C-FLAG-hIGFBP5, puromycin 
resistance / OE vector 
own production 
pds-hTnnT-rluc Luciferase reporter / OE vector for 
AAV9 production 
Prof. Mueller, Klinik 
Innere Medizin III, 
Kiel 
pds-hTnnT-msIgfbp5-FLAG ms-Igfbp5-FLAG insert, removed 
luciferase reporter / OE vector for 
AAV9 production 
own production 
pEXPR-221-EF1a-eGFP eGFP / OE vector  Dr. A. Rhoa, 
Phamakologie 
Goettingen 
pEXP-221-EF1a-hNKX2.5 hNKX2.5 insert / OE vector  Dr. A. Rhoa, 
Phamakologie 
Goettingen 
pGIPZ eGFP /IRES/puromycin resistance / OE 
vector for lentivirus production 
Thermo Scientific 
pGIPZ-hIGFBP5-FLAG C-FLAG-hIGFBP5, removed eGFP , 
IRES, puromycin resistance / vector for 
lentivirus production 
own production 
pGL4.10 firefly luciferase CDS / reporter vector Promega 
pGL4.10-hIGFBP5 hIGFBP5 ChIP peak with firefly 
luciferase CDS 
own production 
pGL4.10- hTNNT2 hTNNT2 ChIP peak, firefly luciferase 
CDS / reporter vector 
own production 
pMD2.G Vector encoding lentivirus envelope 
proteins / lentivirus production 
Addgene 12259 Lab of 
Didié Trono 
psPAX2 Lentiviral packaging plasmid / lentivirus 
production 
Addgene 12260 Lab of 
Didié Trono 
pRL Renilla luciferase CDS / reporter vector Dr. J.C. Gross, Dev. 
Biochemistry, 
Goettingen 
pX335A-hCas9-D10A Human CAS9 nickase / OE vector Prof. Greber, MPI 
Münster 
pX335A-hCas9-D10A-hIGFBP5-
gRNAs 
4 different vectors with hIGFBP5 
targeting gRNAs, hCAS9 nickase / OE 
vector 
own production 
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3.1.13 Oligonucleotides 
3.1.13.1 Primers for ChIP peaks 
Primer name Sequence 5‘→3‘ Product size 
hIGFBP5 ChIP peak 
(promoter region) 
fwd GCTCCAATTCCGGGGTGCA 
980 bp 
rev CGGCGCCGCGCACCGCT 
hTNNT2 ChIP peak 
(promoter region) 
fwd CCTGCACATCTGGTCGTTCT 
1372 bp 
rev AGTGCATGTGCATGGTCAGA 
3.1.13.2 Primers for CRISPR approach 
Primer name Sequence 5‘→3‘ Product size 
gRNA cloning primers (gRNA pair #1) 
gRNA-pair #1-1 
fwd CACCGGGCTGGGGTGCCTGCGAGC 
/ 
rev AAACGCTCGCAGGCACCCCAGCCC 
gRNA-pair #1-2 
fwd CACCGTCTACATTTTTGCAAGTGTC 
/ 
rev AAACGACACTTGCAAAAATGTAGAC 
gRNA cloning primers (gRNA pair #2) 
gRNA-pair #2-1 
fwd CACCGGAGAGGGCTTTCTCGTCGC 
/ 
rev AAACGCGACGAGAAAGCCCTCTCC 
gRNA-pair #2-2 
fwd CACCGCCTGGGCTGCGAGCTGGTCA 
/ 
rev AAACTGACCAGCTCGCAGCCCAGGC 
Plasmid sequencing primers 
gRNA SeqRev 
fwd Forward gRNA oligo 
182 bp 
rev CTCTAGAGCCATTTGTCTGCAG 
Genotyping primers for c 
hIBP5-geno-II 
fwd TTTCTCCGGCCTCCGCTCA 
499 bp 
rev GGAACAAAAAGGGGGAAAAAAGC 
Genotyping primers for cDNA 
cDNA-geno 
fwd ATGGTGTTGCTCACCGCGG 
892 bp 
rev ATTGTGACCGCAAAGGATTC 
3.1.13.3 qPCR primers 
Gene  Sequence 5‘→3‘ Fragment size 
Mouse primer 
ms-Gapdh 
fwd ATGTTCCAGTATGACTCCACTCACG 
171 bp 
rev GAAGACACCAGTAGACTCCACGACA 
ms-Igfbp3 
fwd AGATGCTCCGTGCCACATAA 
170 bp 
rev GTGAGTTAGGGGGCAGATGG 
ms-Igfbp5 
fwd AGGTGGTGACAGAGCAGGTG 
130 bp 
rev GCCGCAGAACAGGTAAGAGG 
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ms-Igfbp5-FLAG 
fwd CAAAGCCAGCCCACGCATGG 
249 bp 
rev TACTTGTCATCGTCGTCCTTGTAATC 
ms-Mef2c 
fwd TGATCAGCAGGCAAAGATTG 
220 bp 
rev ATCAGACCGCCTGTGTTACC 
ms-Myh7 
fwd ATGTGCCGGACCTTGGAA 
170 bp 
rev CCTCGGGTTAGCTGAGAGATCA 
ms-Myocd 
fwd CTGTGTGGAGTCCTCAGGTCAAAC 
109 bp 
rev GATGTGCTGCGGGCTCTTCAG 
ms-Nkx2.5 
fwd CGACAGCGGCAGGACCAGAC 
133 bp 
rev CGTAGGCGGGAGCGTAGGC 
ms-Nppa 
fwd CATCACCCTGGGCTTCTTCCT 
405 pb 
rev TGGGCTCCAATCCTGTCAATC 
ms-Tbp 
fwd CCAGAACAACAGCCTTCCACC 
322 bp 
rev CAACGGTGCAGTGGTCAGAGT 
ms-Tnnt2 
fwd AAGCAGCAGAAATACGAAATCAACG 
183 bp 
rev GCCAAGGAGGACCCAGAG C 
ms-Tpt1 
fwd GTTGCTCTCCTGGACTACCG 
224 bp 
rev AAAAACAATGCCACCACTCC 
Human primer 
h-ACTA2 
fwd GGAAAAGATCTGGCACCACTC 
196 bp 
rev GCGTCCAGAGGCATAGAGAG 
h-AXIN2 
fwd GTGTGAGGTCCACGGAAACT 
153 bp 
rev AATCATCCGTCAGCGCATCA 
h-CyclinD1 
fwd CCCTCGGTGTCCTACTTCAA 
149 bp 
rev AGGAAGCGGTCCAGGTAGTT 
h-GAPDH 
fwd AAGGCTGTGGGCAAGGTCATC 
248 bp 
rev GCGTCAAAGGTGGAGGAGTGG 
h-GDF15 
fwd ACTCACGCCAGAAGTGCGG 
268 bp 
rev CCGTGCGGACGAAGATTCTG 
h-IGFBP5 
fwd TGCACCTGAGATGAGACAGG 
228 bp 
rev GAATCCTTTGCGGTCACAAT 
h-MYOCD 
fwd GGGTCTGAGCATTCCTTGCT 
124 bp 
rev CTGGACGTTTCAGTGGTGGT 
h-NKX2.5 
fwd ACCTCAACAGCTCCCTGACTCT 
155 bp 
rev ATAATCGCCGCCACAAACTCTCC 
h-SOX2 
fwd ATGCACCGCTACGACGTGA 
437 bp  
rev CTTTTGCACCCCTCCCATTT 
h-STC1 
fwd CACTCAGGGAAAAGCATTCGT 
97 bp 
rev GAAAGTGGAGCACCTCCGAA 
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h-TXNIP 
fwd CCCTGAAAAGGTGTACGGCA 
210 bp 
rev TTCTCACCTGTTGGCTGGTC 
3.1.13.4 Sequencing primers for plasmids 
Plasmid Primer Sequence 5‘→3‘ 
pcDNA 
CMV fwd CGCAAATGGGCGGTAGGCGTG 
BGH rev TAGAAGGCACAGTCGAGG 
pGIPZ 
XL79 fwd CGAGGTGCCCGAAGGA  
M100 rev CAGCGTATCCACATAGCGT  
pGL4.10 RV3 rev CTAGCAAAATAGGCTGTCC 
3.1.14 Animals 
Mouse strain Age Application 
NMRI 12-20 weeks Embryo isolation 
NMRI 1-3 days Heart/cell isolation 
BL/6J 12 weeks TAC / Ang II / AAV9 experiments 
αMhc-MerCreMer/  
β-cateninΔex3 
12-20 weeks Heart/cell isolation 
αMhc-MerCreMer/ β-
cateninΔex2-6 
12-20 weeks Heart/cell isolation 
Animal approval 
Animal experiments were approved by the Niedersachsen (AZ-G 15-1840)  
animal review board 
3.1.15 Bacteria  
Species Type Source 
E. coli NEB 10-beta NEB 
E. coli dam-/dcm- Competent E. coli NEB 
3.1.16 Cell Lines 
Cell type Abbreviation Source Application 
Human embryonic 
stem cells with RFP 
tag 
hES2 RFP Kindly provided by 
Gordon Keller [95] 
Cell line generation, cardiomyocyte 
differentiation 
Ethical approval 
German Stem Cell Act by the Robert-Koch-Institute to Wolfram-H. Zimmermann,  
permit #12, reference number: 1710-79-1-4-16 
Ventricular human 
cardiac fibroblasts 
 
hCFB Lonza, NHCF-V 
(CC2904, #26025) 
IBP5 OE, IBP5 uptake, ChIP, EHM 
generation 
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Murine adult 
cardiomyocytes  
 
/ Fresh isolation from 
adult heart (post-TAC 
or β-Cat GOF) 
IF, RNA, WB, ELISA  
Murine adult  
Fibroblasts 
 
/ RNA 
Murine neonatal 
cardiomyocytes  
 
MNCM Fresh isolation from 
neonatal heart 
(2-3-day old mice) 
RNA 
Murine neonatal 
fibroblasts 
 
MNFB RNA 
Human embryonic 
kidney SV40 
transformed cells 
TSA ATCC® CRL-1573 Plasmid validation, virus production, 
conditioned medium production, 
Luciferase assay 
3.1.17 Chemicals 
Substance Manufacturer 
1,4 Dithiotreit (DTT) Roth 
Acetic Acid Merck 
Acrylamide 30% AppliChem 
Agarose UltraPureTM AppliChem 
Ammonium chloride Carl Roth 
Ammonium persulfate (APS) Life technologies 
Ampicillin AppliChem 
Bromophenol blue AppliChem 
BSA (bovine serum albumin) Sigma-Aldrich 
Bromphenol blue Sigma Aldrich 
Butanediome monoxime  Sigma Aldrich 
Calcium chloride dihydrate  Carl Roth GmbH & Co. KG 
Collagen Internal production 
Collagenase Roche 
β-Mercaptoethanol AppliChem 
Dimethyl sulfoxide (DMSO) AppliChem / Thermo Scientific 
dNTP PCR Nucleotide-Mix (10 mM)  Promega 
DSG (disuccinimidyl glutarate) Thermo Scientific 
EDTA AppliChem 
EGTA AppliChem 
Ethanol Carl Roth 
Ethidium bromide Sigma 
Formaldehyde Carl Roth 
Gelatin Sigma-Aldrich 
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Glucose Carl Roth 
Glycerol Gerbu 
Glycine AppliChem 
HEPES, ultrapure Carl Roth 
Ethanol Carl Roth 
Ethanol molecular grade Carl Roth 
Hydrochloric acid (HCl) 25% Carl Roth 
L-ascorbic acid 2 phosphate sesquimagnesium (L-AAP) Sigma 
LB Agar / LB Medium   AppliChem 
Lithium chloride AppliChem 
Magnesium chloride Carl Roth 
Magnesium sulfate Carl Roth 
Methanol  Carl Roth 
Milk, non-fatty dried Carl Roth 
Monopotassium phosphate Merck 
Mowiol 4-88 AppliChem 
NP-40 Sigma 
Ponceau S AppliChem 
Potassium bicarbonate  Carl Roth 
Potassium chloride Carl Roth 
Potassium hydrogenphosphate  Carl Roth 
ProLong®Gold antifade Molecular Probes 
ProLong®Gold antifade with DAPI Molecular Probes 
2-Propanol  AppliChem 
Protein A Sepharose CL-4B  Sigma 
SDS (Sodiumdodecylsulfat) AppliChem 
Sepharose 4B Sigma 
Sodium citrate Sigma 
Sodium chloride Carl Roth 
Sodium deoxycholate Carl Roth 
Sodium fluoride Carl Roth 
Taurine Sigma-Aldrich 
TEMED  AppliChem 
Tris Base, ultrapure  Carl Roth 
Tris-hydrochloride Carl Roth 
TritonX-100 AppliChem 
Tween-20 Sigma-Aldrich 
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3.2 Methods 
3.2.1 Molecular biological methods 
3.2.1.1 Polymerase chain reaction (PCR)  
To generate vector inserts (from gene cDNA sequences or genomic regions), cloning primers 
were designed, which flank the sequence of interest with restriction enzyme sequences found 
in the destination vector. For efficient PCR product digestion, additional nucleotides were 
added at the end of the restriction enzyme sequence. For insert amplification, the Phusion 
polymerase, which possesses high fidelity, was used. 100 ng of template (plasmid) DNA were 
used in a total volume of 20 µl reaction mixture containing 5x Phusion reaction buffer, 200 µM 
dNTPs, 0.5 µM of each primer and 0.01 U/µl Phusion polymerase. In addition, 3% DMSO were 
used to relax DNA for denaturation. To determine optimal primer annealing temperature, a 
gradient PCR was performed. 
 
Table 3-1: Set up of PCR reaction 
Cycle step Temp. Time Cycles 
Initial denaturation 98°C 30sec 1x 
Denaturation 98°C 10sec  
35x Annealing X°C 30sec 
Extension 72°C 30sec 
Final extension 72°C 10min 1x 
 4°C Hold 
 
3.2.1.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to examine and purify PCR products. The constant charge 
to mass ratio of DNA allows a separation of fragments by length. By use of the intercalating 
agent ethidium bromide-, it is possible to visualize DNA fragments with UV light. After PCR 
reaction, desired PCR samples were supplemented with 6x loading dye and were loaded on a 
1% agarose gel which contained 0.002% ethidium bromide. After analysis, desired fragments 
were extracted and purified. 
3.2.1.3 Gel/PCR product extraction 
To purify PCR fragments from agarose gel, the “NucleoSpin®Gel and PCR Clean-up kit” from 
Macherey-Nagel was used according to the manufacturer's protocol. The cut gel band was 
mixed with binding buffer and heated to dissolve the agarose and the DNA was bound to the 
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silica membrane of a NucleoSpin®Gel and PCR Clean-up Column. Contaminations were 
removed by different washing steps. Finally, DNA was eluted in 50 µl water. The concentration 
was determined with NanoDrop spectrophotometer. 
3.2.1.4 Enzymatic digestion 
Restriction enzymes (endonuclease) are enzymes that produce a double-stranded cut in the 
DNA at, or near to, specific recognition nucleotide sequences known as restriction sites. In 
molecular cloning, these enzymes are used to generate “puzzle-like” fragments with blunt or 
sticky overhangs, which can be re-ligated using ligase enzyme. Double digestion of purified 
PCR product (insert) and of desired vector was performed in 20 µl reaction mixture each, which 
contained 2 µl of FastDigest Green Buffer, 1 µl of each restriction enzyme and 1 µg DNA 
(insert/vector). Reactions were incubated at 37°C for 1 hour and inactivation was performed by 
heating to 80°C for 5 min.  
3.2.1.5 Vector dephosphorylation 
Dephosphorylation of 5'-phosphate groups from cloning vectors after enzymatic digestion is 
necessary to prevent re-circularisation during ligation step. One unit of the Fast calf-intestinal 
alkaline phosphatase was directly added to the inactivated digestion reaction mixture and was 
incubated at 37°C for 30 min. Enzymatic reaction was inactivated by heating to 75°C for 5 min.  
3.2.1.6 Ligation 
The process of ligation is used to create recombinant DNA molecules. The enzyme T4 DNA 
ligase joins DNA fragments together by the formation of phosphodiester bonds. The molar mass 
of insert should be higher than the molar mass of vector. To calculate the molar ratios the 
following formula was used: 
ng of insert =  
ng of vector (= 50) × kb size of insert
kb size of vector
 ×  molar ratio
insert
vector
 
 
Digested and dephosphorylated cloning components were purified by agarose gel 
electrophoresis following extraction. Concentrations were determined to calculate the required 
amount of vector and insert DNA. Molar ratios between 1:5 to 1:10 (vector:insert) were used. 
50 ng vector and the required amount of insert were added in a total volume of 20 µl with 10x 
ligation buffer and one unit T4 DNA ligase. Ligation was performed overnight at 16°C with an 
additional incubation at room temperature for two hours.  
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3.2.1.7 Transformation 
The uptake of exogenous genetic material by microorganisms is known as transformation. In 
molecular cloning this process is used to amplify genetically modified DNA. Artificial 
competence of E. coli can be induced thermic under cold conditions, before being exposed to a 
heat pulse (heat shock). By this process the cell membrane becomes passively permeable for 
DNA. Chemically competent NEB-10beta E. coli cells were used according to the 
manufacturer's protocol. Cells were thawed on ice and 50 µl were transferred to a 1.5 ml 
Eppendorf tube. 2-5 µl of ligation mixture was added to the E. coli cells and the tube was 
carefully flicked 4-5 times. Mixture was placed on ice for 30 min and was heat shocked at 42°C 
for exactly 45 sec. After 5 min on ice, 450 µl of room temperature SOC medium was added 
into the mixture and placed on a thermomixer at 37°C for 60 min and 300 rpm. 100-200 µl of 
transfected culture was plated on a LB-agar ampicillin selection plate (100 µg/ml ampicillin) 
and incubated overnight at 37°C. Colonies were picked with a sterile pipette tip and transferred 
to 4 ml LB-medium supplemented with 100 µg ampicillin/ml. Cultures were shaken overnight 
with 220 rpm at 37°C. 
3.2.1.8 Plasmid isolation (Mini Prep) 
To isolate amplified plasmids and to verify successful cloning, the “NucleoSpin® Plasmid kit” 
from Macherey-Nagel was used according to the manufacturer's protocol. Overnight cultures 
were pelleted and resuspended in supplied buffer. Plasmid DNA was released from the E. coli 
host cells by SDS/alkaline lysis. Precipitated protein, genomic DNA, and cell debris were then 
pelleted by a centrifugation step. The supernatant was loaded onto a NucleoSpin® Plasmid 
Column where plasmid DNA was bound to the silica membrane of the column. Contaminations 
were removed by different washing steps. Finally, plasmid DNA was eluted in 50 µl of double-
distilled water. Concentration was determined with NanoDrop spectrophotometer. For a first 
verification of successful cloning, 500 ng plasmid DNA was digested with enzymes used for 
cloning and was analysed by agarose gel electrophoresis.  
3.2.1.9 Sequencing 
After successful enzymatic digestion of cloned vectors, plasmid sequencing is required to verify 
error-free introduction of insert in vector backbone. Sanger DNA sequencing is performed by 
SEQLAB Sequence Laboratories Goettingen GmbH, while primers from the offered “standard 
primer list” or the cloning primers were used for sequencing. 
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3.2.1.10 Plasmid isolation (Midi Prep) 
After verification by sequencing, a glycerol stock of bacteria with positive tested plasmids was 
prepared using 1200 µl overnight culture plus 800 µl 50% glycerol. These stocks were stored 
at -80°C. To prepare a high concentration of desired plasmid, a culture of bacteria in 3 ml LB-
medium supplemented with 100 µg ampicillin/ml was shacked with 220 rpm at 37°C for six 
hours. The culture was then transferred to 250 ml LB-medium supplemented with 100 µg 
ampicillin/ml and was shacked overnight with 220 rpm at 37°C. To isolate amplified plasmids, 
the “NucleoBond® Xtra Midi kit” from Macherey-Nagel was used according to the 
manufacturer's protocol. 
3.2.1.11 DNA isolation  
Isolation of genomic DNA from human embryonic stem cell (hES) clones was done to verify a 
successful deletion of the sequence of interest. For this purpose, the “NucleoSpin® Tissue kit” 
from Macherey-Nagel was used according to the manufacturer's protocol. Cells were lysed by 
incubation with proteinase K/SDS solution. Appropriate conditions for binding of DNA to the 
silica membrane in the NucleoSpin® Tissue Columns were archived by the addition of 
chaotropic salts and ethanol to the lysate. The binding process is reversible and specific to 
nucleic acids. Contaminations were removed by subsequent washing with two different buffers. 
Pure genomic DNA was finally eluted in 50 µl volume under low ionic strength conditions in 
an elution buffer. 
3.2.1.12 RNA isolation 
For isolating RNA, the “NucleoSpin® RNA kit” from Macherey-Nagel was used according to 
the manufacturer's protocol. Cells were scrapped and then lysed by incubation with the provided 
lysis buffer. Tissue samples were homogenized in lysis buffer using a bead mill for 30 sec with 
30 Hz. Contaminating DNA was removed using provided rDNase solution directly applied onto 
the silica membrane during the preparation. Washing steps removed salts, metabolites and 
macromolecular cellular components. Pure RNA was eluted with RNase-free water. 
3.2.1.13 RNA sequencing 
RNA sequencing was performed at the Transcriptome and Genome Analysis Laboratory (TAL, 
University Medical Center, Goettingen), in biological triplicates for murine hearts and in 
technical triplicates for hCFBs. RNA was extracted using the “NucleoSpin® RNA kit” from 
Macherey-Nagel. Quality and integrity of RNA was assessed with the Fragment Analyzer from 
MATERIAL AND METHODS  33 
Advanced Analytical by using the standard sensitivity RNA Analysis Kit (DNF-471). All 
samples selected for sequencing exhibited an RNA integrity number over 8. RNAseq libraries 
were performed using a modified stranded-specific, massively-parallel cDNA sequencing 
(mRNAseq) protocol from Illumina, using the TruSeq stranded mRNA prep Kit. The optimized 
protocol included the dilution of the adapter concentration to increase the ligation efficiency 
(>94%). Furthermore, a reduced number of PCR cycles was used to avoid PCR duplication 
artefacts as well as primer dimers in the final library product. Using a strand-specificity 
protocol, differences in coverage, agreement with known annotations, and accuracy for 
expression profiling were observed. Finally, the incorporation of dot during the second strand 
synthesis was done to perform total stranded RNA sequencing. For accurate quantitation of 
cDNA libraries, a fluorometric based system (QuantiFluor™ dsDNA System from Promega) 
was used. The size of final cDNA libraries was determined by using the dsDNA 905 Reagent 
Kit (Fragment Analyzer from Advanced Bioanalytical) exhibiting a sizing of 300 bp in average. 
Libraries were pooled and sequenced on an Illumina HiSeq 4000 (Illumina) generating 50 bp 
single-end reads (30-40 Mio reads/sample). Sequence images were transformed with the 
Illumina software BaseCaller to BCL files, which was demultiplexed to fastq files with 
bcl2fastq v2.17.1.14. The quality check was done using FastQC (Andrews, Simon. "FastQC a 
quality-control tool for high-throughput sequence data", Bioinformaticsbabraham.ac. 
uk/projects/fastqc (2014), version 0.11.5, Babraham Bioinformatics). Sequence reads were 
aligned to the mouse reference assembly (UCSC version mm9) using Bowtie 2.0. [96]. For each 
gene, the number of mapped reads was counted and DESeq2 was used to analyse the differential 
expression [97]. Gene ontology (GO) analyses were performed using default parameters and 
stringency in ‘ClueGO’: a Cytoscape plug-in [98]. The significant ‘GO Biological Processes’ 
were shown with P≤0.05. 
3.2.1.14 Reverse transcription 
Quantitative (q)PCR was used to quantify mRNA levels. Since mRNA cannot be used as a PCR 
template, transcription to complementary DNA (cDNA) by reverse transcription is necessary. 
RNA was transcribed to cDNA using the moloney murine leukaemia virus reverse transcriptase 
(M-MLV RT). For amplification, an oligo(dT)20 primer was used. This primer consists of a 
string of 20 desoxythymidylic acid residues that hybridizes to the poly(A) tail of mRNA. For 
each reaction 150-500 ng RNA was used together with 1 µl oligo(dT)20 primer (500 ng/µl), 1 µl 
dNTPs (10 mM) and was supplemented with water to 15.5 µl. To eliminate any secondary 
template structures, the mixture was incubated at 65°C for 5 min and cooled down to 4°C to 
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prevent reforming of these structures. 0.5 µl M-MLV RT (200 U/µl) and 4 μl M-MLV RT 5x 
buffer were added to each sample. One sample was prepared without reverse transcriptase (-RT 
control) to determine genomic DNA contamination in isolated RNA samples. Reverse 
transcription was done at 42°C for 50 min. The enzyme was inactivated by incubation at 70°C 
for 15 min.  
3.2.1.15 Primer design 
Cloning primers were flanked with chosen restriction sites and three extra base pairs were added 
to ensure that the restriction enzyme cuts the site correctly. The freeware “Oligo Calc” was used 
to calculate corresponding oligonucleotide properties like salt adjusted melting temperature 
(TM), GC content and to verify the reverse complement strand (5' to 3') and self-complementary. 
To ensure that only the target sequence is amplified by the primers, the “Basic Local Alignment 
Search Tool” (BLAST) was used to predict primer binding on other potential templates. qPCR 
primers were designed using the Primer-BLAST tool (NCBI). Settings were adjusted to 
generate a qPCR product from an exon-exon junction with a size of 70-250 bp. An optimal 
primer melting temperature was set to 60°C.  
3.2.1.16 Standard curve preparation 
There are two methods to calculate PCR based quantification of molecules; the absolute and 
the relative quantification. For absolute quantification using the standard curve method, a 
dilution series of DNA with known copy number is quantified together with the samples. For 
each primer pair a standard curve was prepared. For that, qPCR was run with desired primers 
and a cDNA template. qPCR product was controlled by melting curve analysis and gel 
electrophoresis with subsequent extraction and sequencing. The concentration of the qPCR 
product was determined and the copy number of molecules per microliter was calculated (see 
formula below). A dilution of the qPCR product with 109 molecules/µl in a volume of 110 µl 
was prepared and a serial 1:10 dilution was done using 11 µl of higher dilution, diluted in 99 µl 
water. For every primer pair, standards of 108-103 molecules/µl were prepared and run in 
duplicates for qPCR. 
copy number (
molecules
µl
) =  
DNA concentration in 
g
µl 
DNA lenght in bp x 660
 × 6.022 x 10^23 
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3.2.1.17 SYBR green based quantitative real time PCR 
Real-time PCR monitors the progress of DNA amplification throughout the PCR process. 
SYBR green dye intercalates and detects PCR products when they accumulate during PCR 
cycles, while the increase in fluorescence intensity increases proportional to the amount of PCR 
product produced. The threshold cycle (Ct) is the intersection of the amplification curve to the 
threshold line. It is a relative measure of the concentration of target in the PCR reaction. Using 
a standard curve, the concentrations of the samples can be calculated. For qPCR the GoTaq® 
qPCR Master Mix was used which already contains the buffer with MgCl2, nucleotides and the 
polymerase. 5 µl GoTaq® qPCR Master Mix was supplemented with 0.1 µl carboxy-X-
rhodamine (CXR) reference dye, 1 µl of each primer (stock concentration 3 µM) and 0.9 µl 
RNAse-free water. 1 µl of 1:5 diluted cDNA or of standard dilution was added to a total volume 
of 10 µl in a 384-well plate. cDNA samples, -RT control and water control were run in 
triplicates, standards in duplicates. The plate was sealed, centrifuged and when needed stored 
for a short time at -20°C. Gene expression was normalized to the indicated housekeeper in every 
experiment. Copy numbers were calculated using the SDS2.4 software with a relative standard 
curve obtained using the log dilutions of cDNA of gene of interest. The thermal cycler 
conditions were set as follows: 
 
Table 3-2: Set up of qPCR reaction 
Cycle step Temp. Time Cycles 
 50°C 2 min 1x 
Initial denaturation 95°C 10 min 
Denaturation 95°C 15 sec  
40x Annealing 60°C 1 min 
Extension 95°C 15 sec 
Final extension 60°C 15 sec 1x 
Inactivation 95°C 15 sec 
 
3.2.2 Cell culture 
3.2.2.1 Thawing, freezing and counting of cells 
All used cell types were grown in a humified incubator with 37°C and 5% CO2. For the thawing 
process, the outer part of the frozen cell suspension in the cryovial was melted. Then, 1 ml 
medium (according to cell type) was added before frozen cells were transferred and 
resuspended in a total volume of 10 ml medium in a 15 ml falcon. Cells were centrifuged at 
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300 x g for 4 min at 4°C. Supernatant was removed and remaining cell pellet was resuspended 
in corresponding volume of medium. For freezing, cells were dissociated (according to the cell 
type) and were centrifuged at 300 x g for 4 min at 4°C. Supernatant was removed and remaining 
cell pellet was resuspended in corresponding volume of FCS supplemented with 10% DMSO 
(stem cells with 20% DMSO) and were frozen in 1 ml aliquots at -80°C in a freezing container. 
For long time storage, cells were transferred to -152°C. Standardized cell counting, and viability 
verifications were done by electrical current exclusion using the CASY® TT cell counter and 
analyzer system. For measurement, required cell dilution (mostly 1:500) was prepared in 10 ml 
CASY® ton and was measured with the corresponding counting program. 
3.2.2.2 Isolation, cultivation and stimulation of murine neonatal cardiomyocytes and 
fibroblasts 
For isolation of murine neonatal cardiomyocytes (MNCM) and cardiac fibroblasts (NMCF), 
NMRI mice with large offspring numbers were used. About 50 (two- till four-day old) neonatal 
mice were decapitated and hearts were removed from the thorax. After collection and rinsing 
in ice cold PBS, vessels and atria were removed. For cell isolation, the “Neonatal Heart 
Dissociation Kit mouse and rat” from Miltenyi Biotec was used according to the manufactures 
instructions. Shortly, neonatal hearts were dissociated into single cell suspensions by combining 
enzymatic degradation of the extracellular matrix and mechanical dissociation with the 
gentleMACS™ Dissociator (difference to protocol: incubation without agitation, only two 
mechanical dissociation steps with ms_neonheart program, after enzymatic digestion addition 
of 10 ml medium). After dissociation, the suspension was applied on a 70 μm filter to remove 
any remaining larger particles and was centrifuged for 20 min with 50 rpm at 4°C. To separate 
fibroblast cell fraction from cardiomyocytes, the cells were resuspended in 20 ml 
cardiomyocyte medium (DMEM with 1 g/L glucose, 3.7 g/L NaHCO3, without L-glutamine, 
10% FCS, 1% Pen-Strep, 1% NEAA, supplemented with 100 µM bromodeoxyuridine to 
prevent non-myocyte proliferation). Then, suspension was pre-plated on a 15 cm dish for 
30 min in a humidified incubator (37°C, 5% CO2). During this time the fibroblasts adhered to 
the cell culture dish, while cardiomyocytes mostly remained in the medium. After incubation, 
supernatant was removed and pre-plated again for 15 min. Remaining fibroblasts from first pre-
plating step were grown for one week (DMEM GlutaMAX with 1 g/L glucose, 10% FCS, 1% 
Pen-Strep), whereas medium was replaced every second day. About 5 x 105 cardiomyocytes 
were cultured in 0.1% gelatin coated 12-well plates. Medium was replaced every second day. 
After 48 h, beating cardiomyocytes were stimulated with 1 µM norepinephrine for 48 h, 
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whereas medium was replaced with fresh norepinephrine after 24 h. After 48°h, 
cardiomyocytes were rinsed with PBS and were processed for RNA isolation. Fibroblasts were 
grown till 95% confluence and were dissociated with 4 ml 0.05% trypsin-EDTA. After 3-5 min 
incubation at 37°C, detachment of cells was monitored under a light microscope. The enzymatic 
activity of trypsin was halted by addition of 8 ml medium. Cell number and viability were 
measured by CASY TT system. 5 x 105 neonatal fibroblasts were seeded in a 6-well plate and 
were culture for 48°h in a humidified incubator (37°C, 5% CO2). Then, cells were stimulated 
with 1 µM norepinephrine for 48 h, whereas medium was replaced with fresh norepinephrine 
after 24 h. After 48°h, fibroblasts were rinsed with PBS and were processed for RNA isolation. 
For reuptake experiments, 5 x 105 neonatal fibroblasts were seeded in a 6-well plate and were 
culture for 48°h in a humidified incubator (37°C, 5% CO2). Then, medium was replaced with 
fresh IGFBP5-FLAG-conditioned medium (see chapter 0). After 48°h, fibroblasts were rinsed 
with PBS and were processed for protein isolation. 
3.2.2.3 Isolation and cultivation of murine adult cardiomyocytes and fibroblasts 
Heart excision was done under total anaesthesia using about 100 µl of a mixture of xylazine 
and ketamine (200 µl xylazine, 400 µl ketamine and 400 µl saline solution for 1 ml) which was 
injected intraperitoneally. Beating hearts were removed quickly by cutting across the arch of 
the aorta and were cleaned from blood in ice cold PBS. Then, hearts were transferred to 
perfusion buffer supplemented with Butanedione monoxime to arrest beating. Before perfusion, 
the ascending aorta was mounted on a blunted 20-gauge cannula on ice to achieve retrograde 
perfusion. The heart was fixed with yarn and was manually perfused with a perfusion buffer 
manually to control cannulation. Subsequently, the cannulated heart was transferred to the 
Langendorff perfusion system and was kept at 37°C. The temperature of the perfusate was 
regulated via a heating coil that surrounds the perfusion tubing. Perfusion was done for 1 min 
with perfusion buffer and a flow rate of 4 ml/min. To break down the extracellular matrix, 
perfusion was changed to enzymatic digestion buffer and was done for 8-9 min with 0.3 U/mg 
collagenase. After enzymatic digest was completed, the heart was taken down from the cannula 
and the ventricle was dissected. The preparation was cut into small pieces and cardiomyocyte 
dissociation was achieved by gently triturated with a plastic transfer pipette and the use of 
stopping buffer containing 10% FCS. To enrich the cell suspension with viable cardiomyocytes 
and to remove undigested tissue, suspension was sedimented by gravity for 1 min. Supernatant 
was then transferred to a new 15 ml tube and cardiomyocytes were sedimented for 8 min. This 
process allowed separation of cardiomyocytes from other cell types and from dead myocytes. 
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The sedimentation was repeated several times, while Ca2+ concentration was gradually 
increased in several steps. This allowed cells to gradually return to normal cytosolic Ca2+ levels. 
Supernatants with non-myocytes were collected separately. Non-myocyte cell suspension and 
sedimented cardiomyocytes were then centrifuged for 4 min with 300 x g. Supernatants were 
aspirated and pellets were stored at -20°C until RNA or protein preparation. For cardiomyocytes 
culture, sedimented cardiomyocytes were seeded on laminin coated wells (one heart in two 
12 well wells) or coverslips and were incubated for 1 h in a humidified incubator (37°C, 5% 
CO2), before addition of 600 µl cardiomyocyte medium. 24 h after seeding, supernatants were 
collected, centrifuged for 4 min with 300 x g to remove cell debris and were snap frozen and 
stored at -80°C until processing. Cells on cover slips were fixed for immunofluorescence (IF) 
staining as described in chapter 3.2.4.1. 
3.2.2.4 Cultivation, stimulation and transduction of human cardiac fibroblasts 
Human cardiac fibroblasts, isolated from normal, adult heart ventricle (50-year-old male), were 
purchased from LONZA at passage 2. Cells were cultured with FGM™-3 fibroblast growth 
medium with 10% FCS, 0.5% recombinant human insulin and FGF under standard conditions 
(37°C, 5% CO2). When confluence reached about 95%, cells were washed with PBS and were 
dissociated with 2 ml TrypLE express dissociating enzyme at RT. Digestion was stopped using 
8 ml FGM medium and cell count was determined with CASY TT system. 5x 105 cells were 
seeded on cover slips in a 12-well plate and 2.5x 106 on 6-well plates. 48 h after seeding, cells 
were stimulated with 10 µM norepinephrine or 1 ng/ml TGFβ for 48 h, whereas medium was 
replaced with fresh norepinephrine or TGFβ after 24 h. After 48°h, fibroblasts were rinsed with 
PBS and were processed for RNA isolation or IF staining. For reuptake experiments, growth 
medium was replaced with fresh IGFBP5 conditioned medium (see 0). After 48°h, fibroblasts 
were rinsed with PBS and were processed for protein isolation or IF staining. For transduction, 
FGM medium was supplemented with 2.5 µl/ml purified lentivirus and 8 µg/ml polybrene. 
Transduction was done for 48 h with subsequent medium change. Cells were kept in culture for 
4 days for recovery and transgene expression. Medium change was done every alternate day. 
6 days after transduction, fibroblasts were rinsed with PBS and were processed for RNA 
isolation or IF staining.  
3.2.2.5 Cultivation and transient transfection of TSA201 cells 
TSA201 cells were cultured in T75 flasks and were split 1:5 two times weekly. For seeding in 
wells or on cover slips, surfaces were coated with 1% rat tail collagen (in house made) for 1 min 
and were air dried before use. 24 h prior transfection, cells were seeded to have a confluence of 
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about 80% on the day of transfection. About 200 ng total DNA was used per cm2, whereas DNA 
to TurboFect transfection reagent ratio was 1:2. Required DNA and transfection reagent were 
added to serum free medium, vortexed and incubated for 20 min at RT. Transfection solution 
was added to cells and medium was replaced after 6 h. Cells were harvested 48 h after 
transfection. 
3.2.2.6 Generation and purification of lentivirus particles in TSA201 cells 
To generate non-replicating transducing lentiviral particles for hIGFBP5overexpression, C-
terminal FLAG tagged hIGFBP5 was cloned in the HIV-based pGIPZ Lentiviral shRNA vector 
via removing the shRNA-IRES-Puromycin cassette. pGIPZ vectors contain integration and 
packaging elements of lentivirus particles and a SV40 origin of replication (ori), enabling 
replication in cell lines expressing the large T antigen and allows high-level expression. For 
particle production, three separate plasmids for expression of lentiviral proteins and the 
transgene were co-transfected: pMD2.G encodes for a glycoprotein of the vesicular stomatitis 
virus, pPAX2 is a packaging plasmid containing the viral structural genes, and pGIPZ, either 
for overexpressing hIGFBP5 or as an empty vector with a GFP reporter. TSA201 cells were 
cultured in T75 flasks until 80% confluence and transfection was done according to table 3-3. 
Medium was replaced 6 h after transfection with 10 ml fresh medium and cells were kept in 
culture for 72 h. Lentivirus particle-containing supernatants were harvested, supernatants from 
four T75 flasks were pooled (40 ml total) and filtered with a 45 μm syringe filter to remove cell 
debris. Virus particle production was confirmed using the LentiGo sticks from Takara. For 
purification and concentration of the viral particles, the “Vivapure™ LentiSELECT 40 
Purification and Concentration Kit” from Sartorius was used according to the manufactures 
instructions. Purified particles were aliquoted, snap frozen and stored at -80°C. 
 
Table 3-3: Transfection protocol for lentivirus production 
Reagent Amount 
pGIPZ with GOI 5.11 µg 
pPAX.2 5.11 µg 
pMD2.G 3.41 µg 
DMEM 500 µl 
TurboFect 27 µl 
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3.2.2.7 Generation of conditioned medium in TSA201 cells 
To produce medium containing secreted hIGFBP5, TSA201 cells were cultured in T75 flasks 
until 80% confluence and were transfected with 13.5 µg DNA from pGIPZ overexpression 
plasmid or corresponding empty vector control. Medium was replaced 6 h after transfection 
with 10 ml fresh medium and cells were kept in culture for 48 h. Supernatants were harvested, 
filtered with a 45 μm syringe filter to remove cell debris and were directly applied on target 
cells. 
3.2.2.8 Cultivation of human embryonic stem cells (hES) 
The human embryonic stem cell line “HES2” (Embryonic Stem Cell International, Singapore), 
genetically modified to stably and ubiquitously express a tandem dimer red fluorescence protein 
(tdRFP) from the ROSA26 locus (finally designated hES2.R26) was kindly provided by Gordon 
Keller [99]. hES2-RFP cells were maintained and later differentiated under serum free 
conditions [100]. hES2-RFP cells (later also clones and mock control) were cultured under 
feeder free conditions on Matrigel (1:120 diluted in PBS) coated flasks in TeSR-E8 medium 
under standard conditions (37°C, 5% CO2). Twice a week, when cells reached a confluence of 
90%, cells were passaged. After rinsing with PBS, 4 ml 0.5 mmol/L EDTA solution was added 
and incubated at 37°C for 4 min. EDTA solution was aspirated and cells were resuspended 
using 10 ml TeSR-E8 with 10 µM Rock inhibitor. Cell count was determined using the CASY 
TT system. After seeding, cells were kept in culture with 10 µM Rock inhibitor for 24 h. Then, 
TeSR-E8 medium change was done every day without Rock supplementation. 
3.2.2.9 Generation of a hES knock out cell line using CRISPR/Cas9 technology 
gRNA design and cloning 
To obtain a knock out of the human IGFBP5 gene, the CRISPR/Cas9 nickase system was used 
according to [101]. CRISPR gRNAs were designed to target the transcription start site to 
generate a frame shift or to shift transcription to a next ATG to generate a truncated transcript. 
To avoid off-target effects, a “4n approach” was applied using four different gRNAs and a 
CAS9 nickase enzyme to generate four independent single strand breaks releasing a 300 bp 
long DNA fragment. gRNAs were designed as described by Noack et. al [101]using the 
“DNA2.0” online tool. gRNA offset was set between 0-20 bp with a NGG PAM region. 
Transcription start site was manually set as target sequence for gRNA search. Restriction sites 
for BbsI/BpiI were added to each of the obtained gRNA sequence and a complementary 
sequence was designed for each gRNAs. gRNAs and complementary sequences were 
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synthetized like PCR primers from MWG. Purchased oligos were phosphorylated and annealed 
using 1 µl of 100 µM from each gRNAs and 1 µl of 100 µM of its complementary oligo. For 
the reaction, 0.5 µl of T4 PNK was used and incubation was done for 30 min with subsequent 
cool down of 5°C/min to 25°C. For cloning, the modified pX335 containing GFPT2A-
puromycin cassette and SpCas9-D10A nickase vector [102] was used. The vector was digested 
with BbsI enzyme, dephosphorylated and purified as described in 3.2.1.3. 1 µl of a 1:250 
dilution of the annealed oligo mix was ligated overnight and transformed into high efficiency 
competent E. coli (all cloning steps like described in 3.2.1.2 to 3.2.1.10). Positive clone 
identification was done using PCR. For the reaction, 1 µl plasmid DNA was used with 0.2 µl 
Dream Taq polymerase. For every construct, the specific forward oligo used for cloning was 
used together with a universal reverse primer binding in the vector sequence. Positive clones 
were identified on an agarose gel. 
Electroporation and selection of hES cells 
For electroporation, HES2-RFP cells were dissociated with 0.5 mM EDTA (see section 3.2.2.8) 
and 2x 106 were centrifuged for 4 min at 300x g. After supernatant removal, cell pellet was 
resuspended in nucleofection solution supplemented with 1 μg gRNA/Cas9n plasmid each 
(total DNA amount 4 µg) using the Human Stem Cell Nucleofector Kit 1 (LONZA) according 
to the manufacturer's instruction. Suspension was electroporated with the Nucleofector 2b 
device (program B16). Subsequently, cells were resuspended in 12 ml TeSR-E8 with 10 µM 
Rock inhibitor and were distributed on a Matrigel (1:60 in PBS) coated 6-well plate. After 24 h, 
cell selection was done with different concentrations of puromycin (0.2-0.8 μg/ml) for 24 h. 
After colony formation (about 6-8 days) colonies were reseeded when colonies were fused or 
were directly picked and transferred to a 96-well plate for separation. After 48 h, colonies were 
washed with PBS and dissociated with 0.5 mM EDTA and TeSR-E8 with 10 µM Rock 
inhibitor. Cell suspension from each colony was separated. Half of the volume was seeded on 
a Matrigel (1:60 in PBS) coated 48-well plate, the second half was used for DNA isolation and 
subsequent genotyping. Positive colonies were expanded further and cryo-conserved. 
DNA and RNA genotyping 
Genomic DNA was isolated using the NucleoSpin Tissue kit (Macherey-Nagel). Genotyping 
PCR was performed using 0.02 U/µl Phusion polymerase, 200 µM dNTPs, 5% DMSO and 
1 µM of each genotyping primer flanking the deleted DNA fragment. PCR products were 
analysed using a 1% agarose gel. For band extraction, the NucleoSpin Gel and PCR Clean-Up 
kit (Macherey-Nagel) was used and DNA was sequenced at Seqlab Goettingen. For RNA 
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genotyping, RNA was isolated and transcribed to cDNA as described in3.2.1.12 and 3.2.1.14. 
qPCR was done as described in 3.2.1.17. The forward primer was designed to bind the deleted 
transcriptional start site, whereas reverse primers bind in the next exons.  
3.2.2.10 Spontaneous germ layer differentiation 
Embryoid body (EB) formation was done as described by El-Battrawy et al. [103] in the Stem 
Cell Unit (SCU), UMG, Goettingen (experiment done by Martina Grohe). Shortly, For EB 
formation, 5 x 104 hES cell together with 2.5 x 104 mouse embryonic fibroblasts were plated in 
each well of a 96-well U-bottom plate in hES medium composed of DMEM-F12, 15% knockout 
serum replacement, 1x NEAA, 50 μM β-mercaptoethanol and 2 μM thiazovivin, the plate was 
centrifuged at 250 x g for 5 min and co-cultures were cultivated in suspension to form 
multicellular EB aggregates. At day two, medium was changed to differentiation medium 
composed of IMDM Glutamax, 20% fetal bovine serum, 1x NEAA and 450 μM 1-thioglycerol 
for further 6 days with medium change every other day. At day eight, EBs were plated onto 
0.1% gelatin coated 6-well plates and cultured for up to one month in differentiation medium 
with medium change every other day. 
3.2.2.11 Differentiation of hES cells to cardiomyocytes 
hES cell differentiation to cardiomyocytes was done according to the protocol from Tiburcy et 
al. [100]. Three days prior differentiation, hES cells were passaged (as described in 3.2.2.8) and 
2 x 105 cells (clones and mock control) seeded in a density of 2 x 105 cells on Matrigel (1:120 
diluted in PBS) coated T25 flasks in TeSR-E8 medium under standard conditions (37°C, 5% 
CO2). For differentiation, stem cells were cultured in basal medium (RPMI, 2% B27, 
200 μmol/L L-ascorbic acid, 1 mmol/L Na-pyruvate, 100 U/mL penicillin, 100 μg/mL 
streptomycin). For mesodermal induction 9 ng/mL Activin A, 1 μmol/L CHIR99021, 5 ng/mL 
BMP4, and 5 ng/mL β-FGF were added for three days. For cardiac differentiation, cells were 
cultured in basal medium supplemented with 5 μmol/L IWP4 from day four till 13. 
Differentiated cardiomyocytes were metabolically purified by glucose deprivation using 
selection medium (RPMI without glucose and glutamine, 2.2 mmol/L Na-lactate, 100 μmol/L 
β-mercaptoethanol, 100 U/mL penicillin, 100 μg/mL streptomycin) for five days. 
3.2.2.12 Dissociation, cultivation and fixation of hES derived cardiomyocytes 
To dissociate differentiated monolayer cardiomyocytes from T25 flasks, cells were washed 
twice with PBS and were incubated with 1.5 ml room temperature Accutase/DNAse mix. 
Incubation was done for 10-30 min at room temperature under consistent observation until cells 
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dissociated. Digestion was stopped with 4 ml of basal medium (RPMI, 2% B27, 200 μmol/L L-
ascorbic acid, 1 mmol/L Na-pyruvate, 100 U/mL penicillin, 100 μg/mL streptomycin) 
supplemented with a final concentration of 5 µM Rock inhibitor. Cell suspension was 
homogenized by careful triturating. Cell count was determined using the CASY TT system. 
About 1x 106 cells were collected for RNA isolation, 2x 106 cells were collected for protein 
isolation and for cryoconservation. 5x 105 cells were collected for flow cytometry analysis and 
for IF staining, 5x 105 cells were seeded per cover slip. Independent on downstream application, 
dissociated cells were centrifuged at 300x g for 5 min and supernatants were removed. For 
RNA, protein and flow cytometry sample collection, cell pellets were washed with PBS and 
were centrifuged again. RNA and protein samples were frozen at -20°C until processing. Flow 
cytometry samples were fixed with 1 ml ice cold 70% ethanol and stored for maximum one 
week at 4°C until analysis. Cell pellets for cryoconservation were resuspended in 1 ml FCS 
with 10% DMSO and were frozen in a freezing container at -80°C. Cell pellets for IF staining 
were resuspended in basal medium without Rock inhibitor and plated on Matrigel (1:120 in 
PBS) coated cover slips. Prior treatment, cells recovered for at least four days. Medium was 
replaced every alternate day.  
3.2.2.13 Generation of engineered human myocardium (EHM) 
For construction of engineered human myocardium (EHM, experiment was done by Dr. 
Norman Liaw, Pharmacology and Toxicology, UMG Goettingen) all materials required were 
pre-chilled and all steps performed on ice. Transduced hCFBs and hES2 derived 
cardiomyocytes were cultured and dissociated as described in 3.2.2.12. Cell counts were 
determined with CASY TT system and the required cell number of hCFBs and hES2 derived 
cardiomyocytes were combined and centrifuged at 300 x g for 5 min at RT. Then, cells were 
resuspended in basal medium to achieve appropriate dilution as described by Tiburcy et al. 
[100]. A master mix of bovine collagen type I and concentrated culture medium (2x RPMI, pH 
adjusted to 7.4) was mixed on ice. Then, cell suspension and collagen master mix were carefully 
combined and mixed without air bubble formation. After distributing cell suspension/collagen 
master mix into custom-made circular moulds, mixture was transferred to humidified incubator 
at 37°C and 5% CO2 to consolidate for 1 h. After consolidation, 6 ml SFMM containing TGFβ1 
was added to each mould. Medium was replaced with fresh SFMM containing TGFβ1 the next 
day. On culture day three, EHMs were transferred to custom-made silicone dynamic stretchers 
and were cultured in SFMM medium without TGFβ1. During this phase, EHMs were treated 
with 3 µM Rock inhibitor. Medium was changed every second day and EHMs were cultured 
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for two weeks. After culture, EHM underwent isometric force measurements as described in 
Tiburcy et al. [100]. Then, EHMs were snap frozen and were processed for RNA isolation. 
3.2.3 Biochemical methods 
3.2.3.1 Protein isolation 
To isolate proteins from different cell components, cells are physical disrupted with the use of 
detergents. The cell components can then be separated by different densities using 
centrifugation. Total protein lysates were obtained from cells grown in 6-well or 12-well 
format. Cells were washed twice in PBS and were kept on ice. 300 µl Bäuerle lysis buffer, with 
supplemented proteinase and phosphatase inhibitors, was added to each well and the cells were 
scraped off the plate. Tissue samples were homogenized in 300 µl Bäuerle lysis buffer using a 
bead mill for 60 sec with 30 Hz. Lysates were transferred to cold tubes on ice and were triturated 
with a pipette tip and vortexed vigorously. After 15 min of incubation lysates were vortexed 
again and centrifuged for 15 min with 13000 rpm at 4°C. Supernatants containing proteins were 
transferred to new tubes and were stored at -20°C. 
3.2.3.2 Bradford protein quantification  
The Bradford protein assay is a spectroscopic analytical procedure used to measure the 
concentration of protein in a solution. This colorimetric method is based on an absorbance shift 
of the dye Coomassie Brilliant Blue G-250. Under acidic conditions the red form of the dye is 
converted into its blue complexing with the protein being assayed which leads to an absorbance 
shift from 470 nm to 595 nm. The increase of absorbance at 595 nm is proportional to the 
amount of protein. Using a standard curve with different known concentrations of bovine serum 
albumin (BSA), the concentration of protein can be calculated. The assay was performed in a 
96-well format with a total volume of 50 µl diluted sample or standard and 150 µl Bradford 
reagent (110 µl water plus 40 µl Bradford reagent). The standard curve was prepared in 
duplicates with water blank and five different BSA concentrations diluted from a BSA stock 
concentration of 1 mg/ml. The protein samples were prepared by diluting 2 µl sample in 48 µl 
water and were measured in triplicates. Absorbance was measured rapidly after reagent 
supplementation in a Multi-Mode Microplate Reader. 
3.2.3.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
To discriminate different proteins, denaturating SDS-PAGE was used. SDS disrupts non-
covalent bonds in the proteins, denatures them, and provides them with a negative charge. 
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Separation occurs via traveling of the negatively charged proteins to the positively charged 
electrode through the acrylamide gel mesh and are separated according to size (molecular 
weight in kilodaltons, kDa). Protein samples were prepared with similar protein concentration 
(20-50 µg) and were boiled at 95°C for 5 min in Laemmli-buffer. Samples were loaded on a 
12% polyacrylamide gel, which consisted of two parts; the stacking gel and the separation gel. 
Voltage was adjusted to 70 V for about 20 min, what led to migration and concentration of 
samples in the stacking gel. During entering the separation gel the voltage was adjusted to 
140 V for around 90-120 min until proteins were completely separated. A pre-stained protein 
marker was carried along with the samples. The ladder allows monitoring the progress of SDS-
polyacrylamide gel electrophoresis and is necessary to estimate the approximate size of 
separated proteins after Western blotting. Electrophoresis was stopped when loading buffer was 
passing through the gel. 
3.2.3.4 Western Blot assay 
To make proteins accessible for antibody detection, they must be transferred onto a membrane. 
In a wet environment (semi-dry-technique) negatively charged proteins move from the gel onto 
the hydrophobic polyvinylidene difluoride (PVDF) membrane while maintaining the 
organization they had within the gel. For blotting the PVDF membrane was activated in 
methanol for 30 seconds and was washed with water and with transfer buffer. For equilibration, 
the Whatman-papers and the polyacrylamide gel where soaked in transfer buffer for 2 min. The 
membrane and the gel were placed air bubble free in between six layers of Whatman-paper and 
the transfer was done with 140 mA for 50 min. The transfer was controlled with a reversible 
Ponceau S staining and membrane was cut when needed. All following washing and incubation 
steps were performed on a rocker. After removing Ponceau S with TBS-T buffer, the membrane 
was blocked for unspecific antibody binding with 5% milk powder resolved in TBS-T buffer 
for one hour at room temperature. Primary antibody was diluted in 5% milk/TBS-T and 
membrane was incubated overnight at 4°C. After three washing steps with TBS-T for 10 min 
each, the membrane was incubated for one hour at room temperature with the secondary, 
horseradish peroxidase (HRP) conjugated, antibody diluted in 5% milk/TBS-T. Following three 
washing steps with TBS-T for 10 min each, the membrane was shortly incubated with a 
luminol-based chemiluminescent substrate and a peroxide buffer in equal volumes. In the 
presence of hydrogen peroxide, HRP converts luminol to an excited intermediate dianion which 
emits light. This reaction was visualized with the VersaDocTM Imaging System and was 
evaluated with the ImageLab software. 
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Validation of a customized IGFBP5 antibody 
Since neither murine nor human IGFBP5 (neither endogenous nor an artificial overexpression) 
could be detected with commonly available antibodies (even when these were published), a 
customized IGFBP5 antibody was produced by Thermo Fisher Scientific. Amino acids 255-
272 (last 13 amino acids in IGFBP5 peptide) were chosen as antigen for antibody generation in 
rabbits, since these amino acids are not conserved within the IGFBP-family. Further these 
IGFBP5-amino acids are conserved among different species, aiming to detect IGFBP5 in 
different samples from different animals. To test the antibody in different samples from 
different antibody, an immunoblot was done. This blot shows two bands in all different species 
at ~35 kDa and 32 kDa. These two bands can be attributed to IGFBP5 with and without signal 
peptide. A third, larger band can be detected upon overexpression of IGFBP5 fused to a FLAG 
protein. 
 
 
Figure 3-1: Immunoblot for customized IGFBP5 antibody 
 
3.2.3.5 Chromatin immunoprecipitation (ChIP) and rapid immunoprecipitation of 
endogenous proteins (RIME) 
Two step cross-linking of cells 
Since IGFBP5 has no DNA binding motive it might act as a coactivator which is not directly 
associated to DNA. The conventional single-step crosslinking technique does not preserve all 
protein-DNA interactions, therefore a “two-step” XChIP method that involves sequential 
protein-protein fixation followed by protein-DNA fixation was used according to Nowak et al. 
2005. Briefly, cells were washed with PBS and fixed with 2 mM DSG in PBS/Mg/Ca for 
45 min. Subsequent DNA cross-linking was done using 1% formaldehyde in PBS with 
proteinase inhibitors for 15 min. Reaction was quenched with 125 mM glycine for 5 min and a 
subsequent PBS wash on a low speed shaker. Before nuclei isolation, cells were frozen at -
20°C.  
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Chromatin immunoprecipitation (ChIP) 
ChIP is used to investigate the interaction between proteins and DNA in the cell. It aims to 
determine whether specific proteins are associated with specific genomic regions, such as 
transcription factors on promoters or other DNA binding sites. Protein are cross-linked to its 
associated chromatin, then, the DNA-protein complexes are then sheared into DNA fragments 
by sonication. Cross-linked DNA fragments associated with the protein of interest are 
selectively immunoprecipitated using a specific antibody for the protein of interest. The 
associated DNA fragments are purified, and their sequence can be analysed. The precipitated 
chromatin is quantified via sequencing. All following steps until DNA isolation were performed 
on ice. 3 ml cold nuclear preparation buffer (all buffers were freshly supplemented with 
inhibitors; see material part 3.1.7) was added to a T75 flask and cells were scrapped. Lysate 
was distributed on two 1.5 ml tubes and was homogenized with gentle triturating. Then lysates 
were centrifuged with 12000 × g for 2 min at 4°C, supernatants were aspirated before adding 
700 µl of nuclear preparation buffer. Cell pellets were solubilised with gentle triturating and 
lysates from one flask were combined again. After centrifugation with 12000 × g for 2 min at 
4°C, supernatants were aspirated and 750 µl sonication buffer 1 and 750 µl sonication buffer 2 
were added. Cell pellets were solubilised with gentle triturating and incubation was done for 
10 min on ice. Every sample was split on three 1.5 ml TPX Diagenode tubes and sonication 
was done for 20 cycles. Then, the samples were centrifuged at 12.000 x g for 2 min at 4°C and 
supernatants were combined again in a 2 ml tube. For pre-clearing 200 µl sepharose beads (50% 
slurry in dilution buffer) were added and were incubated for 1 hour at 4°C on a rotating wheel. 
Samples were centrifuged at 2.000 x g for 5 min at 4°C. A total of 1300 µl supernatant was 
used for IP, whereas 130 µl (10%) of supernatants were stored as inputs at -20°C. For 
precipitation, supernatants were supplemented with 650 µl IP buffer and 2 µg FLAG-antibody. 
Precipitation was done overnight at 4°C on a rotating wheel. On the next day, 60 µl protein A-
sepharose was added to each sample and was incubated for 2 hours at 4°C on a rotating wheel. 
After centrifugation at 12.000 x g for 2 min at 4°C the ChIP immune complexes were washed 
twice with 800 µl ice cold IP buffer (inhibitors were not necessary), twice with ice cold ChIP 
wash buffer, again twice with ice cold IP buffer and last, twice with ice cold TE buffer. For 
each washing step tubes were inverted several times and were centrifuged at 2.000 x g for 2 min 
at 4°C. Supernatant was completely removed and 150 µl Elution Buffer was added and 
incubated at 65°C for 30 min with vigorous shaking. The input samples were thawed and 150 µl 
Elution Buffer was added. The inputs samples were left at room temperature till DNA isolation. 
The samples were transferred to new tubes and 6 µl sodium chloride solution (5 M) and 2 µl 
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Proteinase K (20 mg/ml) was added to samples and to inputs. After an incubation time of 
90 min at 65°C, the DNA was isolated form samples and inputs using the "Macherey-Nagel 
“PCR clean-up kit” with buffer NTB (for samples with more than 0.1% SDS). Then, the 
extracted chromatin was analysed by sequencing. 
Rapid immunoprecipitation of endogenous proteins (RIME) 
Instead of purifying the precipitated DNA fragments, the cross-linked proteins including 
associated proteins can be analysed via Western blot assay. For this, beats with ChIP immune 
complexes were incubated with 40 μl of 4× Laemmli buffer for 10 min at 95°C with 700 rpm. 
After cooling, eluate was centrifuged at 2000 × g for 5 min and eluate was collected and directly 
used for Western blotting.  
ChIP sequencing 
ChIP sequencing was performed at the Transcriptome and Genome Analysis Laboratory (TAL, 
University Medical Center, Goettingen), in biological triplicates. ChIPseq library preparation 
was performed using the "TruSeq ChIP Library Preparation Kit - Set A from Illumina as per 
manual’s instructions. DNA libraries were amplified and sequenced by using the cBot and 
iSeq2500 from Illumina (25–30 million reads per sample). Since there was a high background 
and low signal throughout, relevant regions had to be manually identified. Published/public 
ChIPseq datasets for H3K4me3 ChIP from hCFBs were used from: 
https://www.encodeproject.org/experiments/ENCSR000DTE/. 
3.2.3.6 Dual-Luciferase reporter gene (DLR™) assay 
Genomic regions which showed a peak in IGFBP5 ChIP were amplified and cloned upstream 
the firefly luciferase reporter gene in NheI and HindIII digested pGL4.10 vector (Promega). In 
this assay, reporter expression indicates promoter activity. The activities of firefly (Photinus 
pyralis) and Renilla (Renilla reniformis) luciferases are measured sequentially from a single 
sample. The term “dual reporter” refers to the simultaneous expression and measurement of 
these two individual reporter enzymes within a single system. Typically, the “experimental” 
reporter (firefly luciferase) is correlated with the effect of specific experimental conditions, 
while the activity of the co-transfected “control” reporter (Renilla luciferase) provides an 
internal control that serves as the baseline response used for normalizing. TSA201 cells were 
transfected with either pGL4.10-empty vector, pGL4.10-hIGFBP5-ChIP-promoter or 
pGL4.10-hTNNT2-ChIP-promoter. Co-transfection was done with pExp-hNKX2.5 or 
pcDNA3.1-hIGFBP5. Empty plasmids were used for adjustment of equal DNA content per 
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transfection. Transfection mixture was prepared in DMEM without supplements and TurboFect 
transfection reagent in a ratio 1:2 for DNA amount:TurboFect reagent. After 48 h, cells were 
washed with PBS and were passively lysed by adding 100 µl Passive Lysis Buffer and rocking 
with 400 rpm for 15 min. Lysates were then transferred to tubes placed on ice, were vortexed 
vigorously and centrifuged. For the Dual-Luciferase reporter gene (DLR) assay 20 µl of each 
lysate sample was pipetted in triplicates in a 96-well plate. The firefly and Renilla luciferase 
reporter were sequentially detected in the GloMax-96 Microplate Luminometer (Promega) with 
reagent auto-injectors. Luciferase activity was normalized to Renilla luciferase activity and 
expressed as fold change against the empty vector pGL4.10. Every experiment was done in 
technical and biological triplicates. 
3.2.4 Immunochemistry 
3.2.4.1 Immunofluorescence staining 
Immunohistochemistry (IHC) or Immunocytochemistry (ICC) are used to detect antigens, for 
example distinct proteins, in living or fixed cells and in tissue sections by maintaining the 
morphology. To detect the proteins of interest, antibodies-, against specific antigens on these 
proteins are used. Visualising an antibody-antigen interaction is accomplished for example by 
a fluorophore-conjugated secondary antibody. For IF staining, cells were washed with PBS and 
were fixed with 4% paraformaldehyde for 20 min. After three-times rinsing with PBS cells 
were permeabilized with buffer A for 10 min and were rinsed once for 5 min with PBS. Then, 
coverslips were incubated with blocking buffer B for 60 min or kept in buffer B at 4°C until 
staining. The primary antibody or and a corresponding IgG antibody was diluted 1:200 in 
buffer C. In a dark humid chamber, coverslips were placed upside down on a 30 µl droplet of 
antibody solution and were incubated overnight at 4°C. Coverslips were placed in a 12-well 
plate again and were carefully rinsed three times with PBS. The secondary fluorophore-
conjugated antibody was diluted 1:200 in buffer C and coverslips were placed upside down on 
a 30 µl droplet of antibody solution. Incubation was done for 60 min at room temperature in a 
dark humid chamber. Again, coverslips were placed in a 12-well plate and were carefully rinsed 
three times with PBS. Hoechst 33342 dye (1 mg/ml) was diluted 1:1000 in buffer C and nucleus 
staining was done by incubation with of 500 µl of Hoechst 33342 solution on each cover slip 
for 5 min at room temperature. Then, cover slips were rinsed with PBS and consecutive PBS 
dilutions with distilled water to prevent crystallisation of PBS on cover slips. For embedding, 
coverslips were placed upside down on a 20 µl droplet of SlowFade Gold antifade reagent. 
Stained cells were examined with a confocal laser scanning microscope. 
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3.2.4.2 Flow cytometry 
(Experiment was done by Dr. Farah Raad, Pharmacology and Toxicology, UMG Goettingen). 
Dissociated and with 4% PFA fixed hES cells were washed with PBS. After centrifugation for 
4 min with 300 x g at 4°C, cells were resuspended in PBS and were kept at 4°C until flow 
cytometry. Pellets from dissociated hES derived cardiomyocytes were fixed with 1 ml ice cold 
70% ethanol and stored for maximum one week at 4°C. For flow cytometry, fixed cells were 
centrifuged for 4 min with 300 x g at 4°C and were resuspended in blocking buffer (PBS 
supplemented with 5% FBS, 1% bovine serum albumin, 0.5 % Triton X-100 and sodium azide; 
used for internal markers) or 5% FBS in PBS (for cell surface markers) and permeabilized for 
10 min at 4°C. Then cells were filtered using a cell strainer (40 μm). Samples were incubated 
for 45 min at 4°C with primary antibodies (see 3.1.11), followed by two washing steps with 
blocking buffer prior to incubation with secondary antibodies in blocking buffer. Nuclei 
staining with Hoechst 33342 was done for 30 min at 4°C. Samples were then again washed with 
blocking buffer and resuspended in PBS for analysis with a BD LSRII flow cytometer (BS 
Biosystems). Viable cells were first gated based on Hoechst staining. Single cells were gated 
based on forward scatter signal, IgG controls were used to determine non-specific staining. BD 
FACSDiva Software (version 6.1.3, BD Biosciences) was used for analysis. 
3.2.4.3 Enzyme-linked immunosorbent assay (ELISA) 
ELISA (enzyme-linked immunosorbent assay) is a plate-based assay used to detect and quantify 
soluble antigens like e.g. on proteins. Here, a direct sandwich ELISA assay was used, where 
the capture antibody is immobilized on the solid surface of the plate. After incubation with the 
soluble antigen (protein), the formed complexed is detected with an antibody that is linked to 
an enzyme. Detection is accomplished by assessing the conjugated enzyme activity via 
incubation with a substrate to produce a measurable product. Samples were generated as the 
following: Mouse serum was purified from whole blood directly collected from mouse hearts. 
Blood was centrifuged for 10 min with 2000 x g at 4°C to separate serum from blood cells. Cell 
supernatants from cell culture were filtered using a 45 µm filter to remove cells and debris. All 
samples were snap frozen and stored at -80°C. Prior to assay procedure, samples were thawed 
on ice. Mouse serum was diluted 1:200 and cell supernatant was diluted 1:10 with provided 
dilution buffer. All steps were done according to the manufacturer’s instructions. Shortly, 
100 µl of diluted samples and prepared standards were applied on ELISA plate and were 
incubated overnight at 4°C with gentle shaking. On the next day, samples were aspirated, and 
plate was washed 4 times with provided washing buffer. Then, 100 µl of prepared detection 
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antibody was applied and incubated for 1 h at RT with gentle shaking. Solution was discarded 
and washing steps were repeated. Then, 100 µl of prepared Streptavidin solution was applied 
and incubated for 45 min at RT with gentle shaking. Solution was discarded and washing steps 
were repeated. After aspirating the remaining solution, 100 ml of TMB substrate was applied 
and incubated for 30 min at RT with gentle shaking. Reaction was stopped with 50 µl stopping 
solution and absorbance was read at 450 nm immediately in a Multi-Mode Microplate Reader. 
Protein quantities were calculated using the standard curve with known protein concentrations.  
3.2.5 Animal work 
3.2.5.1 Induction of cardiac specific Wnt gain of function and loss of function  
Inducible, cardiac specific β-catenin gain of function (β-cateninΔex3) as well as loss of function 
(β-cateninΔex2-6) was achieved by mating αMHC-merCremer mice with either β-cateninfloxed-ex3 
and  β-cateninfloxed-ex2-6 (Jackson Lab). Heart-specific expression of the Cre recombinase under 
control of the αMHC promoter was activated by administration of Tamoxifen (T5648, 30 mg/kg 
body weight/day) i.p. for 3 days in 12-20 weeks old mice. Excision of loxP-flanked exon 3 of 
the β-catenin coding region in αMHC-merCremer/β-cateninfloxed-ex3 resulted in a non-
degradable mutant of β-catenin and in αMHC-merCremer/β-cateninfloxed-ex2-6 in non-functional 
β-catenin. Littermates WT at β-catenin locus and positive for Cre recombinase were used as 
control as well as WT without Cre recombinase expression. 
3.2.5.2 Murine model of Ang-II induced cardiac hypertrophy 
Angiotensin II (Ang II) is known as an important hormonal mediator of cardiac hypertrophy 
and fibrosis [104] and is commonly used in in vivo experiments. For induction of cardiac 
hypertrophy, micro-osmotic pumps (model 1002, Alzet) releasing Ang II or sodium chloride 
solution as a control (Sigma; 1.4µg x kg-1 x min-1, solvent 0.9% NaCl/0.01 N acetic acid) were 
implanted subcutaneously in 12-weeks old BL/6J mice after anaesthesia with 
ketamine/xylazine (30 mg/10 mg x kg-1 intraperitoneal). Development of hypertrophy was 
assessed by echocardiography two weeks after minipump implantation. Experiment was 
performed in two different set-ups. First, two weeks after minipump implantation and second, 
4 weeks after implantation, while Ang II infusion was expected to be depleted already two 
weeks after minipump implantation. 
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3.2.5.3 Transverse aortic constriction model  
Transverse aortic constriction (TAC) in mice is an experimental model for pressure overload-
induced cardiac hypertrophy and HF. Surgery was done in 12 weeks-old mice. The intervention 
was performed by tying a non-absorbable braided 5-0 polyviolene suture ligature around the 
aorta and a blunted 26-gauge needle and subsequent removal of the needle. For sham controls 
the suture was not tied. TAC was confirmed by echocardiography and measurement of blood 
flow gradient. To determine the level of pressure overload by aortic ligation, a high frequency 
Doppler probe was used to measure the ratio between blood flow velocities in right and left 
carotid arteries. Heart function was analysed by echocardiography. All these procedures were 
performed by the SFB 1002 service unit (S01 Disease Models). The observer was unaware. All 
animal experiments were approved by the Niedersachsen (AZ-G 15-1840) animal review board. 
3.2.5.4 AAV9 mediated gene transfer 
To overexpress FLAG tagged Igfbp5 in the heart, AAV serotype 9 (AAV9) was used, which 
exhibits the highest cardiac tropism in mice resulting in a homogeneous long-term transfer of 
intact cDNA throughout the heart [105]. A murine Igfbp5-FLAG-fragment was generated using 
a validated overexpression vector (pcDNA-Igfbp5-FLAG) as a template. The overexpression 
construct was inserted with NheI/XbaI into a self-complementary AAV vector genome plasmid, 
derived from pdsCMV-MLC0.26-EGFP, under control of the human troponin T promoter 
(hTNNT2) [106], resulting in pds-hTNNT2-msIgfbp5-FLAG. AAV9 particle production for 
expression of Igfbp5 or luciferase (LUC control) was done by the laboratory of Prof. O. Mueller 
(Klinik für Innere Medizin III, UKSH, Kiel). Shortly, vectors were generated by co-transfection 
of pds-hTNNT2-msIgfbp5-FLAG or pds-hTNNT2-LUC together with pDP9rs, a derivate from 
pDP2rs with the AAV9 cap gene from p5E18-VD2–9, in HEK293T cells using 
polyethylenimine AAV was purified and titrated. 12-week old BL/6J mice received a systemic 
single dose of 2 x 1012 AAV9 vectors by intravenous injection via the tail vein under 
anaesthesia using 2.4% isoflurane inhalation. Echocardiography was done pre-injection and 
was repeated after six-, ten and 18 weeks post-injection. Then mice were sacrificed for 
characterization. 
AAV9 particle test 
In a previous experiment (not part of this study), a cardiac specific downregulation of Igfbp5 
was achieved using the same approach as described above. Instead of an overexpression 
construct, a shRNAmir construct was used to target murine Igfbp5 while a non-silencing 
shRNAmir served as a control. qPCR analysis of heart-, liver-, and spleen tissue revealed a 
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downregulation of Igfbp5 in the heart but not in the liver or the spleen, confirming the cardiac 
tropism of these particles. 
 
 
Figure 3-2: AAV9 particles test in different organs 
 
3.2.5.5 Echocardiography 
For echocardiography mice were anesthetized by 2.4% isoflurane inhalation and ventricular 
measurements were done with a VisualSonics Vevo 2100 Imaging System equipped with a 
MS400, 30MHz MicroScan transducer. The observer was unaware of the genotypes and 
treatments.  
3.2.6 Statistical analysis 
Differences between experimental groups were analysed using the two-tailed Student’s t-test. 
Data is presented as mean ±SEM. p<0.05 values were considered significant. For RNA-
sequencing analyses, adjusted p-value of ≤0.05 was considered for statistical significance 
respectively.  
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4 Results 
4.1 IGFBP5 is upregulated during the transition to heart failure 
4.1.1 Igfbp5 is upregulated upon murine heart failure 
Previous experiments indicated an association between increased Igfbp5 expression in murine 
failing hearts upon induced cardiac specific Wnt/β-catenin activation. So far, no evidence was 
provided that the upregulation of Igfbp5 in these mice was Wnt/β-catenin-dependent. Therefore, 
the expression of Igfbp5 was analysed in a cardiac disease model leading to HF. Transversal 
aortic constriction (TAC) pressure overload-induced cardiac hypertrophy and failure is a well-
established experimental mouse model for mimicking cardiac disease. In preliminary work, 
Igfbp5 was found significantly upregulated in mice upon TAC operation when compared to 
sham operated mice (see Figure 2-3, n=8/12, P<0.05). In this study the expression dynamics of 
Igfbp5 during the progression to HF was investigated. Murine hearts were analysed at different 
time points after TAC surgery, namely three days, one week, two weeks and eight weeks post-
TAC operation (scheme in Figure 4-1A). This analysis showed no significant changes in Igfbp5 
expression during the early stage of hypertrophic remodelling (three days post-TAC). A 
significant upregulation of Igfbp5 was observed eight weeks post-TAC when compared to sham 
operated mice (Figure 4-1B, n=6/8 per group, P<0.05), while HF was indicated by 
echocardiographic analysis of cardiac function (Figure 4-1D-E, n=6/8 per group, P<0.05; 
P<0.01). Measurement of anterior wall thickness (AWThd) showed a significant increase in 
wall diameter starting one week post-TAC, indicating hypertrophic remodelling (Figure 4-1C, 
n= 24/38 per group, P<0.01; P<0.001). Concomitant with the upregulation of Igfbp5 eight 
weeks post-TAC, fractional area shortening (FAS) and ejection fraction (EF), indicators for HF, 
were significantly reduced when compared to sham controls (Figure 4-1D-E, n=6/8 per group, 
P<0.05; P<0.01). Since both IGFBP7 and IGFBP3 are described in the context of 
cardiovascular disease [107–109], the expression of one of these IGFBP family members was 
investigated. Studying Igfbp3 expression during early hypertrophic response and upon HF, its 
expression was examined three days and eight weeks post-TAC as described before. No 
difference in Igfbp3 expression was observed in TAC mice in comparison to sham mice, neither 
three days (Figure 4-2A, n=7 per group) nor eight weeks post-TAC (Figure 4-2B, n=6/7 per 
group). 
This data suggests a role for IGFBP5 during the transition to HF but not during early 
hypertrophic remodelling. 
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4.1.2 Igfbp5 expression is normalized upon preserved cardiac function post-TAC 
To investigate whether the upregulation of Igfbp5 is directly linked to the transition state to HF, 
a TAC rescue experiment was studied. Wnt-transcriptional activation is known to drive 
hypertrophic remodelling and HF. Consequently, blocking cardiac Wnt-transcriptional 
activation in mice subjected to Ang II and upon TAC has beneficial effects, as previously shown 
[92, 93]. Cardiac Wnt-transcriptional repression is achieved by inducible, cardiomyocyte 
specific β-catenin loss of function (β-Cat LOF). β-Cat LOF and control mice which underwent 
TAC and sham surgery were analysed (scheme of experimental set up in Figure 4-3A). 
Echocardiographic analysis post-TAC showed a significant decrease in ejection fraction (EF) 
in non-transgenic TAC mice when compared to non-transgenic sham mice. In contrast, EF was 
preserved in TAC mice with cardiac β-Cat LOF in comparison to transgenic and non-transgenic 
sham mice (Figure 4-3B, n(CT)=3/5 per group and n(β-Cat LOF)=3/6 per group). As expected, 
the molecular hypertrophy marker natriuretic peptide B (Nppb) was significantly upregulated 
upon TAC in comparison to sham operated mice, while this elevation was attenuated in β-
Cat LOF hearts when compared to sham mice. (Figure 4-3C, n(CT)=8/5 per group and n(β-
Cat LOF)=12/8 per group, P<0.01). Regarding Igfbp5 expression, transcript levels were 
significant upregulated in non-transgenic TAC mice in comparison to sham operated mice, 
confirming previous results (Figure 4-3D, n(CT)=8/5 per group, P<0.05). In contrast, there was 
no significantly elevated Igfbp5 expression comparing sham and TAC operated β-Cat LOF 
mice, which showed preserved function post-TAC (Figure 4-3D, n(β-Cat LOF)=13/8 per 
group).  
Collectively these data confirm that regulation of Igfbp5 is directly linked to the disease state 
of the heart and is only upregulated during HF progression. 
4.1.3 IGFBP5 is upregulated in human heart failure with a concomitant downregulation 
of IGFBP5 targeting microRNAs 
IGFBP5 is the most evolutionary conserved of all IGFBPs and is more than 97% identical 
among human, mouse and rat [110]. To investigate whether it is also regulated upon HF in 
human, RNA sequencing data from ventricle samples from human aortic stenosis patients were 
used to analyse IGFBP5 expression (Dr. Sarah Khadjeh, Department of Cardiology and 
Pneumology, UMG). There was no significant IGFBP5 regulation in patients with preserved 
ejection fraction (ejection fractions >55%) in comparison to ventricular samples from non-
failing control patients, even when a trend could be observed. In contrast, IGFBP5 expression 
was significantly upregulated in samples from patients with HF (ejection fractions <55%) in 
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comparison to ventricular samples from non-failing control patients. (Figure 4-4A, 
n=NF 4/CH 5/HF 5, cut off >100% change in expression, adjusted p-value P<0.05). 
Concomitant with the increasing IGFBP5 transcript abundance in diseased ventricles, mir146b-
5p and mir139-5p, two microRNAs predicted to target the IGFBP5 transcript, are gradually 
downregulated in aortic stenosis patients (Figure 4-4B, n=4). RNA sequencing data showed in 
total 650 genes upregulated from non-failing control samples to HF, while only 95 genes 
showed a dynamic increase in expression from non-failing control-, to compensated 
hypertrophy-, to HF (Figure 4-4C). In line with this, RNA sequencing data from mice, one week 
and eight weeks post-TAC (data from Dr. Sarah Khadjeh, Department of Cardiology and 
Pneumology, UMG) showed a similar result. From a total of 114 genes upregulated from sham 
hearts- to failing hearts (eight weeks post-TAC), only 64 genes showed a dynamic increase in 
expression from sham hearts to compensated hyperopic hearts (one weeks post-TAC) to failing 
hearts (eight weeks post-TAC). Only 14 of these dynamically upregulated genes were found 
conserved between mice and humans, including IGFBP5. 
These data collectively confirm a conserved upregulation of IGFBP5 during the transition to 
HF in mice and in humans.  
4.1.4 Intracellular protein levels of IGFBP5 are not altered in the diseased heart 
To confirm results obtained from mRNA analysis, IGFBP5 protein expression in failing hearts 
from mice and humans was validated. Immunoblot analysis of murine failing hearts post-TAC 
did not show any difference between the TAC and sham group (Figure 4-5A, n=6/8 per group, 
blot was done twice). To investigate IGFBP5 protein expression in human HF, protein 
quantification was done in left ventricular heart tissue samples from patients with dilated 
cardiac myopathy (DCM). There was no consistent difference between patient tissue and tissue 
from human control heart samples detectable as shown in Figure 4-5B (n=3/10 per group, blot 
was done twice). 
Collectively these data show that an increased IGFBP5 transcript abundance is not represented 
on intracellular protein levels. 
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Figure 4-1: Expression dynamics of Igfbp5 upon transverse aortic constriction (TAC) 
(A) Timeline of performed TAC operations and echocardiographic analysis. (B) qPCR data shows mRNA expression of 
Igfbp5. Data is normalized to Tbp (TATA-binding protein). n=7/8 per group. (C) Echocardiographic analysis showing 
change in anterior wall thickness during diastole in mm [AWThd], (D) fractional area shortening in % [FAS], and (E) 
ejection fraction[ EF] in %. Animal number for echocardiographic analysis are n(pre-echo)=24/40 per group, n(1 week)= 
24/38 per group, n(2 weeks)=18/27 per group, n(8 weeks)=6/8 per group. Data are mean ± SEM; t-test, * P<0.05; ** 
P<0.01, *** P<0.001. 
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Figure 4-2: Igfbp3 expression is not changed in the diseased murine heart 
(A) Igfbp3 expression 3 days and (B) 8 weeks post-TAC. n(A)=7 per group, n(B)=6/7 per group. Tbp (TATA-binding 
protein) was used for normalization. 
 
 
 
 
Figure 4-3: Igfbp5 expression upon preserved cardiac function post-TAC  
(A) Scheme of TAC rescue experiment using mice with inducible cardiomyocyte specific β-catenin depletion [β-Cat 
LOF]. TX=tamoxifen. (B) Cardiac function depicted by ejection fraction [EF] in % comparing control mice with 
transgenic mice upon TAC and sham operation. n(CT)=3/5 per group and n(β-Cat LOF)=3/6 per group. (C) Nppb and 
(D) Igfbp5 expression in TAC versus sham operated control mice and in mice with β-Cat LOF. Data is normalized to 
Tbp (TATA-binding protein). n(CT)=8/5 per group and n(β-Cat LOF)=12/8 per group. n(CT)=6/3 per group and n(β-
Cat LOF)=13/7 per group. Data mean ±SD; t-test, (ns) not significant, * P<0.05, ** P<0.01. 
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Figure 4-4: hIGFBP5 expression and expression of hIGFBP5 targeting microRNAs in aortic stenosis patients 
(A) Analysis of transcriptome of non-failing control patients [CT], compensated hypertrophy (ejection fractions >55%) 
[CH] and heart failure (ejection fractions <55%) [HF] patients. n=4/5/5 per group. Cut off >100% change in expression, 
adjusted p-value * P<0.05. (B) hIGFBP5 and hIGFBP5-targeting microRNA expression (miR146b-5p [light grey], 
miR139-5p [dark grey]) in aortic stenosis patients. (C) Expression of genes found increasingly upregulated from non-
failing to compensated hypertrophy, to heart failure in mice and humans depicted in outer intersects. Middle intersect 
shows conserved increasingly upregulated genes. (Data provided by Dr. Sara Khadjeh, Department of Cardiology and 
Pneumology, UMG, Khadjeh et al., unpublished). 
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Figure 4-5:Validation of IGFBP5 protein expression in the diseased murine and human heart 
(A) Immunoblot analysis from murine hearts upon experimental heart failure (TAC versus sham operated) showing 
hIGFBP5 protein. n=6/8 per group. (B) Immunoblot analysis from patients with dilated cardiomyopathy [DCM] versus 
non-failing control hearts [NF] showing hIGFBP5 protein. n=3/10 per group. Tpt1 (Translationally-controlled tumor 
protein 1), and Ponceau-S staining were used as loading controls, L=ladder, blots are done twice. 
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4.2 Cardiac overexpression of Igfbp5 alters function and gene expression in 
the murine heart 
To investigate the direct effect of IGFBP5 on the murine heart in vivo, an adeno‐associated viral 
(AAV) vector mediated approach was used (see experimental setup Figure 4-6B). AAV9 
mediated gene transfer is a robust approach for cardiomyocyte specific OE of a gene of interest. 
Serotype 9 AAVs process high cardiac tropism and only show little genome distribution in other 
tissues [105]. To further achieve cardiomyocyte specificity, the GOI was expressed under the 
control of the human cardiac troponin T promoter. For this experimental setup, a C-terminal 
FLAG tagged murine Igfbp5 overexpression (IBP5 OE, representing the Igfbp5 cDNA), 
construct and a corresponding luciferase control (Luc CT) construct were cloned in a pSSV9 
vector (see scheme in Figure 4-6A) and were used for AAV9 particle production (done by the 
laboratory of Prof. O. Mueller, Klinik für Innere Medizin III, UKSH, Kiel). With an age of 
16 weeks mice underwent baseline echocardiography to determine cardiac functionality. Mice 
were divided in two treatment groups (IBP5 OE or Luc CT) and received a single dose of 
2 x 1012 AAV9 particles via tail vein injection. Echocardiography was repeated after six-, ten 
and 18 weeks post-injection and mice were subsequently sacrificed for characterization.  
To verify the expression of the artificial IBP5 OE in the murine heart, qPCR validation was 
done using a primer covering the artificial FLAG sequence. This analysis showed a qPCR 
product amplification in samples from mice with IBP5 OE, whereas there was no qPCR product 
in hearts from Luc CT mice (Figure 4-6CD, n(gel)=9/7 per group, n(qPCR)=9 per group, 
P<0.01). Further, analysis of total Igfbp5 expression (endogenous Igfbp5 plus artificial 
IBP5 OE) showed a significant upregulation in IBP5 OE mice in comparison to Luc CT mouse 
heart samples (Figure 4-6E, n=9 per group, P<0.001). To confirm the IBP5 OE on protein level, 
heart lysates were investigated via immunoblotting and FLAG detection. FLAG detection 
showed several unspecific bands, but no band at 37 kDa, where the tagged IGFBP5 protein was 
expected (Figure 4-6F, arrow, n=4/9 per group). Since IGFBP5-FLAG shows a separate and 
lager band (~37 kDa) than the endogenous IGFBP5 (35 kDa and 33 kDa), detection was also 
done with a customized IGFBP5 antibody, to detect all variants. There was neither an additional 
IGFBP5-FLAG band at 37 kDa nor an increased protein abundance at 35 kDa for the 
endogenous IGFBP5 in IBP5 OE heart samples detectable.  
Comparing RNA sequencing (RNAseq) data from Luc CT and IBP5 OE heart samples with 
heart samples from mice which did not receive virus particles (termed Wt), revealed a strong 
AAV9-mediated effect on gene expression (Figure 4-7AB, see intersects of regulated genes). 
RESULTS  62 
Gene ontology analysis of AAV9-mediated gene regulation clustered the upregulated genes 
into regulation of transport, signalling, apoptotic signalling pathways and regulation of cell 
growth, while downregulated genes included cellular response to stress, cell cycle and 
chromatin organization. Gene ontology analysis of IGFBP5 mediated gene regulation clustered 
the downregulated genes into ECM organization, tissue morphogenesis, cell junction 
organization and heart contraction, while the upregulated genes are clustered in carboxylic acid 
metabolic process, oxidation-reduction process and lipid metabolic process (Figure 4-7C). 
Interestingly, gene associated with the diseased heart are upregulated in Luc CT mice when 
compared to non-treated mice (Figure 4-7C). Echocardiographic analysis of Wt mice which did 
not receive AAV9 particles, as well as Luc CT AAV9 and IBP5 OE AAV9 receiving mice 
18 weeks post-virus administration was done. Analysis showed a significant smaller left 
ventricular inner diameter during systole (LVIDS) as well as a reduced end systolic volume 
(Volsys) in IBP5 OE mice when compared to age-matched non-treated Wt mice and the Luc CT 
mice (Figure 4-8AB, n(Wt)=3, n(Luc CT)=6, n(IBP5 OE)=5 mice per group, P<0.05, P<0.01). 
Heart- to body weight ratio was significantly reduced in mice which received IBP5 OE AAVs 
in comparison to mice which received the Luc CT AAVs, but did not reach statistical 
significance in comparison to the Wt mice (Figure 4-8C, n(Wt)=3, n(Luc CT)=6, n(IBP5 OE)=5 
mice per group, P<0.05, P<0.01). Next, transcript expression of the cytoskeletal genes Myh7 
and cardiac troponin T (Tnnt2) were analysed and showed a significant downregulation in 
IBP5 OE mice when compared to Luc CT mice (Figure 4-8DE, n=9/6 per group, P<0.05; 
P<0.01). Further, the developmental genes myocardin (Myocd), Nkx2.5 and myocyte-specific 
enhancer factor 2C (Mef2c) were significantly downregulated in IBP5 OE mice when compared 
to Luc CT mice (Figure 4-8F-H, n=9/6 per group, P<0.05). Since a direct effect of the Luc CT 
construct on the heart cannot be exclude, an additional control will be used to further validate 
this study 
Taken together, these data indicate that IBP5 OE in vivo seems to affect cardiac physiology and 
gene expression, independent from an AAV9-mediated effect on gene expression. 
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Figure 4-6: Validation of AAV9 mediated expression of Igfbp5 in murine hearts in vivo 
(A) Scheme of Igfbp5 expression-construct in AAV particles. (B) Timeline of AAV9 mediated gene transfer in vivo. (C, 
D) cDNA genotyping of artificial Igfbp5-FLAG expression from heart samples 18 weeks post virus application (with 
scheme of used primers) and (E) qPCR analysis of total Igfbp5 expression. Gapdh is used for normalization in (C) and 
(E). n(C, E)=9 per group, n(D)=9/7 per group. (F) Immunoblot analysis of heart/cardiomyocyte specific FLAG-tagged 
IGFBP5 overexpression in murine hearts. Tumor protein translationally-controlled 1 [TPT1] and Ponceau-S staining 
were used as loading controls. Arrows indicate where tagged protein should appear. n=4/9 per group. Data are mean ± 
SEM; t-test, ** P<0.01; *** P<0.001. 
  
RESULTS  64 
 
 
Figure 4-7: RNA sequencing results of murine hearts with AAV9 mediated Igfbp5 overexpression 
RNA sequencing analysis showing (A) upregulated and (B) downregulated genes in Luc control virus- [Luc CT] and 
Igfbp5 overexpression [IBP5 OE] virus treated mice in comparison to non-treated mice [Wt]. Intersect shows AAV9 
mediated gene expression. Gene ontology analysis of AAV9-mediated and IGFBP5 mediated gene regulation shows 
clustering of genes to processes. (C) Heatmap depicting raw Z-scores of RPKMs of regulated genes involved in 
hypertrophy, immune response, extra cellular matrix, conduction/cell communication, lipid metabolism and 
mitochondria turnover. 
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Figure 4-8: Analysis of murine hearts with AAV9 mediated Igfbp5 overexpression 
Echocardiographic analyses of Luc control virus [Luc CT] and Igfbp5 overexpression [IBP5 OE] virus treated mice in 
comparison to non-treated mice [Wt]. (A) Left ventricular inner diameter during systole [LVIDS], (B) end systolic 
volume [Volsys] and (C) heart- to body weight ratio 18 weeks post AAV9 administration. n(A-C)=3/6/5 mice per group. 
(D-H) qPCR analysis of Igfbp5 overexpression (IBP5 OE) hearts in comparison to Luc control [Luc CT] hearts. (D) 
myosin heavy chain beta [Myh7], (E) cardiac troponin T [Tnnt2], (F) myocardin [Myocd], (G) Nkx2.5 and (H) myocyte-
specific enhancer factor 2C [Mef2c] expression. n(D-H)=6-9 hearts per group. Data are mean ± SEM; t-test, * P<0.05; 
** P<0.01. 
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4.3 IGFBP5 originates from cardiomyocytes of the diseased murine heart 
and can be detected in blood serum 
To investigate which cell population in the diseased murine heart is responsible for the 
upregulation of Igfbp5, cardiomyocyte and non-myocyte cell populations were examined upon 
TAC-induced HF. Mice underwent TAC and sham operation and cell populations were isolated 
using the Langendorff perfusion technique (see scheme for sample utilization in Figure 4-9A). 
qPCR analysis of the non-myocyte population showed no difference in Igfbp5 expression 
comparing TAC and sham-derived non-myocytes (Figure 4-9B, n=4 mice/isolations per group). 
In contrast, a significant upregulation of Igfbp5 expression could be observed in the 
cardiomyocyte population comparing TAC with sham-derived cardiomyocytes (Figure 4-9C, 
n=5 mice/isolations per group, P<0.05). Further, the hypertrophy marker Nppb showed a 
significant upregulation in cardiomyocyte isolated from TAC hearts, when compared to 
cardiomyocytes from sham hearts (Figure 4-9D, n=5 mice/isolations per group, P<0.05). 
Moreover, Langendorff isolated cell populations from hearts with cardiomyocyte specific β-
catenin gain of function (β-Cat GOF), which developed HF, showed a comparable result. 
Expression analysis of the non-myocyte population showed no difference in Igfbp5 expression 
comparing control and β-Cat GOF heart-derived non-myocytes (Figure 4-9E, n=5 
mice/isolations per group). In contrast, Igfbp5 expression was significantly upregulated in 
cardiomyocytes with β-Cat GOF in comparison to cardiomyocytes from control hearts (Figure 
4-9F, n=5 mice/isolations per group, P<0.0001). Since the expression of Igfbp5 was very strong 
in cardiomyocyte with β-Cat GOF, protein quantification was done. There was no difference 
between β-Cat GOF and control cardiomyocytes detectable (Figure 4-10A, n=6/8 per group, 
blot was done twice). IF staining from isolated β-Cat GOF cardiomyocytes further confirmed 
these results. No difference in IGFBP5 staining intensity could be observed comparing IF 
staining from β-Cat GOF cardiomyocytes to control cardiomyocytes (Figure 4-10B, one 
representative picture/group). Since IGFBPs have secretory signal peptides and are mainly 
found extracellularly [111], it was hypothesized that increased protein quantities are 
immediately secreted. To test this hypothesis, control and β-Cat GOF cardiomyocytes were 
isolated and cultured for 24 hours. Secreted IGFBP5 in cell supernatant was quantified using 
ELISA assay. This analysis revealed a significant increase in IGFBP5 protein abundance in cell 
supernatants from β-Cat GOF cardiomyocytes in comparison to supernatants from control 
cardiomyocytes (Figure 4-10C, n=4 isolations, P<0.0001). To investigate whether secreted 
IGFBP5 from diseased cardiomyocytes might enter the circulation and is also detectable in 
blood serum, ELISA protein detection of IGFBP5 was done (see scheme of sample origin, 
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Figure 4-10A). Serum IGFBP5 quantities from TAC mice and from mice with cardiac β-
Cat GOF were compared to serum from control mice. This analysis showed a significant 
increase of serum IGFBP5 in mice post-TAC and in mice with β-Cat GOF in comparison to 
control mice (Figure 4-10D, n(CT/TAC/ β-Cat GOF=11/9/4 per group, P<0.05). Collectively 
this data indicate that Igfbp5 is mainly expressed from cardiomyocytes of the diseased heart, 
while increased protein quantities are found extracellularly.  
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Figure 4-9: Igfbp5 expression originates from cardiomyocytes 
(A) Scheme of Langendorff-cell and serum utilization. (B) Igfbp5 expression in isolated non-myocytes and (C) 
cardiomyocytes from TAC and sham operated mice. (D) Nppb expression in isolated cardiomyocytes. Data is normalized 
to Tpt1 (Translationally-controlled tumor protein 1). n(cardiomyocytes)=5 mice/isolations per group, n(non-
myocytes)=4 mice/isolations per group. Data mean ±SD; t-test, * P<0.05. (E) Igfbp5 expression in isolated non-
myocytes and (F) cardiomyocytes from mice with cardiomyocyte specific β-catenin stabilization [β-Cat GOF]. Data is 
normalized to Tbp (TATA-binding protein). n(cardiomyocytes)=5 mice/isolations per group, n(non-myocytes)=5 
mice/isolations per group. Data are mean ± SEM; t-test, **** P<0.0001. 
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Figure 4-10: IGFBP5 is secreted from cardiomyocytes 
(A) Immunoblot analysis and (B) immunofluorescence staining from isolated cardiomyocytes from mice with 
cardiomyocyte specific β-catenin stabilization [β-Cat GOF] showing IGFBP5 protein. n(blot)=4/5 isolations per group, 
one representative picture/group. α-actinin (green), IGFBP5 (red), DAPI nuclei staining (blue). Scale bar is 100 µm. (C) 
ELISA quantification of IGFBP5 protein in supernatants from 24 h cultured cardiomyocytes from mice with 
cardiomyocyte specific β-catenin stabilization [β-Cat GOF]. n=4 isolations, cell culturing in duplicates. (F) ELISA 
quantification of IGFBP5 protein in blood serum from mice with TAC and with β-Cat GOF. n=11/9/4 per group. Data 
are mean ± SEM; t-test, * P<0.05; **** P<0.0001. 
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4.4 IGFBP5 can be uptaken by cardiac fibroblasts affects gene expression 
4.4.1 IGFBP5 can be uptaken by cardiac fibroblasts and activates its own expression 
Since IGFBP5 was found highly secreted from cardiomyocytes in the diseased heart, it was of 
interest to investigate whether secreted IGFBP5 can act in a paracrine manner on adjacent cells. 
Since bidirectional cardiomyocyte-fibroblast crosstalk is a well-known mechanism in both 
normal and diseased hearts, it was examined whether IGFBP5 can be uptaken by cardiac 
fibroblasts. For this, human cardiac fibroblasts (hCFBs) were treated for 48 h with IGFBP5-
FLAG conditioned medium, while uptaken IGFBP5 was later detected using a FLAG antibody 
(see scheme for experimental setup in Figure 4-11A). IF imaging showed a FLAG staining in 
cardiac fibroblasts treated with IGFBP5-FLAG conditioned medium, while no FLAG 
expression was detectable in control medium treated cells (Figure 4-11B, n=2 representative 
pictures/group). However, it was not possible to detect IGFBP5-FLAG in samples of 
conditioned medium treated hCFBs via immunoblotting. Possibly this was due to an insufficient 
uptake of detectable IGFBP5 amounts, which could be explained by a rapidly decreasing 
proliferation rate of hCFBs in vitro. To overcome this problem, highly proliferative murine 
embryonic cardiac fibroblasts (MEFs) were used. Immunoblot analysis of MEFs treated with 
IGFBP5-FLAG conditioned medium showed an additional band of about 37 kDa using a 
FLAG-antibody. This band represents FLAG tagged IGFBP5, while there was no band 
detectable in control medium treated MEFs (Figure 4-11D, n=3/group, blot was done twice). 
Further, IGFBP5 conditioned medium treated hCFBs were examined on RNA level. Analysis 
of IGFBP5 expression showed a significant upregulation of the transcript in IGFBP5-FLAG 
conditioned medium treated cells in comparison to control cells (Figure 4-11C, n=4 different 
passages, P<0.05). 
These data suggest that secreted IGFBP5 can be reuptaken by cardiac fibroblasts and changes 
its own expression.  
4.4.2 Molecular and physiologic effect of IGFBP5 on human cardiac fibroblasts 
Since exogenous IGFBP5 was shown to affect cardiac fibroblasts (hCFBs), cellular events 
triggered by IGFBP5 in these assumed receiver cells were investigated. To achieve a consistent 
and robust artificial expression of hIGFBP5 in hCFBs, lentiviral particles with an IBP5 OE 
construct were generated and cells were transduced. Lentiviral particles with a GFP OE 
construct served as control (see experimental setup in Figure 4-12A, see GFP transduction 
efficiency in Figure 4-12B). After cell processing, IBP5 OE was confirmed on RNA level 
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(Figure 4-12C, n=3 different passages, P<0.0001). Alpha-smooth muscle actin (ACTA2), which 
was often described to be upregulated upon IBP5 OE was not regulated in cells with IBP5 OE 
when compared to GFP CT cells (Figure 4-12D, n=3 different passages). Other RNAs were 
detected using RNA sequencing (done by Transcriptome and Genome Analysis Laboratory 
(TAL) Goettingen). Data analysis (done by Lavanya M. Iyer, Institute of Pharmacology and 
Toxicology, UMG Goettingen) revealed in total twelve differentially expressed genes 
comparing IBP5 OE versus a GFP CT (Figure 4-12E, n=3, technical triplicate, log2FC ±0.5, 
P<0.05). Some of the downregulated genes were already described in the context of 
cardiovascular disease, like MYOCD [112], stanniocalcin-1 (STC1) [113], thioredoxin-
interacting protein (TXNIP) [114], CC-chemokine ligand 2 (CCL2) [115] and hyaluronan 
synthase 2 (HAS2) [116]. Also, among the upregulated genes some could be assigned to 
cardiovascular diseases like growth differentiation factor 15 (GDF15) [117] and NR3C2 
(nuclear receptor subfamily 3 group C member 2) [118]. Validation of the most relevant 
differentially expressed genes showed an expression according to the RNA sequencing results 
(Figure 4-12F, n=3 technical replicates in one passage, P<0.05; P<0.01; P<0.001; P<0.0001).  
The previous results showed that IGFBP5 can alter gene expression of hCFBs. To investigate 
the functional performance of these hCFBs with IBP5 OE, engineered human myocardium 
(EHM) was generated (see scheme in Figure 4-13A. Experiment was done by Dr. Norman 
Liaw, Pharmacology and Toxicology, UMG Goettingen). This tissue model allows to measure 
functional performance by determining differences in contraction force. EHMs were produced 
by casting of hCFBs with lentiviral IBP5 OE or GFP CT together with stem-cell derived 
cardiomyocytes into a collagen matrix. Stable transduction efficiency after tissue generation 
and maturation was visualized via fluorescence microscopy, showing a GFP CT hCFBs in 
EHMs (Figure 4-13B, representative picture). Functional performance was measured as force 
of contraction (FOC) in response to extracellular calcium concentration (Figure 4-13B, 
n=6/group) and as beating frequency per minute (Figure 4-13D, n= 6/group), while there was 
no difference between EHMs with GFP CT hCFBs and EHMs with hCFBs with IBP5 OE. In 
contrast to the velocity of tissue contraction, the time to 50% tissue relaxation was significantly 
reduced in EHMs with IBP5 OE hCFBs when compared to the control (Figure 4-13F, 
n=6/group, 3 independent measurements, P<0.05). Moreover, rate of isometric contraction and 
rate of isometric relaxation was significantly reduced in EHMs with IBP5 OE hCFBs when 
compared to EHMs with GFP CT hCFBs (Figure 4-13K-L). To investigate whether the 
IBP5 OE in hCFBs was stable 20 days post transduction and if it has an influence on expression 
of other genes in the engineered tissue, qPCR analysis of the generated EHMs was done. 
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Validation of IGFBP5 showed a significant higher expression in EHMs generated with 
IBP5 OE hCFBs than in EHMs generated with GFP CT hCFBs (Figure 4-13I, n=6 EHMs per 
group, P<0.001). Regulated genes found upon RNA sequencing analysis of IBP5 OE in hCFBs 
like GDF15, MYOCD as well as STC1 were not regulated in EHMs generated with IBP5 OE 
hCFBs when compared to control EHMs (Figure 4-13J-L, n(I-L)=4-6 EHMs per group). 
These findings confirm that IGFBP5 has an effect on cardiac fibroblasts and influences gene 
expression. Moreover, the increased IGFBP5 expression in cardiac fibroblasts in an EHM 
influences tissue physiology. 
4.4.3 Myofibroblast activation and IGFBP5 upregulation are not directly associated 
Several publications provide evidence that IGFBP5 has a pro-fibrotic effect in different tissues 
(see chapter 5.4.4). Interestingly, this study showed that Igfbp5 is upregulated upon HF, while 
the cardiomyocytes were found being the source for Igfbp5 upregulation suggesting no direct 
association between cardiac fibrosis and Igfbp5 expression. To investigate whether pro-fibrotic 
effects and IGFBP5 expression are not associated in cardiac cells, hCFBs were treated with 
10 µM NE and with 1 ng/ml TGFβ for 48 h to activate myofibroblast transformation [119] (see 
experimental setup in Figure 4-14A). After 48 h of stimulation, qPCR analysis shows a 
significant upregulation of ACTA2, which is commonly used as a marker of myofibroblast 
formation, after TGFβ and NE treatment in comparison to non-treated controls (Figure 4-14B, 
n=3 passages, P<0.01; P<0.001). Moreover, NE treatment showed an upregulation of IGFBP5 
in comparison to non-treated controls, while there was no regulation upon TGFβ treatment 
(Figure 4-14C, n=3 passages, P<0.001). 
These data provide evidence that cardiac fibroblasts are not only receiver cells being responsive 
to IGFBP5, they also possess the capability to regulate IGFBP5 in response to NE, however 
myofibroblast activation and IGFBP5 upregulation are not directly associated. Importantly, in 
vivo data from this study (see chapter 4.2) further supports this assumption and even indicates 
an anti-fibrotic effect of IGFBP5. 
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Figure 4-11: IGFBP5 is uptaken by cardiac fibroblasts 
(A) Scheme of sample generation. (B) Immunofluorescence staining and (C) hIGFBP5 qPCR validation of human 
cardiac fibroblasts treated with IGFBP5-FLAG conditioned medium for 48 h. n(IF)=2 representative pictures/group. α-
smooth muscle actin [αSMA] (green), FLAG (red), DAPI (blue). Scale bar is 50 µm. Arrows indicates IGFBP5-FLAG 
protein. n(qPCR)=4 different passages in technical multiplicates. hGAPDH is used for normalization. Data are mean ± 
SEM; t-test, * P<0.05. (D) Immunoblot analysis of neonatal cardiac fibroblasts treated with IGFBP5-FLAG conditioned 
medium for 48 h. α-tubulin and Ponceau-S staining are used as loading controls. n=3/group, blots are done twice. 
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Figure 4-12: Effect of lentiviral overexpression of hIGFBP5 on human cardiac fibroblasts 
(A) Scheme of lentiviral overexpression (OE) of hIGFBP5 in human cardiac fibroblasts (hCFB). (B) Representative 
pictures of expression efficiency of GFP control virus in hCFBs. BF=bright field. Scale bar 200 µm. (C) qPCR validation 
of hIGFBP5 overexpression [hIBP5 OE] and (D) hACTA2 expression. n=3 passages. (E) Heatmap depicting normalized 
counts of differentially expressed genes (log2FC ±0.5, p<0.05). (F) qPCR validation of some RNAseq results from 
hCFBs after hIBP5 OE. hGAPDH is used for normalization. n(E-F)=3 technical replicates, data are mean ± SEM; t-test, 
* P<0.05; ** P<0.01; *** P<0.001; **** P<0.0001. 
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Figure 4-13: Cardiac fibroblast specific overexpression of hIGFBP5 in engineered human myocardium  
(A) Schematic overview of engineered human myocardium (EHM) generation with hIGFBP5 overexpression 
[hIBP5 OE] transduced human cardiac fibroblasts (hCFB). (B) Representative pictures of GFP control virus transduced 
hCFBs in EHMs. Scale bar 1 cm. (C) Force of contraction (FOC) in response to extracellular calcium concentration in 
EHMs with GFP control hCFBs [GFP CT] and hCFBs with hIBP5 OE. n= 6/group. (D) Beating frequency per minute 
(bpm) of control versus IBP5 OE hCFB EHMs. n= 6/group. (E) Time to 90% contraction, (F) time to 50% relaxation, 
(G) rate of isometric contraction and (H) rate of isometric relaxation in control- versus IBP5 OE hCFB EHMs. 
n=6/group, 3 measurements. (I) qPCR analysis of overexpressed hIGFBP5 and some potential target genes like (J) 
hGDF15 and (K) hMYOCD and (L) hSTC1. n=6 EHMs per group. Data are mean ± SEM; t-test and 2way ANOVA, * 
P<0.05; *** P<0.001. Experiment done by Dr. Norman Liaw, Pharmacology and Toxicology, UMG Goettingen.  
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Figure 4-14: Myofibroblast activation and hIGFBP5 upregulation are not directly associated 
(A) Schematic overview of hCFB treatment. (B) mRNA expression of hACTA2 and (C) hIGFBP5 in human cardiac 
fibroblasts treated with 10 µM NE and 1 ng/ml TGFβ. n=3 passages in technical multiplicates. qPCR data is normalized 
to hGAPDH. Data are mean ± SEM; t-test, (ns) not significant, ** P<0.01; *** P<0.001. 
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4.5 IGFBP5 acts as a transcriptional co-factor 
4.5.1 IGFBP5 binds to DNA and regulates promoter activity 
The previous results show that IGFBP5 can be uptaken by hCFBs and influences gene 
expression in these possible receiver cells. In the following, the direct influence of IGFBP5 on 
gene expression was investigated. A nuclear localisation sequence enables IGFBP5 to enter 
nuclei. Several authors already showed that IGFBP5 might has transcriptional co-regulator 
functions [85, 120], but so far, no direct IGFBP5 binding to DNA with subsequent target 
activation was shown. To determine whether IGFBP5 is associated to genomic regions, ChIP 
was used. As a preliminary experiment, it was tested whether overexpressed, FLAG tagged 
IGFBP5 enters the cell nucleus and can be precipitated. For this, rapid immunoprecipitation of 
endogenous proteins (RIME) was used. RIME follows the exact protocol used for ChIP, but 
instead of purifying the precipitated chromatin, the precipitated protein of interest and 
associated proteins are detected using immunoblotting. For this experiment, TSA201 cells 
(human embryonal kidney cells) with flag tagged IBP5 OE or an empty vector control were 
used for ChIP. IGFBP5-FLAG was precipitated using a FLAG antibody, a customized anti-
IGFBP5 antibody or an IgG control. The precipitated proteins were investigated using 
immunoblotting and FLAG detection. Whereas there was no visible band at 37 kDa 
(representing the artificially FLAG-tagged IGFBP5) from IgG precipitated samples, samples 
with IBP5 OE showed a band at 37 kDa when precipitated with FLAG antibody and with 
customized anti-IGFBP5 antibody. No band was detectable at 37 kDa in samples with an empty 
vector control (Figure 4-15A, n=2 different precipitations). Since IBP5 OE protein could be 
precipitated from TSA201 nuclei using a FLAG antibody, ChIP was done with FLAG antibody 
using samples from hCFBs with lentiviral-mediated IBP5 OE. Precipitated chromatin was 
analysed via whole genome sequencing (done by Transcriptome and Genome Analysis 
Laboratory (TAL) Goettingen, analysis was done by Lavanya M. Iyer, Institute of 
Pharmacology and Toxicology, UMG Goettingen). Validation of the precipitated chromatin 
revealed binding to gene loci of IGFBP5 (Figure 4-15B) and TNNT2 (Figure 4-15C, n=2 
precipitations/sequencing per conditions respectively). Precipitated IGFBP5 and TNNT2 
chromatin partially covered the first exon and the chromatin upstream the ATG of both genes, 
representing putative promoter regions. Published ChIP data from reference hCFBs for 
methylation at the 4th lysine residue of the histone H3 protein (H3K4me), which marks 
accessible chromatin, was compared to IGFBP5 bound loci. This comparison revealed a 
recruitment of H3K4me in cardiac fibroblasts to the IGFBP5-bound IGFBP5 locus, but not to 
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the TNNT2 locus. To analyse the effect of IGFBP5 on its own putative promoter region and on 
the putative TNNT2 promoter region, the IGFBP5-occupied gene loci (ChIP peaks, referred as 
“promoters”) were cloned in a luciferase reporter system (see scheme in Figure 4-15D). The 
cloned reporter vectors were co-transfected with an IBP5 OE vector in TSA201 cells. 
Validation of luciferase activity for the cloned IGFBP5 promoter did not give any conclusive 
data due to a very high baseline promoter activation when compared to the empty luciferase 
vector. Validation of the cloned TNNT2 promoter showed a significant lower TNNT2 promoter 
activation when compared to the empty luciferase vector. Moreover, co-transfection of IGFBP5 
leads to a significant reduction of TNNT2 promoter luciferase activity when compared to 
empty-vector co-transfection (Figure 4-15E, n=4 independent, P<0.05).  
This data confirms that IGFBP5 can enter cell nuclei where it acts as a transcriptional co-factor 
repressing the TNNT2 promoter.  
4.5.2 NKX2.5 occupies and regulates same genomic regions as IGFBP5  
In silico analysis of the IGFBP5-occupied loci (IGFBP5 and TNNT2 promoter) predicted 
potential NKX2.5 binding motifs (Figure 4-16AB). To analyse whether NKX2.5 can bind to 
these predicted regions and to validate its potential effect on the promoter activity, the cloned 
IGFBP5 promoter (ChIP peak) was co-transfected with a NKX2.5 overexpression construct in 
TSA201 cells. Luciferase signal quantification revealed a significant increase in luciferase 
intensity already at baseline (with co-transfection of an empty vector) when compared to a 
luciferase empty vector control. Co-transfection of NKX2.5 leads to a significant increase of 
the IGFBP5 promoter luciferase activity when compared to empty-vector co-transfection 
(Figure 4-16C, n=4 independent experiments, P<0.05; P<0.01). Investigation of the interplay 
of IGFBP5 with NKX2.5 on the putative IGFBP5 promoter was not possible due to du a very 
high baseline promoter activation when compared to the empty luciferase vector. To investigate 
the interplay of both factors on the putative TNNT2 promoter, a double co-transfection 
experiment was done. A significant repressive effect of co-transfected IGFBP5 on the TNNT2 
promoter was observed as before (Figure 4-15E). As already shown by Kobayashi et al., co-
transfection of NKX2.5 led to a significant activation of the TNNT2 promoter. Interestingly, 
double co-transfection of NKX2.5 and IGFBP5 had a repressive effect on the TNNT2 promoter, 
decreasing the luciferase activity below baseline activity (Figure 4-16D, 4 independent 
experiments, P<0.05; P<0.01) 
Together, these data provide evidence that IGFBP5 antagonizes the activating effect of NKX2.5 
on the TNNT2 promoter.  
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Figure 4-15: Overexpressed hIGFBP5 binds to DNA and regulates promoter activity 
(A) Immunoblot analysis of overexpressed and precipitated hIGFBP5-FLAG [OE] from TSA201 nuclei, using an 
IGFBP5 antibody, a FLAG antibody and an IgG control. An empty vector [ev] was used as control. Detection was done 
with FLAG antibody. n=2 IPs. (B) Occupancy profile of hIGFBP5 locus and (C) hTNNT2 locus after chromatin 
immunoprecipitation (ChIP) in human cardiac fibroblasts (hCFB) with hIGFBP5-FLAG overexpression [hIBP5 OE] 
(red) and GFP control [GFP CT] (purple). ChIP was done with FLAG antibody and subsequent sequencing. Published 
data for H3K4me (blue) from normal hCFBs marking accessible chromatin was used as a reference . Blue brackets show 
gene body. n=2 precipitations/sequencing per conditions. (D) Scheme of luciferase constructs. (E) Relative luciferase 
activation by overexpressed hIGFBP5 [IBP5] (grey bars) binding to the cloned hTNNT2 promoter (prom) region in 
comparison to activation by an empty vector control [ev] (black bars). Basal luciferase activity was set as 1 (dashed 
line). Renilla luciferase expression was used for normalization, n=4 independent experiments. Data are mean ± SEM; t-
test, *P<0.05; **P<0.01, ***P<0.001. 
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Figure 4-16: hNKX2.5 occupies same genomic regions as hIGFBP5 and regulates promoter activity 
(A) In silico prediction of potential NKX2.5 binding sites/motifs (blue arrows) in the identified hIGFBP5 and (B) 
hTNNT2 promoter regions bound by hIGFBP5 (red peaks). (C) Relative luciferase activation by overexpressed 
hNKX2.5 (white bars) binding to the cloned hIGFBP5 ChIP promoter region in comparison to activation by an empty 
vector control [ev] (black bars). (D) Relative luciferase activation of the cloned hTNNT2 promoter region. Activation is 
achieved by overexpression of hNKX2.5 (white bars), hIGFBP5 (grey bar), the combination of hNKX2.5 with hIGFBP5 
(grey-squared bar) or by an empty vector control [ev] (black bar). Basal luciferase activity was set as 1 (dashed line). 
Renilla luciferase expression was used for normalization, n(C-D)=4 independent experiments. Data are mean ± SEM; t-
test, *P<0.05; **P<0.01. 
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4.6 IGFBP5 controls human cardiac cell commitment  
4.6.1 Generation and validation of an IGFBP5 knockout hES cell line using the 
CRISPR/Cas9 technology 
Previous reports associate sustained IGFBP5 expression with impaired stem cell and cardiac 
progenitor cell differentiation, while IGFBP5 downregulation was associated with 
cardiomyocyte differentiation [87, 89, 92]. To investigate the impact of IGFBP5 on stem cell 
commitment and cardiomyocyte differentiation, a KO hES cell line was generated using a 
double-paired CRISPR/Cas9-D10A nickase (Cas9n) genome editing approach. CRISPR 
gRNAs were designed to target the transcription start site in the IGFBP5 locus (see scheme in 
Figure 4-17A) to prevent transcription or to generate a frame shift mutation. To avoid off-target 
effects, a “4n approach” was applied using four different gRNAs and a CAS9 nickase enzyme 
generating four independent single strand breaks and releasing a 300 bp long DNA fragment 
(see scheme in Figure 4-17B). The work flow of the KO hES cell line generation included 
gRNA design and synthesis, gRNA cloning in a SpCas9-D10A nickase vector, electroporation 
of hES cells with gRNA vectors including a Cas expression cassette, clone selection and single 
clone isolation, genotyping and subsequent characterization (see scheme in Figure 4-17C). A 
control cell line (mock control) was generated using hES cells electroporated without plasmids 
but with subsequent single clone selection. 
To validate a successful cell line generation, genotyping of isolated single clones was done 
using primers flanking the deleted DNA fragment including the TSS. Genotyping PCR of 
control hES cells show a 500 bp long IGFBP5 wildtype PCR product. PCR analysis of two 
different hES cell clones revealed one truncated PCR product (deletion, homozygous) for clone 
K22 and two longer PCR products for the second clone K12 (insertion, heterozygous) (Figure 
4-18A). Immunoblot analysis of genotyped clones showed no difference between deletion and 
insertion clones in comparison to mock control (Figure 4-18B, n=2/group, blot was done twice). 
To examine whether the corresponding transcript was expressed, a qPCR forward primer was 
designed to bind the deleted TSS on the transcript (see scheme in Figure 4-18C). qPCR analysis 
for wildtype hES cells and mock control cells showed a product of ~700 bp and a longer qPCR 
product for the insertion clone (Figure 4-18D). The deletion clone as well as the corresponding 
controls did not show any qPCR products.  
To investigate a potential impact of IGFBP5 KO on the hES cells, hES cells were 
morphologically, physiologically and molecularly characterized. Morphologically, there was 
no apparent difference between hES cells derived from the deletion clone (K22) and the 
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insertion clone (K12) when compared to the mock control (Figure 4-19A, representative 
pictures). Cell size was determined using automated “CASY TT” cell counter and analyser 
system, whereas the mean diameter of cells from the insertion clone (K12) was significantly 
smaller in in comparison to the deletion clone (K22) and the mock control (Figure 4-19B, n=8 
different passages, P<0.05). Pluripotency of the stem cell lines was assessed by flowcytometry 
(Experiment was done by Dr. Farah Raad, Pharmacology and Toxicology, UMG Goettingen) 
using the stemness markers OCT4 and TRA1-60. 90.0% of cells from the mock control and 
88.7% cells of the deletion clone (K22) were positive for OCT4 and TRA1-60, whereas only 
70.7% cells of the insertion clone (K12) were positive for both markers (Figure 4-19C, n=3, 
P<0.05). A significant reduced stemness of the insertion clone (K12) in comparison to the 
deletion clone (K22) and the mock control can also be detected on qPCR level, determining the 
expression of SOX2 (Figure 4-19D, n=7 different passages, P<0.05). Since the pluripotency of 
the insertion clone (K12) was reduced, it was of interest to validate whether all used cell lines 
possessed the capacity to differentiate into all three germ layers. To test the spontaneous 
differentiation potential of the generated IGFBP5 KO hES cell lines, embryoid body (EB) 
formation was done as described by El-Battrawy et al. [103] in the Stem Cell Unit (SCU), 
UMG, Goettingen (experiment done by Martina Grohe). Germ layer-specific markers such as 
α-feto-protein (AFP, endodermal), α-smooth muscle actin (α-SMA, mesodermal), as well as 
βIII-tubulin (ectodermal) were detected using IF staining of formed EBs. In this preliminary 
experiment, no apparent difference in germ layer differentiation potential between the deletion 
clone (K22) and the insertion clone (K12) was detectable, when compared to the mock control 
(Figure 4-20A-C, n=2 differentiations, representative pictures). 
Altogether these data showed the successful use of the CRISPR/Cas9 technology to generate 
two different IGFBP5 KO hES cell lines with genomic changes in the IGFBP5 locus. These 
genomic changes comprise the homozygous deletion of the TSS in clone 22 and a heterozygous 
random integration of plasmid DNA in clone 12. Although both cell lines do not show major 
morphological changes and possess the capacity to differentiate in all three germ layers, 
clone 12 owns a reduced pluripotent potential.  
4.6.2 Characterization of directed cardiomyocyte differentiation in IGFBP5 knockout 
cells 
To investigate the suitability of the generated IGFBP5 KO hES cell lines to differentiate in 
cardiomyocytes, directed 2D differentiation followed by metabolic lactate selection was 
performed to obtained spontaneously beating cardiomyocytes (see schematic overview in 
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Figure 4-21A). Differentiated cardiomyocytes were morphologically-, physiologically and 
molecularly characterized. Examining the beating frequency of the differentiated 
cardiomyocytes, the deletion clone (K22) and the insertion clone (K12) showed a significant 
higher beating frequency when compared to the mock control (Figure 4-21B, n=3 different 
differentiations, counting at 3 different areas, P<0.05; P<0.01). After cell dissociation, cell size 
was determined using the automated “CASY TT” cell counter system. Compared to the mock 
control, the deletion clone (K22) and the insertion clone (K12) showed a significant smaller 
cell size (Figure 4-21C, n=4 different differentiations with technical duplicates, P<0.01; 
P<0.001). To investigate whether the decreased cell size can be correlated with increased cell 
proliferation, the expression of cell G1/S-specific cycle marker cyclin D1 was determined. In 
comparison to the mock control and the deletion clone (K22), the insertion clone (K12) showed 
a significant upregulation of cyclin D1 expression (Figure 4-21D, n=3 different 
differentiations, P<0.05). Evaluation of the expression of IGFBP5 in the KO cardiomyocytes 
revealed a significant upregulation of the transcript in the insertion clone (K12), whereas there 
was a non-significant trend towards upregulation in the deletion clone (K22) when compared 
to the mock control (Figure 4-21E, n=3 differentiations, P<0.01). To investigate whether the 
increased transcript abundance was also represented on protein level, ELISA quantification of 
secreted IGFBP5 in cell supernatants was done. Analysis revealed a significant higher 
concentration of IGFBP5 in cell supernatants of the insertion clone (K12) in comparison to the 
mock control, while the slightly higher concentration of IGFBP5 in supernatants of the deletion 
clone (K22) did not reach statistical significance (Figure 4-21F, n=2 different passages, 
P<0.05). To examine cardiac progenitor cell commitment, the expression of developmental 
genes was determined. NKX2.5 was significantly upregulated in the insertion and deletion clone 
(Figure 4-21G, n=3 differentiations, P<0.01; P<0.0001), while MYOCD was only upregulated 
in the insertion clone (K12) when compared to the mock control (Figure 4-21H, n=3 
differentiations, P<0.01). Active Wnt signalling, which indicates impaired cardiomyocyte 
differentiation, was detected in the insertion clone (K12), showing upregulated AXIN2 
expression in comparison to the deletion clone and the mock control (Figure 4-21I, n=3 
differentiations, P<0.001). Immunoblot analysis from differentiated cardiomyocytes confirmed 
qPCR results and showed a stronger NKX2.5 protein expression in the insertion and deletion 
clone compared to the mock control (Figure 4-22A, n=3 differentiations). Further, an increased 
protein abundance of the transcription factor TBX5, a regulator of cardiogenesis, was detected 
in the insertion and deletion clone when compared to the mock control (Figure 4-22B, n=3 
differentiations). This observation was confirmed by IF images shown in Figure 4-23A. To 
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determine a cardiomyocyte specific protein, immunoblot analysis of cTNT was done. Nearly 
no cTNT protein expression was detected in the insertion clone (K12), whereas a reduced 
expression was detected in the deletion clone (K22) in comparison to the mock control (Figure 
4-22C, n=3 differentiations). This was also appreciated in IF images which showed less cTNT 
signal in the insertion clone (K12) in comparison to the mock control (Figure 4-23A). In 
addition, IF staining also showed a decreased signal for α-sarcomeric-actinin in the insertion 
clone (K12) and the deletion clone (K22) in comparison to the mock control (Figure 4-23BC). 
Further, IGFBP5 KO cardiomyocytes and the mock control showed quite comparable signal 
intensities of the gap junction protein connexin-43 (CX43). Of note, the protein expression of 
CX43 appeared to be more circumferential in the insertion clone (K12), whereas in the deletion 
clone and the mock control, the protein was rather polarized to intercalated disks (Figure 
4-23B). In line with this, IF images of the cell adhesion component N-cadherin (NCAD) showed 
higher and more organized expression in the mock control when compared to the IGFBP5 KO 
cardiomyocytes (Figure 4-23C).  
Collectively, these data suggest that the insertion of genomic material in clone 12 resulted in an 
IGFBP5 gain-of function (GOF) mutation, indicated by increased transcript and extracellular 
protein abundance. This phenotype could potentially be due to a subcellular protein 
accumulation of IGFBP5 with a subsequent positive feedback regulation of IGFBP5 
transcription. Interestingly, the GOF clone showed a decreased potential in cardiomyocyte 
differentiation and maturation with a concomitant increased cyclin D1 expression, assuming an 
arrested cardiac cell commitment.  
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Figure 4-17: Generation of a hIGFBP5 knockout hES cell line using CRISPR/Cas9 technology 
(A) Illustration of the 4n CRISPR/Cas9-D10A nickase (Cas9n) genome editing strategy for targeting the transcriptional 
start site (TSS) of hIGFBP5. Four different gRNAs are indicated with red arrows, cutting offset of ~300 bp including 
the TSS. (B) Magnification of schematic overview. (C) Work flow of knockout cell line generation. 
  
C
A
B
RESULTS  86 
 
 
Figure 4-18: Validation of generated hIGFBP5 knockout hES cell clones 
(A) Genotyping PCR of two different hES cell clones [K=clone with individual number] and an electroporated mock 
control [Wt (mock)]. Primers are framing the deleted TSS, amplifying a 500 bp long hIGFBP5 wild type PCR product. 
Black arrow indicates a shorter fragment, white arrows indicate two longer fragments. (B) Immunoblot analysis of 
hIGFBP5 protein. Tumor protein translationally-controlled 1 [TPT1], α-Tubulin and Ponceau-S staining were used as 
loading controls. (C) Scheme of cDNA genotyping approach of hES cell clones. Forward primer was designed to cover 
the deleted TSS (purple). (D) qPCR amplification with described primers for wild type hES cells and mock control with 
a PCR product of ~700 bp and a longer PCR product size for K12 (ins). Clone K22 (del) shows no PCR product. Non-
template control [NTC] and minus reverse transcriptase control [-RT] were used to detect potential DNA contaminations 
and show no qPCR product. Melting curve analysis shows peaks of amplified PCR products corresponding to gel bands. 
NTC and –RT (blue frame), K12(ins) (red frame), K22(del) (green frame). 
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Figure 4-19: Characterisation of generated hIGFBP5 knockout hES cell lines 
(A) Light microscopy pictures of cultured hES cells showing mock control cells [Wt (mock)], clone with targeted 
deletion [K22 (del)] and clone with insertion [K12 (ins)]. Scale bar 100 µM. (B) Mean diameter of dissociated hES cells 
measured with automated “CASY TT” cell counter and analyser system, n=8 different passages. (C) FACS analysis 
(done by Dr. Farah Raad, Pharmacology and Toxicology, UMG Goettingen) of pluripotency markers OCT4 and TRA160 
expressing hES cell clones and control cells, n=3 different passages. (D) qPCR analysis of pluripotency marker hSOX2 
in hES cell clones and control, n=7 different passages. Data are mean ± SEM; t-test, (ns) not significant, * P<0.05. 
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Figure 4-20: Spontaneous germ layer differentiation of hIGFBP5 knockout hES cell lines 
Differentiation in three germ layers is shown by immunofluorescence staining of formed embryoid bodies (EBs). (A) α-
feto-protein [AFP] (red) is used as endodermal marker. (B) α-smooth muscle actin [α-SMA] (green) is used as a 
mesodermal marker. (C) βIII-tubulin (green) is used as an ectodermal marker. DAPI nuclear staining in blue, scale bar 
is 100 µm. Experiment done by Martina Grohe/Lukas Cyganek, Stem cell unit, UMG Goettingen. 
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Figure 4-21: Characterisation of differentiated hIGFBP5 knockout cardiomyocytes 
(A) Schematic overview of 2D hES cell differentiation to cardiomyocytes (CMs). (B) Spontaneous beating frequency in 
beats per minute (bpm), measured by manual counting. n=3 different differentiations, counting at 3 different areas, before 
and after re-seeding of cells. (C) Mean diameter of dissociated CMs measured with automated “CASY TT” cell counter 
system. n=4 different differentiations with technical duplicates. (D) qPCR analysis of proliferation marker cyclin D1 in 
differentiated CMs. n=3 different differentiations with technical duplicates or triplicates. (E) qPCR analysis of hIGFBP5 
in differentiated CMs. n=3 different differentiations with technical duplicates or triplicates. (F) ELISA protein 
quantification in cell supernatants. n=2 different passages, technical duplicates. (G) qPCR analysis of hNKX2.5, (H) 
myocardin [hMYOCD] and (I) the Wnt target gene Axin2 [hAXIN2] in CMs. n(D-F)=3 different differentiations with 
technical duplicates or triplicates. Data are mean ±SEM; t-test, (ns) not significant, *P<0.05; **P<0.01; ***P<0.001; 
****P<0.0001. 
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Figure 4-22: Protein expression in differentiated hIGFBP5 knockout cardiomyocytes 
(A) Immunoblot from cardiomyocytes of three different differentiations [D210-D212] showing NKX2.5 protein, (B) 
TBX5 and (C) cardiac troponin T [cTNT]. α-tubulin and Ponceau-S staining were used as loading controls. L=ladder. 
n= 3 different differentiations, blots are done twice. 
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Figure 4-23: 2D differentiation of hIGFBP5 knockout hES cells to cardiomyocytes 
(A) Immunofluorescence staining of cardiomyocytes showing cardiac troponin T [cTnT] (green) with transcription 
factor TBX5 (red). (B) α-sarcomeric-actinin (green) with gap junction protein connexin-43 [CX43] (red) and (C) α-
sarcomeric-actinin (green) with cell adhesion component N-cadherin [NCAD] (red). Representative pictures. DAPI 
nuclear staining in blue, scale bar is 50 µM. 
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4.7 Igfbp5 is downregulated upon norepinephrine and angiotensin II 
mediated hypertrophy  
Physiological hypertrophy is an essential part of cardiomyocyte maturation in the developing 
heart. NE as an α and β-adrenergic receptor agonist is known to have a potential role in 
physiological cardiomyocyte maturation in vitro [102, 121, 122]. Also Ang II, the principal 
circulating hormone of the renin-angiotensin system and mediator cardiac hypertrophy in vivo 
[123], was shown to increase fetal cardiomyocyte maturation in sheep [124]. To study the role 
of IGFBP5 in the context of cardiac maturation, NE and Ang II treated murine neonatal 
cardiomyocytes (MNCM) were used (see scheme in Figure 4-24A). Upon a 48h treatment with 
1 µM NE or 1 µM Ang II, a significant downregulation of Igfbp5 was observed in treated 
MNCMs in comparison to non-treated controls (Figure 4-24BC, n=3 different isolations of 
several neonatal hearts, P<0.01; P<0.001). Further, treated MNCMs showed a significant 
downregulation of the predominant fetal cardiac muscle filament gene Myh7 isoform (Figure 
4-24D, n=3 different isolations with multiple hearts). 
Ang II is known as an important hormonal mediator of cardiac hypertrophy and fibrosis [104] 
and is commonly used in vitro and in vivo models. After the described in vitro experiments with 
neonatal cardiomyocytes, it was of interest to investigate the expression of Igfbp5 in an Ang II 
disease model. Mice were examined two weeks after minipump implantation and in a second 
set-up, 4 weeks after implantation, while Ang II infusion was expected to be depleted already 
two weeks after minipump implantation (see timeline in Figure 4-24E). Comparing the 
expression of Igfbp5 in mice with chronic Ang II infusion for two weeks to control mice, treated 
with saline solution, Igfbp5 was significantly downregulated (Figure 4-24F, n=9/8 per group, 
P<0.05), while the pro-hypertrophic gene Nppa was significantly upregulated in Ang II mice 
(Figure 4-24G, n=9/group, P<0.001). In the second experimental setup, four weeks after 
minipump implantation, Igfbp5 was significantly downregulated (Figure 4-24H, n=6/group, 
P<0.05), while there was no significant regulation of Nppa (Figure 4-24I, n=6/group). 
Taken together, these findings provide evidence that Igfbp5 is downregulated during NE and 
Ang II mediated hypertrophy in vitro as well as in vivo. 
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Figure 4-24: Igfbp5 expression upon norepinephrine and angiotensin II stimulation 
(A) Scheme of murine neonatal cardiomyocyte (MNCM) isolation and stimulation. (B) Igfbp5 expression in MNCMs 
upon angiotensin II [Ang II] stimulation (1 µM; 48h). (C) Igfbp5 and (D) Myh7 expression in NMCMs upon 
norepinephrine [NE] stimulation (1 µM; 48h). n=3 different isolations. (E) Time line of Ang II and saline solution [NaCl] 
infusion via osmotic minipumps. (F) Igfbp5 and (G) Nppa expression in Ang II and NaCl treated mice 2 weeks after 
minipump implantation. n=6 per group. (H) Igfbp5 and (I) Nppa expression in Ang II and NaCl treated mice 4 weeks 
after minipump implantation. n=9 per group. Gapdh was used for normalization. Data are mean ±SEM; t-test, *P<0.05; 
**P<0.01; ***P<0.001; ****P<0.0001; ns=not significant.  
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5 Discussion 
5.1 IGFBP5, a conserved developmental gene, is re-activated during the 
transition to heart failure 
5.1.1 IGFBP5 is upregulated during the transition to heart failure in mice and in 
humans 
Investigation of the Wnt/β-catenin pathway, a well-characterized developmental signalling 
pathway that is re-activated in the diseased heart, revealed an upregulation of Igfbp5 [92, 93]. 
The inducible, cardiac specific β-Cat GOF in mice led to cardiac hypertrophy with increased 
heart sizes, cardiac mass, myocyte cross-sectional area, fibrosis and increased mortality 
culminating in HF. Igfbp5 expression consequent to murine HF was studied to investigate 
whether the regulation of Igfbp5 is directly related to Wnt activation or rather is a consequence 
of disease progression. An upregulation of Igfbp5 was detected in a murine TAC model. 
Determining the expression dynamics of Igfbp5 revealed an upregulation upon HF initiation 
post-TAC, but not during early compensatory hypertrophy phase three days post TAC, when 
hypertrophy markers like Nppb and associated pathways like the Wnt signalling pathway [93] 
were already activated. A direct association between Igfbp5 upregulation and HF was 
demonstrated in a TAC-rescue experiment. Previous data showed that inhibiting Wnt-
transcriptional activation in the murine heart upon TAC abrogates HF progression [93]. In this 
setup, Igfbp5 was only upregulated when echocardiographic parameters indicated HF, whereas 
transgenic mice with preserved cardiac function post-TAC showed no significantly regulation 
of Igfbp5 expression. In line with observations in mice, IGFBP5 was also found highly 
expressed in heart samples from patients with aortic stenosis in comparison to non-failing 
control samples. Interestingly, even when the regulation of IGFBP5 in samples from patient 
with compensated hypertrophy showed a trend, IGFBP5 was not significantly upregulated in 
comparison to non-failing control samples, similar to observations made in the TAC mouse 
model. As in mice, human IGFBP5 was only found significantly upregulated upon HF. 
Intriguingly, RNA sequencing data from mice and humans consequent to HF revealed that only 
very few genes show a dynamic increase in expression from the non-failing heart, to 
compensated hypertrophy, to HF. Moreover, only 25 of these dynamically upregulated genes 
are found conserved between mice and humans, including IGFBP5. IGFBP3 is the most similar 
IGFBP to IGFBP5 [50] and has been associated with an increased risk of ischemic heart disease 
and found upregulated upon HF [108, 109]. However, no significant regulation of Igfbp3 was 
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observed upon compensated hypertrophy or in HF, neither in mice nor in humans in this study. 
Taken together, these results show an upregulation of IGFBP5 in the context of the failing heart 
in mouse and in human, providing evidence that IGFBP5 might play a conserved role during 
the transition to HF. 
Concomitant with the upregulation of the IGFBP5 transcript in ventricles from aortic stenosis 
patients, miR-139-5p and miR-146b-5p, two micro RNAs (miRNAs) which can potentially 
target the human IGFBP5 transcript, were found progressively downregulated in patients with 
pathologies extending from compensatory hypertrophy to HF. miRNAs are small endogenous 
non-coding RNAs that play important gene-regulatory roles, either regulating gene expression 
via mRNA silencing (degradation) or via post-transcriptional regulation (preventing 
translation) (Lee et al., 1993). Decreased levels of miR-139-5p were also reported in patients 
with different classes of HF [125–127] as well as in patients with left ventricular ischemia [128]. 
miR-139-5p, is also predicted to target NR3C2, a gene which is upregulated in patients with 
congestive HF [118]. Interestingly, NR3C2 was found to be a potential target of IGFBP5 (see 
chapter 4.4.2), suggesting a dual regulatory role for miR-139-5p on expression of both genes 
during HF. Another link between IGFBP5 and miR-146b-5p is the gene CCL2, also found to 
be a potential target of IGFBP5 (see chapter 4.1.3), whereas CCL2 was shown to be 
downregulated by miR-146b-5p [129]. In aortic stenosis patients, when miR-146b-5p 
expression decreased, both potentially targeted transcripts (IGFBP5 and CCL2) were 
upregulated. The concomitant upregulation of transcripts with downregulation of their targeting 
miRNAs indicates their mutually dependent expression. This data indicates how tightly 
controlled gene regulation and expression is on every regulatory level and provides evidence 
that IGFBP5 and its targets can be regulated by the same miRNAs. 
5.1.2 IGFBP5 is part of the fetal gene program 
Cardiac remodelling is accompanied by a re-activation of genes (mostly transcription factors) 
which have important functions during cardiogenesis [10, 130]. The restoration of these genes 
in the adult heart in response to disease stimuli promotes the compensatory hypertrophic 
response, as part of the so-called “fetal gene program”. However, the signalling mechanisms 
mediating the critical transition from compensated hypertrophy to decompensated HF remain 
elusive. Igfbp5 expression is high in the early cardiac crescent in mouse embryos [87] and was 
shown to decrease during cardiogenesis with progressing heart maturation in this study. Several 
authors associated persistent expression of Igfbp5 with impaired cardiomyocyte differentiation, 
whereas enhanced cardiomyocyte differentiation was correlated with decreasing Igfbp5 
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expression [87–89]. Hence, a downregulation of Igfbp5 during cardiogenesis seems to be 
important for cardiomyocyte differentiation and cardiac maturation. The expression pattern of 
Igfbp5 during cardiogenesis and its upregulation upon HF supports the hypothesis that the fetal 
gene program is re-activated in the diseased heart. Similarly, HAND2, a developmental 
transcription factor, essential for right ventricle development [131] is re-employed in the 
diseased and failing heart [132]. Dirkx et al. reported that this re-activation led to pathological 
hypertrophy, whereas cardiac specific HAND2 deletion upon TAC led to a marked resistance 
to TAC-induced hypertrophy, fibrosis, and ventricular dysfunction [132]. This example shows 
that revealing the precise role of genes from the re-activation program could provide a 
mechanistic link to understand cardiac hypertrophy progression and might help to identify novel 
approaches to delay or even prevent HF. Collectively this data indicates diverging functions of 
IGFBP5 during cardiogenesis and HF.  
Since previous data and data from this study sheds light upon the impact of Igfbp5 on cardiac 
progenitor cell (CPC) homeostasis (see 2.2.3 and 4.6.2), it can be speculated that a re-activation 
of IGFBP5 in the diseased heart has an effect on residual CPCs. Some authors advocate the idea 
that CPCs reside in specific niches with a certain microenvironment characterized by hitherto 
unknown key components [32]. A change in the microenvironments changes the behaviour of 
the CPCs on the one hand inducing senescence and apoptosis [30], on the other promoting CPC 
migration, as well as proliferation and differentiation [32]. The role of Igfbp5 re-activation on 
CPC behaviour in the adult diseased heart must be further investigated.  
5.2 IGFBP5 stimulates atrophic and anti-fibrotic processes in vivo 
5.2.1 IGFBP5 mediates atrophy in the normal heart via downregulation of ECM and 
sarcomeric genes  
To investigate the direct effect of IGFBP5 on the murine heart in vivo, an adeno-associated viral 
(AAV) vector mediated approach was used. For the comparison of transcriptome data from Luc 
CT and IBP5 OE heart samples, mice which did not receive virus particles were included, since 
AAV9 particle mediated gene transfer can trigger undesirable immune responses. It was 
reported that innate immune responses to AAV vectors are primarily mediated by the TLR9–
MyD88 pathway which induces the production of pro-inflammatory cytokines by activating the 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway [133]. In the 
heart, NF-κB signalling promotes HF by eliciting signals that trigger chronic inflammation 
through enhanced elaboration of cytokines or interleukin signalling [134]. In the current study, 
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activators of NF-κB signalling like Tnfsf1a- (TNFα), different members of the tumor necrosis 
factor ligand superfamily- (Tnfsf) as well as Rela (p56) and Relb, two family members of the 
NF-κB family were found significantly upregulated in AAV9 treated mice when compared to 
non-treated mice, indicating a potential increase in NF-κB pathway activity. Active NF-κB 
signalling and upregulation of TNFα are not only indicative of a host response to AAV particles, 
but also of cardiac impairment [134, 135]. In line with this, upregulation of markers of the 
diseased heart like Myh7, Nppb, Gdf15 and Gata4 [130, 136] were found in AAV9 treated mice 
indicating an early hypertrophic cardiac response. Gene ontology (GO) analysis clustered the 
upregulated genes into apoptotic signalling pathways and those involved in the regulation of 
cell growth, whereas downregulated genes included those related to cellular response to stress 
and cell cycle. To evaluate potential IGFBP5 targets which are regulated independently of the 
AAV9-mediated transcriptional activation, the intercept of regulated genes found in IBP5 OE 
and Luc CT expressing hearts was excluded (see scheme in Figure 4-7A).  
To investigate whether IGFBP5 influences cardiac physiology, echocardiographic analyses was 
done 18 weeks post AAV9 administration. Parameters like left ventricular inner diameter, end-
systolic volume and heart to body weight ratio showed a significant decrease in mice which 
received IBP5 OE particles in comparison to Luc CT mice and untreated mice, all indicating a 
decrease in heart size. The decrease in the size of a tissue or organ due to cellular shrinkage is 
called atrophy, whereas the decrease in cell size can be caused by the loss of organelles, 
cytoplasm and proteins [137]. Several publications indicate an association of IGFBP5 with 
atrophy in skeletal muscle, whereas in these studies, Igfbp5 was found downregulated and 
associated with inflammation in an IGF-dependent manner [138–141]. RNAseq data from IBP5 
OE heart samples with hearts from untreated mice, revealed a downregulation of several genes 
which are important for the structural integrity of the heart. For instance, pro-fibrotic genes like 
collagens, TGFβ (Tgfb2) [119], Ddr2 [142], fibronectin (Fn1) [143], platelet-derived growth 
factor-C and D (Pdgfc, Pdgfd) [144, 145] and Sox9 [146], were downregulated upon IBP5 OE, 
indicating an anti-fibrotic or even a potential ECM destabilizing effect. Recently, SOX9 was 
reported to be a key regulator of cardiac fibrosis during ischemic injury [146]. These authors 
showed that SOX9 is a common transcriptional regulator of a large portion of the fibrosis-
related genes, whereas lineage-tracing experiments indicated that the majority of collagen-
positive fibroblasts stem from a pool of Sox9-expressing cells. Moreover, it could be shown 
that in vivo loss of Sox9 reduces the cardiac fibrotic response upon ischemic injury, which 
supports observations made in this study. COLA4A1 and COLA4A2 are the major structural 
components of the cardiomyocyte basement membrane, linking the sarcolemma of individual 
DISCUSSION  98 
myocytes to the surrounding ECM and interstitial cells [147]. Downregulation of both genes 
upon cardiomyocyte specific IBP5 OE suggests a loss of cell integrity. In line with this, the gap 
junction proteins CX43 (Gja1) and CX40 (Gja5) are downregulated in IBP5 OE mice, 
indicating an uncoupling of cell-cell contacts [148]. Moreover, downregulation of the 
potassium channel genes Kcnn2 and Hcn4 indicate a potential decrease in electrical conduction 
between cells, further supporting the loss of cellular integrity. Furthermore, a downregulation 
of myosin light chain kinase (Mylk) was observed in IBP5 OE hearts when compared to 
controls. Mylk is known to be downregulated upon TAC, whereas this downregulation was 
shown to coincide with the functional transition from compensated to decompensated 
hypertrophy [149] which is in agreement with the expression pattern of Igfbp5 in the transition 
to HF. Knockdown of Mylk was reported to be associated with sarcomeric disorganization in 
vitro [150] as well as in vivo with concomitant cardiomyocyte atrophy [151]. Another gene 
downregulated in IBP5 OE mice is the chaperone heat shock protein 90 (Hsp90aa1). Hsp90aa1 
was found upregulated in mice upon TAC and forms a complex with TGFβ receptor I (TGFβRI) 
in fibroblasts. Hsp90aa1 KO mice show drastically reduced collagen protein synthesis as well 
as inhibition of canonical TGFβ signalling with improved myocardial fibrosis [152]. 
Interestingly, cardiac fibroblasts conditioned with HSP90AA1-inhibited hypertrophied 
myocyte supernatant were reported to express less collagen which highlights the role of 
cardiomyocytes in the regulation of collagen expression in fibroblasts [153]. Further, these 
authors showed a novel signalling mechanism where myocyte-derived HSP90AA1 orchestrates 
interleukin-6 (IL-6) synthesis and its release by exosomes. In turn, exosomal IL-6 activates 
STAT3 in cardiac fibroblasts which culminates in excess collagen synthesis, leading to severely 
compromised cardiac function during cardiac hypertrophy. These findings might suggest a 
potential mechanism by which IGFBP5-induced downregulation of Hsp90aa1 in 
cardiomyocytes mediates the decrease in collagen production in cardiac fibroblasts, which 
needs further investigation. Furthermore, the IL6/STAT3 axis has been shown to be involved 
in IGFBP5 signalling [129, 154], supporting the hypothesized mechanism. In line with this, 
Stat5a, which was also shown to be involved in fibrotic processes mediated by Ang II [155], is 
downregulated upon cardiac IBP5 OE, further corroborating an anti-fibrotic effect of IGFBP5. 
These results were intriguing, since several publications provide evidence that IGFBP5 has a 
pro-fibrotic effect [91, 156–161] (discussed in detail in 5.4.4). Moreover, RNAseq data 
indicates a downregulation of the protein kinase C alpha (PKCα, Prkca) in IBP5 OE hearts. 
PKCα activity was found associated with hypertrophy, dilated cardiomyopathy, ischaemic 
injury and HF. Inhibition of PKCα was shown to reduce fibrosis and hypertrophy, enhance 
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cardiac contractility and attenuates HF [162]. To investigate gene regulation independent of the 
AAV9 mediated cardiac effect, expression of some IGFBP5-related genes was validated 
comparing hearts from Luc CT mice with hearts from IBP5 OE mice. qPCR analysis revealed 
a decreased expression of the developmental genes Mef2c, Nkx2.5 and Myocd. Mef2c loss-of-
function mutations were reported to contribute to congenital heart defects due to a reduced 
transcriptional activity [163], while loss of Mef2c in skeletal muscle results in improper 
sarcomere organization [164]. Moreover, Type I muscle atrophy was shown to be caused by 
microgravity-induced decrease of Mef2c in rats [165], all associating Mef2c downregulation 
with a reduced muscle integrity. Expression of Nkx2.5 [166] and Myocd [112] is known to be 
required for adult heart homeostasis, whereas reduced expression has detrimental effects on 
cardiomyocytes, such as apoptosis. Remarkably, ablation of the Myocd gene in the adult heart 
leads to a dissolution of sarcomeric organization, disruption of the intercalated disc and to the 
rapid-onset of HF and death [112]. In line with this, the downregulation of myocardin-related 
transcription factors were already associated with skeletal muscle atrophy in mice [167]. 
Additionally, the sarcomeric genes Myh7 and Tnnt2 are downregulated in IBP5 OE mice when 
compared to Luc controls. Gene ontology analysis clustered the downregulated genes into ECM 
organization, tissue morphogenesis, cell junction organization and heart contraction, whereas 
the upregulated genes are clustered in carboxylic acid metabolic process, oxidation-reduction 
process and lipid metabolic process which will be discussed later. A reduced heart size 
concomitant with a decreased ECM and sarcomeric gene expression as well as an altered 
cardiac cell integrity, suggests an atrophic process in the healthy adult heart upon IBP5 OE.  
On the one hand IGFBP5 downregulated Mylk, Myocd, Mef2c, Nkx2.5, Myh7 and Tnnt2 which 
seems to have detrimental effects on cardiomyocyte physiology, while on the other hand 
IGFBP5 induces the downregulation of key regulators of fibrotic processes like Sox9, Prkca 
(PKCα), and Hsp90aa1 which might have beneficial anti-fibrotic effects. Collectively, this data 
indicates that IGFBP5 could be both detrimental or beneficial for cardiac function. Investigation 
of IBP5 OE post-TAC will help to determine its function during HF. 
5.2.2 IGFBP5 increases fatty acid metabolism in the healthy heart  
RNAseq analysis indicated increased fatty acid metabolism in murine hearts upon cardiac IBP5 
OE. Fatty acid β-oxidation in the mitochondria is the main ATP source of the adult healthy 
heart. In the diseased heart, the primary myocardial energy source switches from normal fatty 
acid β-oxidation to glycolysis, a reversion to the energy metabolism in the fetal heart, reviewed 
by Doenst et al. [168]. The shift in substrate preference towards anaerobic glycolysis, also 
DISCUSSION  100 
called metabolic remodelling [169], might be an oxygen-sparing modulation of the diseased 
heart. Since fatty acid oxidation provides a greater capacity for energy production compared 
with glucose, reverting the heart back to using fatty acids might be an effective therapeutic 
option for treating HF [170]. Recently it has been reported that switching glycolysis back to 
fatty acid β-oxidation via PPARα activation alleviates HF [171, 172]. PPARα (peroxisome 
proliferator-activated receptor α, NR1C1) is a member of the nuclear hormone receptor 
superfamily of ligand-activated transcription factors and is highly expressed in cardiomyocytes. 
PPARα regulates the expression of key components of fatty acid metabolism [173] and its 
expression decreases continuously after TAC induced hypertrophy to HF [174]. IGFBP5 was 
already shown to interact with other nuclear receptors like the vitamin D receptor (VDR, 
NR1I1) and the retinoid X receptor-α (RXRα, NR2B1) [175, 176]. IGFBP3, the closest family 
member to IGFBP5, is known to interact with PPARγ (NR1C3) [177]. Interestingly, several 
PPARα target genes like Cyp4a14, Cyp4f15, Cyp8b1, ACADS, Acad10, TXNIP and Ccl2 [178] 
are found upregulated in murine hearts of IBP5 OE mice when compared to the controls. 
Moreover, TXNIP and CCL2 were also found regulated in hCFBs upon IBP5 OE in vitro (see 
chapter 4.4.2), further supporting a direct connection between PPARα and IGFBP5. Metabolic 
remodelling is not only characterized by changes in substrate utilization but also by 
mitochondrial dysfunction, which ultimately can result in ATP deficiency and impaired 
contractility [168]. Defective mitochondria are targeted for autophagic elimination 
(mitophagy), a process which controls mitochondrial quality. Reduced autophagy and 
accumulation of impaired mitochondria have been linked to the progression of HF, whereas 
increased autophagy in the myocardium in response to stress is initially a protective mechanism 
(see reviews from Sabbah and Moyzis et al. [179, 180]). RNAseq data from murine hearts with 
IBP5 OE revealed a downregulation of Bcl2 and Bcl2l13, which participate in mitophagy [181] 
and an upregulation of Fis1, a protein that promotes mitochondrial fission [180]. Moreover, 
Pink1 (PTEN-induced putative kinase 1), a mitochondrial serine/threonine-protein kinase was 
found upregulated. The PINK1/Parkin pathway is involved in marking dysfunctional 
mitochondria for clearance by autophagy and is indispensable for normal heart function. PINK1 
protein levels are markedly reduced in end-stage human HF. In line with this, PINK1 deficient 
mice develop left ventricular dysfunction, hypertrophy and a higher degree of fibrosis due to 
oxidative stress and impaired mitochondrial function [182]. Recently it was reported that Fis1-
mediated upregulation of PINK1 expression in senescent human umbilical vein endothelial cells 
(HUVECs) might present a protective mechanism against oxidative damage in mitochondria 
[183], suggesting that IGFBP5 might have a beneficial effect on mitochondria turnover. 
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Collectively, this data indicates that IGFBP5 has a positive effect on fatty acid metabolism, 
potentially mediated via PPARα, and suggests a role in mitochondrial turnover. Further 
investigation of IBP5 OE in the diseased heart is necessary to reveal whether it is detrimental 
or beneficial for cardiac function 
5.3 IGFBP5 is a novel cardiokine with paracrine and endocrine features  
5.3.1 IGFBP5 is a potential cardiokine which might serve as a biomarker 
To determine which cell population in the diseased murine heart is responsible for the 
upregulation of Igfbp5, isolated cardiomyocyte and non-myocyte cell populations from TAC-
mice and mice with cardiomyocyte specific β-Cat GOF were investigated. qPCR analysis 
revealed that cardiomyocytes exclusively upregulate Igfbp5 in both models when compared to 
controls. Interestingly neither immunoblot analysis, nor IF staining from isolated β-Cat GOF 
cardiomyocytes, could confirm this upregulation. A similar observation was made in total heart 
lysates from TAC mice and in total heart lysates from patients with dilated cardiomyopathy. 
There, no differences in intracellular IGFBP5 protein quantity was observed in murine or 
human HF samples when compared to controls. Since IGFBPs have secretory signal peptides 
and the mature proteins are mainly found extracellularly [111], this data suggests that increased 
protein quantities might be directly secreted. ELISA analysis of cell supernatants from β-
Cat GOF cardiomyocytes indicated a high IGFBP5 secretion in comparison to controls which 
is in line with the mRNA expression data. Since it is known that another IGFBP member, 
IGFBP3, is detectable in blood serum [184], it was investigated whether increased IGFBP5 
secretion can also be detected in blood serum. ELISA analysis from serum samples from TAC 
mice and from mice with cardiac β-Cat GOF showed a significant increase of serum IGFBP5 
in comparison to control mice. IGFBP5 is already under investigation as a potential biomarker 
for several diseases, excluding cardiovascular disorders [185–187]. For example, differences in 
serum IGFBP5 levels could be detected in Crohn’s disease [188] or in type 1 and type 2 diabetes 
mellitus [189] patients when compared to controls. In lung cancer, IGFBP5 is already a well 
recommended biomarker, since its serum levels correlate with the progression and outcome of 
the disease [190]. In contrast to IGFBP5, IGFBP3 serum levels were shown to correlate with 
increased risk of developing ischemic heart disease [108]. To date, no correlation between HF 
and IGFBP3 serum levels were shown, which is in line with this study, where no difference in 
Igfbp3 expression could be observed on comparing human or murine failing heart samples to 
controls. 
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Proteins secreted by the heart are termed cardiokines [191]. Cardiokines play a crucial 
physiological role in maintaining heart homeostasis (e.g. growth factors and endocrine 
hormones), sending signals of distress and exacerbating pathology (e.g. cytokines) or 
responding to myocardial damage with remodelling or healing (e.g. extracellular matrix 
proteins and stem cell-homing factors) [191, 192]. Apart from their paracrine function, 
cardiokines also exert endocrine regulatory effects on peripheral organs and tissues. Alteration 
in the repertoire of cardiokines serves as both a determinant of cardiac disease-response and an 
indicator of cardiac disease state. Therefore, cardiokines could represent potential biomarkers 
and might serve as promising therapeutic targets. As an example, the most prominent and 
longest known cardiokine is ANP (atrial natriuretic peptide, encoded by the gene Nppa) [193]. 
ANP was identified as a heart-secreted hormone that provides a peripheral signal to the rest of 
the organism to modify blood pressure and volume under conditions of HF [194]. Thus, ANP 
is a suitable early prognostic marker throughout for cardiac disease and was even recommended 
as a potential therapeutic target [195]. However, ANP, as a marker, is unable to ascertain a 
distinct disease state and cannot be used to classify disease progression. The regulatory effects 
of cardiokines are often complex, as they can exert bidirectional actions to promote repair after 
cardiac injury and/or aggravate an imbalance of cardiac function [192].  
In conclusion, this data provides evidence that IGFBP5 might be a cardiokine, primarily 
secreted from the cardiomyocytes in the failing heart. Further, IGFBP5 might act in an 
autocrine/paracrine manner to contribute in intercellular communication within the 
myocardium. This study showed IGFBP5 upregulation and secretion at the onset of HF, making 
it a suitable biomarker candidate indicating HF transition.  
5.3.2 IGFBP5 can mediate cardiomyocyte-fibroblast crosstalk 
In the previous section it was shown that IGFBP5 is primarily secreted from cardiomyocytes in 
the diseased heart. Bidirectional cardiomyocyte-fibroblast crosstalk is a well-known 
mechanism in both, normal and diseased hearts. To investigate whether secreted IGFBP5 can 
act in a paracrine manner on possible receiver cells, hCFBs were cultured with IGFBP5-FLAG 
conditioned medium and showed an uptake of the exogenous IGFBP5. A cellular uptake of 
IGFBP5 was already described in human breast cancer cells, human osteosarcoma cells and 
porcine vascular smooth muscle cells [64, 85, 120] but so far, no IGFBP5 uptake was shown in 
cardiac cells. Bidirectional cardiomyocyte-fibroblasts crosstalk during cardiac disease can lead 
to structural and functional changes and finally to cardiomyocyte hypertrophy, fibrosis and 
arrhythmias [2]. As an example, it was shown that under disease stimuli, cardiomyocytes 
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induced paracrine secretion of the cardiokine Ang II and reactive oxygen species (ROS), which 
mediate the expression of TGFβ in cardiac fibroblasts. In the fibroblasts, TGFβ induces the 
expression of CTGF, COLA1A1 (also cardiokines [191, 192]) and led to myofibroblast 
formation [196]. TGFβ secreted by fibroblasts in turn can induce cardiomyocyte hypertrophy 
[197], affects cardiomyocyte electrophysiology [198] and Ca2+ handling [199]. A similar 
concept was already described for HSP90AA1 [153], which was found regulated in mice with 
cardiomyocyte specific IBP5 OE in this study, potentially mediating anti-fibrotic effects (see 
chapter 4.2, 5.2.1). Interestingly, a significant upregulation of the IGFBP5 transcript was 
detected in IGFBP5-FLAG conditioned medium treated hCFBs, indicating a positive feedback 
activation. The activation of IGFBP5 expression due to exogenous IGFBP5 could be explained 
via three possible mechanisms: (i) Exogenous receptor activation with subsequent signalling 
cascade activation and initiation of transcription by unknown factors. (ii) Reuptake of IGFBP5 
and activation of an endogenous receptor. (iii) Direct action as a possible transcription co-
factor. Indicative for the first hypothesis is a characterization of a 420 kDa membrane protein 
which was identified as an IGFBP5-receptor. However this potential IGFBP5-receptor could 
not be cloned and validated [57]. Flynn et al. provided further evidence that IGFBP5 mediates 
its actions via binding to an uncharacterized cell surface receptor, since they found IGFBP5-
dependent activation of Gαi3, a heterotrimeric G protein subunit [200]. Several studies show 
that exogenous addition of IGFBP5 to cells in vitro led to different cellular effects, but none of 
these authors could describe how the signal was mediated [201–203]. IGFBP5 has the ability 
to enter cell nuclei via its nuclear localisation sequence [65] and could potentially mediate 
transcriptional processes via binding to co-factors, nuclear receptors or the histone-DNA 
complex which supports the third conjecture [85, 86, 176, 204]. These findings underline a 
possible role for IGFBP5 as a transcriptional co-factor, potentially activating its own 
expression.  
Collectively, this data suggests a dynamic paracrine relationship between cardiomyocytes and 
fibroblasts mediated by IGFBP5. Subsequent to secretion by donor cells (cardiomyocytes), 
IGFBP5 could be reuptaken by receiver cells (cardiac fibroblasts) and influences its own 
expression. In the next chapter, it will be demonstrated that cardiac fibroblasts that received an 
IGFBP5 signal, can respond and even reply via secretion of different cardiokines.  
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5.4 Potential role of IGFBP5 in cardiac fibroblasts and the failing heart 
5.4.1 Identification of potential IGFBP5 targets in human cardiac fibroblasts 
The previous data regarding IGFBP5 secretion and reuptake indicate a paracrine mediator role 
for IGFBP5 in cardiomyocyte-fibroblast crosstalk. Furthermore, the effect of IGFBP5 (secreted 
from the sender cell, the cardiomyocyte) on possible receiver cells (cardiac fibroblasts) was 
investigated in this study. RNA sequencing of hCFBs with an OE of IGFBP5 (IBP5 OE) 
revealed twelve differentially expressed genes. Strikingly, among the downregulated genes, 
there were few genes which could mainly be attributed to cardiomyocytes and there is minimal 
insight into these genes in the context of cardiac fibroblasts.  
{1} The most prominent downregulated gene in IBP5 OE hCFBs is MYOCD. MYOCD is a 
transcriptional coactivator of serum response factor (SRF) which plays an important role in the 
development of cardiac myocytes and vascular smooth muscle cells [205]. Even when 
exclusively expressed in cardiac and smooth muscle cells, MYOCD can also be detected in 
human fibroblasts [206]. MYOCD is essential for adult heart function due to maintenance of 
cardiomyocyte structure and sarcomeric organization. Conditional cardiomyocyte specific KO 
leads to severe HF due to cardiomyocyte apoptosis and fibrosis [112]. {2} Thioredoxin-
interacting protein (TXNIP, also known as vitamin D3 upregulated protein 1 or thioredoxin 
binding protein 2), is an endogenous inhibitor of the antioxidant thioredoxin. Maintained 
expression of TXNIP post-TAC was reported to have cardioprotective effects due to 
thioredoxin inhibition [114]. {3} Another downregulated gene found upon IBP5 OE in hCFBs 
was stanniocalcin-1 (STC1). Stanniocalcin-1 is a secreted glycoprotein hormone [207], 
reported to cause reversible inhibition of transmembrane calcium currents in rat cardiomyocytes 
through L-channels which might alter calcium homeostasis of the failing heart [113]. {4} CC-
chemokine ligand 2 (CCL2, also monocyte chemoattractant protein 1 (MCP1)) is a potent 
chemoattractant for monocytes, T cells, and natural killer cells to the sites of inflammation 
[208]. Increased CCL2 levels were reported to contribute to fibrotic processes and modulate 
ECM components in human skin fibroblasts [209]. KO of Ccl2 attenuated post-infarction 
remodelling, at the expense of a prolonged inflammatory phase and delayed replacement of 
injured cardiomyocytes with granulation tissue [210]. {5} Hyaluronan synthase 2 (HAS2) is 
one of three synthases for the acidic carbohydrate hyaluronan, which is one of the major 
components of the ECM [211]. It was shown that OE of Has2 in mesenchymal cells in mice 
promotes invasiveness of fibroblasts and causes severe lung fibrosis [212]. {6} Among the 
upregulated genes due to IBP5 OE in hCFBs, the most prominent gene is the growth 
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differentiation factor 15 (GDF15), a member of the transforming growth factor β superfamily. 
Recently GDF15 was evaluated as a biomarker of cardiovascular stress but also as a predictor 
of progression, prognosis and mortality in patients with HF and other established diseases [117, 
213]. {7} PLEKHA7 (pleckstrin homology domain containing family A member 7) is a 
cytoplasmic component of the epithelial adherens junction belt [214]. The PLEKHA7 zebrafish 
homolog HADP1 was shown to interact with the PI4K pathway to regulate normal Ca2+ 
dynamics, and is thus required for myocardial contractility [215]. {8} AHNAK2 (meaning giant 
in Hebrew) is considered a plasma membrane support protein in muscle and lining epithelium. 
In cardiomyocytes, AHNAK2 localizes at both the sarcolemma and at Z-band sites suggesting 
a role in the excitation/contraction coupling mechanism [216]. Haase et al. reviewed that 
AHNAK has an inhibitory role on the L-type Ca2+ channel (ICaL) predominantly through 
slowing the channel inactivation [217]. {9} Another gene found being upregulated in hCFB 
upon IBP5 OE is NR3C2 (nuclear receptor subfamily 3 group C member 2, also known as 
mineralocorticoid receptor). NR3C2 regulates the expression of ionic and water transporters 
and serves for renal salt-balance maintenance, whereas antagonists are widely used in treating 
HF [218]. Noteworthy, miR-139-5p, a microRNA found downregulated upon HF [125–127] is 
predicted to target both, IGFBP5 and NR3C2 [219].  
 
Table 5-1: Comparison of gene expression 
Sample type hCFB whole heart 
Gene hIBP5 OE HF mouse HF human 
AMDHD2 ↑ ↑ (TAC)* ↓ (DCM)* 
GDF15 ↑ ↑ (TAC) [117] ↑ (HF)[220] 
PLEKHA7 ↑ ↑ (TAC)* ↓ (DCM)* 
NR3C2 ↑ ↓ (MI, TAC) [221] ↑ (CHF) [118] 
SH2D5 ↑ ↑ (TAC) * ↑ (DCM)* 
AHNAK2 ↑ / ↓ (DCM)* 
STC1 ↓ ↑(Hypoxia) [222] ↑ (HF) [113] 
CCL2 ↓ ↑ (MI) [210] ↑ (CHF) [115] 
VEPH1 ↓ ↑ (TAC)* ↑ (DCM)* 
HAS2 ↓ ↑ (TAC)* ↑ (HF, MI) [116, 223] 
MYOCD ↓ ↓ (TAC)* ↓ (DCM)* 
TXNIP ↓ ↓ (TAC) [114] ↑ (DCM)* 
 
Comparison of gene expression in human cardiac fibroblasts (hCFB) upon IBP5 OE with gene expression in ventricles 
from mice and humans with heart disease. HF: heart failure, DCM: dilated cardiomyopathy, CHF: congestive HF, MI: 
myocardial infarction, TAC: transverse aortic constriction. Red indicates upregulation, blue indicates downregulation, * 
indicates sequencing data (Dr. Sara Khadjeh, Department of Cardiology and Pneumology, UMG. Khadjeh et al., 
unpublished) which is not described/confirmed in literature so far.  
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5.4.2 Potential role of IGFBP5-induced genes in human cardiac fibroblasts 
STC1, AHNAK2 and PLEKHA7, which were found regulated upon IBP5 OE in hCFBs could 
be associated with calcium handling. Besides the conduction system, calcium plays a role in 
cell communication between cardiomyocytes and fibroblasts and is mediated via gap junctions 
[224]. In the diseased heart, cardiomyocyte-fibroblast interactions change and facilitate disease 
progression [225, 226]. Another reason for the changed expression of these calcium handling 
related genes might be their involvement in the cellular conduction system. Recent in vitro 
evidence indicates electrical coupling between cardiomyocytes and fibroblasts which could be 
a consequence of cardiomyocyte decoupling [227]. A changed expression of calcium handling 
genes could potentially be due to fibroblast-cardiomyocyte coupling. HAS2, CCL2 and VEPH1 
could be associated with fibrotic effects. These genes are downregulated upon IBP5 OE in 
cardiac fibroblasts, whereas upon hypertrophy and HF in mice and in humans, they are 
upregulated. Since fibrosis is a process which accompanies and even leads to HF [3], an 
upregulation of these genes in disease is not surprising. However, the downregulation in cardiac 
fibroblasts indicates that IGFBP5 might attenuate fibrotic effects, which will be discussed in 
detail below. Moreover, regulation of the membrane associated proteins PLEKHA7, AHNAK2 
and HAS2 might indicate an altered cell integrity. Cardiogenic genes like MYOCD, TXNIP and 
STC1 are regulated in IBP5 OE cardiac fibroblasts. It was recently shown that cardiac 
fibroblasts possess potential plasticity and express cardiogenic genes [228]. These authors 
showed evidence that a subpopulation of cardiac fibroblasts are primed for trans-differentiation 
by expression of cardiogenic factors. Notably, some studies show that MYOCD, in combination 
with other cardiac transcription factors, has the capacity to activate the cardiac gene program 
[229, 230]. The cardiogenic identity of cardiac fibroblasts is characterised by the presence of 
transcription factors that are fundamental for cardiogenesis and are found re-activated in the 
diseased heart [231]. In line with this idea, the appearance of IGFBP5 and its potential target 
MYOCD in hCFBs is not unexpected. Both genes are developmental transcriptional co-
activators (evidence for IGFBP5 see 4.5.1), re-activated in the event of cardiac disease. The 
potential adaptability of cardiac fibroblasts to a cardiogenic gene program implicates a broader 
spectrum of functions for cardiac fibroblasts during disease besides myofibroblast formation. It 
can be speculated as to how these primed cardiogenic fibroblasts contribute to the maintenance 
of cardiac function during disease. 
In summary, IBP5 OE in hCFB leads to downregulation of genes which can be associated with 
fibrotic processes and upregulation of genes which have a cardiogenic identity. Strikingly, 
GDF15 and MYOCD, two genes which are of great importance in the diseased heart, show the 
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same regulation upon IBP5 OE in hCFBs as they do in the event of HF in mice and in humans. 
This indicates a direct and maybe even conserved connection between IGFBP5 and these genes 
consequent to HF.  
5.4.3 Functional performance of fibroblasts with IGFBP5 overexpression 
The prior data clearly indicates that IGFBP5 induces gene expression in cardiac fibroblasts, but 
so far it is not known how this might influence hCFB behaviour. Cardiomyocytes-fibroblasts 
crosstalk is bidirectional. Since IBP5 OE in hCFBs leads to the expression of secretory proteins 
like GDF15, STC1, HAS2 and CCL2, it needs to be investigated whether these proteins might 
act in a paracrine manner and influence cardiomyocytes in a feedback reaction. To examine 
functional performance of these cells, engineered human myocardium (EHM) was generated. 
Validation of functional performance did not show any difference between EHMs with GFP 
control hCFBs and EHMs with hCFBs with IBP5 OE regarding force generation, whereas the 
velocity of tissue relaxation was significantly reduced in EHMs with IBP5 OE hCFBs. 
Additionally, a faster rate of change in force over the rate of time (isometric contraction and 
isometric relaxation) could be observed in EHMs with IBP5 OE hCFBs. These results indicate 
a faster calcium shuttling per contraction, suggesting a more efficient calcium handling in 
EHMs with IBP5 OE hCFBs. This observation is in agreement with the already mentioned IBP5 
OE-induced secretion of proteins which are associated with calcium handling. Further, it cannot 
be excluded that secreted IGFBP5 itself, alters cardiomyocyte physiology. Such a phenomenon 
was already described by Cartledge et al., who reported that soluble mediators secreted from 
either fibroblasts- or myofibroblast have a contrary influence on calcium transient amplitudes 
in co-cultured rat cardiomyocytes [232]. Furthermore, IGFBP5 mediated change in isometric 
contraction and isometric relaxation could be due to changed tissue stiffness, while a faster 
contraction indicates softer tissue which could be due to a change in ECM components. These 
observations are in line with in vivo data from this study, where gene regulation in hearts with 
cardiomyocyte specific IBP5 OE is clustered in ECM organization, cell junction organization 
and heart contraction, indicating that these processes are partially due to the effect of IGFBP5 
on cardiac fibroblasts. 
Collectively, this data suggests that the IGFBP5 mediated effects on hCFBs alter EHM 
physiology, which might be due to IGFBP5-induced paracrine actions on cardiomyocytes in 
the tissue.  
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5.4.4 Potential influence of IGFBP5 on fibrosis and premature fibroblast senescence 
Several publications provide evidence that IGFBP5 has a pro-fibrotic effect. Upregulated 
expression of IGFBP5 was found in two human fibrotic disorders namely dermal systemic 
sclerosis [156] and idiopathic pulmonary fibrosis [157]. Both disease phenotypes could also be 
observed in mouse models, where mice showed increased thickness of the dermis [160] and 
pulmonary fibrosis [161] upon in vivo IBP5 OE. In liver, IGFBP5 improved the survival of 
myofibroblasts via enhanced expression of pro-fibrotic genes [158]. Regarding the heart, 
IGFBP5 was shown to mediate high glucose-induced pro-fibrotic effects in rat neonatal cardiac 
fibroblasts [91]. All these reports show evidence that IGFBP5-dependent pro-fibrotic effects 
are accompanied by augmented synthesis of ECM components like collagen and fibronectin. 
Further, it was shown that IBP5 OE led to increased expression of vimentin and ACTA2, 
indicating fibroblast-myofibroblast trans-differentiation in vitro and in vivo [160, 161]. 
Strikingly, in this study IBP5 OE in hCFBs did not lead to an upregulation of ACTA2. Proof-
of-concept experiments confirmed that cardiac fibroblast had the capacity to transdifferentiate 
to myofibroblasts upon TGFβ treatment, while TGFβ led to the expression ACTA2 but did not 
influence IGFBP5 expression. Milyavsky et al. reported that TGFβ treatment activates 
MYOCD (MYOCD), which is essential for TGFβ-induced myofibroblast differentiation [233]. 
In this study, MYOCD was found downregulated upon IBP5 OE in hCFBs. Interestingly, a 
null-mutation of the myocardin-related transcription factor A (MRTF-A) was shown to has 
anti-fibrotic effects post-MI [234] suggesting a correlation between MYOCD downregulation 
and anti-fibrotic effects. Among the downregulated genes found in hCFBs upon IBP5 OE, not 
only MYOCD can be regulated in a TGFβ-dependent manner. The pro-fibrotic genes HAS2, 
CCL2 and VEPH1 are also known to be associated with TGFβ as well [235–237]. Additionally, 
GDF15 was found upregulated in dermal systemic sclerosis in which TGFβ plays a central role 
[238]. It was shown that GDF15 directly activates CCL2 [235], which in turn leads to fibrosis. 
Interestingly, CCL2 is downregulated in hCFB upon IBP5 OE even when its direct activator 
GDF15 is upregulated in this condition. This data provides evidence that the pro-fibrotic effect 
of GDF15, which intrinsically upregulates CCL2, is TGFβ dependent. Taken together, pro-
fibrotic genes which are known to act in a TGFβ-dependent manner are downregulated in hCFB 
upon IBP5 OE, indicating an anti-fibrotic effect of IGFBP5 in these cells. Significantly, in vivo 
data from this study indicated that cardiomyocyte specific IBP5 OE downregulates several 
ECM genes, decreasing the expression of fibrotic key mediators (see chapter 4.2), supporting 
the recent in vitro data. 
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In line with the previous conclusion, Sokolović et al. reported that AAV-mediated liver specific 
IBP5 OE in mice reduced liver fibrosis in chronic cholangiopathy [159]. The anti-fibrotic effect 
was shown to be constituted by a reduced cell proliferation due to enhanced cellular senescence. 
In line with this, IGFBP5 was found to be a paracrine mediator of STAT3-induced premature 
senescence in TIG3 human fibroblasts [239]. In contrast to replicative senescence, which plays 
a fundamental role in ageing and which is originally characterized by telomere erosion [240], 
premature senescence is an irreversible cell-cycle arrest primarily designed to initiate the 
elimination of damaged cells [241]. In cardiac fibroblasts, premature senescence was found to 
be associated with cardiac fibrosis subsequent to murine myocardial infarction [242] and in 
patients with atrial fibrillation [243]. Both studies show that premature fibroblast senescence 
has beneficial anti-fibrotic effects in vitro. In vivo, premature senescence induced anti-fibrotic 
effects and cardio-protection in the event of HF in mice as reported by Meyer et al. [244]. There 
is further evidence for a critical role of IGFBP5 in the process of premature senescence. Both 
OE and exogenous IGFBP5 induced premature senescence in endothelial cells through a p53-
dependent signalling pathway [245]. In silico prediction showed that IGFBP5 contains a p53 
response elements [246]. Further, It was shown that coagulation factor FXa-induced- [247] as 
well as irradiation-induced [248] premature senescence in endothelial cells is mediated by 
IGFBP5. Notably, IGFBP3, -4, and -6 were also associated with the process of cell senescence 
[249]. In this study, IBP5 OE in vivo did not disclose any premature senescence markers which 
is most likely due to the absence of myofibroblast trans-differentiation [244]. Nevertheless, 
some of the identified IGFBP5 targets can be correlated to this process. The transcriptome data 
revealed an upregulation of GDF15 upon IBP5 OE in cardiac fibroblasts. It was shown that 
GDF15 is a downstream target of p53 [250], which is activated in premature senescence [221, 
251]. Furthermore, IGFBP5 caused the upregulation of AHNAK2 in hCFBs. Ahnak2 was also 
found upregulated in an in vitro model with overexpressed histone variant H2A.Bbd [252], 
which was reported to be a senescence marker [253]. Depletion of HAS2 was shown to induced 
pulmonary fibroblast senescence [254]. In this study, HAS2 was also downregulated in hCFBs 
upon IBP5 OE. Another characteristic of senescent cells is that they can communicate with their 
environment through a so-called senescence-associated secretory phenotype (SASP). These 
paracrine factors can locally propagate the senescence response to the surroundings [255]. This 
cell characteristic is consonant with features of IGFBP5, which acts in a paracrine manner, 
mediating cellular crosstalk. 
To summarize, this data provides evidence that a divergence from the existing literature, 
IGFBP5 has an anti-fibrotic- or at least fibrosis extenuating effect on cardiac fibroblasts which 
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is confirmed by in vivo data from this study. Results from this study further support a role for 
IGFBP5 in premature fibroblast senescence, which is described to arrest or even antagonize 
fibrosis.  
5.5 IGFBP5 acts as a transcriptional co-factor  
In the last chapters it was shown that hCFBs can uptake IGFBP5 and in this way IGFBP5 can 
influence its own gene expression in these receiver cells. As mentioned before, IGFBP5 has a 
nuclear localisation sequence which enables it to enter nuclei [64]. Its nuclear import appears 
to share a common pathway with IGFBP3, both mediated by importin-α/importin-β complex 
[65, 256]. It has been reported that IGFBP5 interacts with nuclear components [85, 86]. Since 
IGFBP5 possesses no DNA binding domain, it might function as a transcriptional co-regulator. 
Direct evidence for such a transcriptional co-regulator role of IGFBP5 was provided by 
Schedlich et al. The authors reported that IGFBP5 interacts with the nuclear vitamin D receptor 
(VDR, NR1I1) and blocks its heterodimerization with the nuclear retinoid X receptor-α (RXRα, 
NR2B1) [175, 176]. In silico prediction of annotated protein-protein interactions [257] indicate 
other nuclear receptors (NR2F2, NR2F1, NR4A1) potentially binding IGFBP5. Moreover, an 
interaction with the nuclear receptors PPARα is further supported by in vivo data from this 
study, whereas cardiac IBP5 OE led to the activation of several PPARα targets (see chapter 
5.2.2), indicating that IGFBP5 is a transcriptional co-factor. However, no IGFBP5 association 
with any DNA loci with subsequent target activation was reported. To determine whether 
IGFBP5 is associated with genomic DNA regions, ChIP analysis of potentially IGFBP5-
(co)bound chromatin was done in hCFBs. It revealed two bound gene loci namely IGFBP5 
itself and TNNT2. Since the IGFBP5 occupied loci in both, IGFBP5 and TNNT2 mark the 
5´region from the TSS of both genes, both loci represent putative promoter regions. Published 
data for H3K4me, from reference hCFBs, mark accessible chromatin in IGFBP5-FLAG bound 
loci. Whereas there is H3K4me occupancy in the IGFBP5 locus, no H3K4me occupancy is 
visible for TNNT2 in hCFBs indicating no TNNT2 gene activity. TNNT2 is a regulatory protein 
that plays a crucial role in muscle activity. Since TNNT2 is predominantly expressed in 
cardiomyocytes and not in fibroblasts, the absence of H3K4me occupancy in cardiac fibroblasts 
confirms the epigenetic silencing of this gene. IGFBP5 was found associated to these loci, 
which suggests a repressive function of IGFBP5 in this context, which was supported by 
luciferase reporter assays. Further in silico analysis of the IGFBP5-occupied loci of IGFBP5 
and TNNT2 predicts potential NKX2.5 binding motifs. NKX2.5 is a cardiac transcription factor 
which was shown to regulate both, the TNNT2 [258] and the IGFBP5 promoter [259]. In 
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contrast to findings by Nimura et al., luciferase assays revealed that the IGFBP5 promoter is 
activated upon NKX2.5 expression. In line with these findings, Dorn et. al showed, that OE of 
NKX2.5 increases IGFBP5 transcription [88]. In line with observations by Kobayashi et al., the 
TNNT2 promoter showed activation upon NKX2.5 expression. Evaluation of double co-
transfection luciferase experiments showed that IGFBP5 led to a significant reduction of 
NKX2.5-mediated TNNT2 promoter activation, indicating an antagonistic action of IGFBP5 
on NKX2.5-mediated actions. NKX2.5 is a cardiac transcription factor and a marker for 
myocardial progenitor cells. NKX2.5 can activate TNNT2 expression [258], with TNNT2 
expression being commonly used as a marker for stem cell or cardiac progenitor cell 
differentiation [88, 89, 103, 258, 260, 261]. NKX2.5, which commits cells to the cardiac 
lineage, could promote cardiac cell differentiation by activating TNNT2 expression. Gene 
regulation is a complex and tightly controlled process. The presence and absence of 
transcriptional activators and repressors is time and context dependent. Both, IGFBP5 and 
NKX2.5 are expressed in the early cardiac crescent [87]. It can be hypothesized that the 
simultaneous occurrence of NKX2.5 and IGFBP5, which keeps cells in a cardiac progenitor 
like state [87, 89], might be due to, among other things, IGFBP5 which represses the promoter 
activation of TNNT2 and even antagonizes its NKX2.5-mediated activation. During murine 
cardiogenesis in vivo, Igfbp5 expression decreases with progressing heart maturation (as 
described in chapter 2.2.3), which might be in line with its abolished repression of (NKX2.5-
mediated) TNNT2 activation and subsequent cardiomyocyte differentiation. Of special interest 
is the revelation that IGFBP5 is primarily a secreted protein that mediates extracellular effects, 
predominantly in an IGF-dependent manner. There is considerable evidence that secreted 
factors like hormones and growth factors are capable of modulating cellular responses not only 
indirectly by activating classical signal transduction pathways, but also directly by nuclear 
targeting. A duality of function was already been shown for insulin [262], platelet-derived 
growth factor [263], and fibroblast growth factor [264]. Besides being a binding protein for 
IGF, IGFBP5s capacity for nuclear uptake and its potential for interactions with nuclear 
receptors (transcription factors) represents its capacity to act as both, binding protein and ligand.  
The collected data provide evidence that IGFBP5 can act as a transcriptional co-factor via 
indirect association with DNA. Besides binding its own promoter, it can repress the TNNT2 
promoter and even antagonize NKX2.5-mediated TNNT2 promoter activation. Furthermore, 
there is a growing body of evidence that IGFBP5 interacts with nuclear receptors to mediate 
transcriptional processes. Additional investigations of the nuclear role of IGFBP5 is necessary, 
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since a better understanding of IGFBP5 action in the nucleus may open new opportunities for 
therapeutic intervention in HF and other diseases like cancer. 
5.6 IGFBP5 plays a central role in the cardiac regulatory hierarchy 
mediating cardiac progenitor fate 
5.6.1 IGFBP5 controls stem cell commitment and arrests cardiomyocyte differentiation 
Comparing different cell populations of the adult murine heart, the expression of Igfbp5 is 
highest in the undifferentiated Sca1-positive progenitor cell pool (unpublished, see preliminary 
data chapter 2.2.3). In vitro, downregulation of Igfbp5 was correlated with increased stem cell 
and progenitor differentiation [87–89], while sustained expression was reported to impair 
cardiomyocyte differentiation. To investigate the impact of IGFBP5 on stem cell commitment 
and differentiation, a KO hES cell line was generated using a double-paired CRISPR/Cas9-
D10A nickase (Cas9n) genome editing approach. Application of this technique led to two 
different hES cell lines where the genomic changes comprised the planned homozygous 
deletion of the TSS in one cell line (clone (K)22) and an unexpected heterozygous random 
integration of plasmid material in a second cell line (clone (K)12). Despite deletion of the TSS 
in in the deletion clone (K22), an expression of the remaining IGFBP5 transcript was detectable, 
where there was neither a significant difference in transcript quantity nor in protein secretion 
measurable in comparison to the mock control. Since neither geno-, nor phenotyping of the 
deletion clone (K22) delivered any conclusive result, the discussion will only focus on the 
insertion clone (K12). Cell line characterization of clone K12 revealed an increased IGFBP5 
transcript abundance and an increased IGFBP5 protein secretion when compared to the control. 
As indicated in the last chapters, IGFBP5 can activate its own expression. The gain-of-function 
(GOF) phenotype could potentially be due to a cellular protein accumulation of IGFBP5 with 
subsequent positive feedback regulation of IGFBP5 transcription. So far, it can only be 
speculated how the insertion of genetic material leads to a GOF phenotype, but it might be due 
to a protein stabilization or an aggravated ER release due to the changed protein size and 
changed biochemical properties. These observations indicate that the insertion of genetic 
material in this clone led to a GOF-like mutant. The underlying molecular features, leading to 
this GOF still need further investigation.  
Analysing the influence of increased IGFBP5 abundance in stem cells, a decreased expression 
of pluripotency markers OCT4, TRA1-60 and SOX2 was detected in comparison to control cells 
indicating reduced stemness of clone K12. Recently it was shown that SOX2 alone is needed 
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to preserve self-renewal and pluripotency in hES cells and besides, it regulates OCT4 and TRA-
1-60 [265]. A direct effect of IGFBP5 on SOX2 and OCT4 was reported by Wang et al. [266]. 
These authors showed that OE of IGFBP5 in human melanoma cells led to a decrease of SOX2 
and OCT4, indicating a direct impact of IGFBP5 on stemness. In the present study, clone K12 
possessed the capacity to differentiate in all three germ layers, indicating that IGFBP5 GOF 
does not fully determine the cell fate at this early stage. Directed differentiation of K12-hES 
cells led to spontaneously beating cardiomyocytes with a reduced cell size (which was already 
seen in the hES cells) and a concomitant increased in cyclin D1 expression, all indicating a 
potential increase in cell proliferation. An IGFBP5-dependent cyclin D1 activation was also 
shown in human prostate cancer cells [267], underlining a stimulatory effect of IGFBP5 on 
proliferation in this study. Moreover, AXIN2, a direct Wnt target was found upregulated in the 
differentiated K12 cells. Wnt-signalling is known to activate proliferation, what is in line with 
increased cell cycling. Besides, Wnt-signalling plays a multiphasic role during cardiogenesis 
and cardiomyocyte differentiation [268]. Coherent with increased proliferation of cardiac 
progenitor cells, active Wnt-signalling is known to inhibit cardiomyocyte differentiation. To 
investigate stem cell commitment and the potential of the IGFBP5 GOF hES cells to 
differentiate into cardiomyocytes, the expression of some key markers was investigated after 
directed differentiation. Analysis of early cardiogenic progenitor markers such as NKX2.5 and 
TBX5 revealed an increased expression in differentiated K12 cells when compared to control 
cells. Together with the reduced stemness of K12 hES cells, these observations indicated a stem 
cell specification towards the cardiac lineage. Further, Myocd, a potential target gene of 
IGFBP5 as reported earlier in this study, was found upregulated in differentiated K12 cells. 
Myocd was shown to be important for cardiac cell determination and differentiation [269]. 
Whereas ectopic OE of Myocd seems to promote cardiac differentiation, repression of Myocd 
dramatically inhibits cardiomyocyte differentiation and cardiogenesis and in vitro and in vivo 
[270, 271]. Intriguingly, in over-specified progenitor cells, which highly express IGFBP5, 
NKX2.5 and TBX5 [87], Myocd was found downregulated [269]. Taken together, the increased 
NKX2.5 and TBX5 expression with a concomitant MYOCD upregulation indicates that the 
differentiated K12 cells are determined to the cardiac lineage. In line with this, a very low cTNT 
protein abundance along with circumferentially expressed CX43 and less organized protein 
expression was observed in K12 cardiomyocytes in comparison to the control, indicating an 
impaired cardiomyocyte differentiation. Cardiomyocyte maturation is characterized by CX34 
and NCAD polarization at the intercalated disks. This localization enables cardiomyocytes to 
electrically integrate, to propagate signals more efficient and faster, which corresponds with 
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increased cardiomyocyte maturation [272]. Hence, ectopic organization of CX34 and NCAD, 
as found in K12 cardiomyocytes, is a feature of immaturity [273, 274]. Interestingly, K12 
cardiomyocytes showed an increased beating frequency when compared to control cells. These 
fetal-like electrophysiological properties could also be due to the unorganized CX34 and NCAD 
protein expression and could be a result of inappropriate electrical coupling and subsequent 
unsynchronized beating. With subsequent cardiomyocyte maturation, there is a decrease in 
spontaneous beating frequency due to higher cellular organization [275, 276]. This corroborates 
the immature character of the K12-derived cardiomyocytes. Hence, active Wnt signalling, low 
cTNT expression as well as unorganized CX34 and NCAD protein abundance with subsequent 
fetal-like electrophysiological properties indicate a limited potential of IGFBP5 GOF hES cells 
to fully differentiate in cardiomyocytes. A very similar phenotype was observed in murine 
embryonic stem cells (mESCs) overexpressing Fhl2, which mediates Wnt/β-catenin dependent 
transcriptional activation [89]. These stem cells showed mesodermal cell formation and cell 
proliferation while arresting cardiac differentiation in an early cardiogenic mesodermal 
progenitor state. Igfbp5 was found upregulated in these arrested progenitor cells, supporting the 
findings in the IGFBP5 GOF cell line. A physical interaction between FHL2 and IGFBP5 was 
reported earlier [85] while an association between IGFBP5 and active Wnt/β-catenin signalling 
was reported in fibroblasts [277] and cardiomyocytes of the adult diseased heart [92, 93] as 
well as in the developing [278] and diseased intestine [202]. Besides the interaction of FHL2 
and IGFBP5, it is not clear how the Wnt/β-catenin pathway and IGFBP5 are connected, but 
requires further investigation.  
IGFBP5 causes the expansion of cardiac progenitor cells as indicated by increased expression 
of cyclin D1, AXIN2, TBX5 and NKX2.5 and seems to assign cells to the cardiac lineage as 
indicated by an increased MYOCD expression. Taken together, this data shows that IGFBP5 
drives stem cell specification but arrests cardiac cell commitment. 
5.6.2 IGFBP5 in the cardiac regulatory hierarchy 
NKX2.5, the pivotal regulator of the cardiac lineage, is high in the cardiac regulatory hierarchy 
[87] and connects IGFBP5 to this complex network. Igfbp5 expression follows NKX2.5 
dependent cardiac progenitor states. Upregulated Igfbp5 levels were found in murine Nkx2.5 
null embryos in the context of cardiac progenitor over-specification [87], whereas forced OE 
of Nkx2.5 in vitro, led to the inhibition of cardiac specification and negatively regulated Igfbp5 
[88]. Interestingly, ChIP revealed that NKX2.5 can regulate IGFBP5 on the promoter level. 
Whiles this study showed IGFBP5 activation by NKX2.5, Nimura et al. showed the opposite 
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[259]. These authors showed a co-occupancy of H3K36me3-specific histone methyltransferase 
and NKX2.5 on the Igfbp5 promoter, concluding that the methyltransferase enhances the 
repressive effect of NKX2.5 on Igfbp5 expression in the context of cardiogenesis. These 
findings show a dual function of NKX2.5 on the Igfbp5 promoter. Furthermore, a dosage-
sensitive effect of another important cardiogenic transcription factor, TBX5, was found to be 
mediated in a synergy with Nkx2.5 [279]. This Tbx5 dosage-sensitive genetic program involves 
a network of cardiac transcription factors including IGFBP5 and further supports the conjecture 
that IGFBP5 is directly connected to cardiac key regulators. Moreover, it is known that 
NKX2.5-dependen transcriptional repression inhibits Isl1 and restricts its expression to the 
progenitor cell state [88]. Since ChIP analysis showed that Igfbp5 is a direct ISL1 target [88], 
the restriction of ISL1 to the progenitor state might also restrict Igfbp5 expression to this state. 
Interestingly, OE of Isl1 and subsequently sustained Igfbp5 expression did not prevent cardiac 
differentiation, which was also observed in the differentiated IGFBP5 GOF cells. Instead, Isl1 
OE led to enhanced specification of cardiac progenitors and an earlier cardiac differentiation. 
Further, as in the IGFBP5 GOF cells, an increase in beating frequencies was observed in the 
Isl1 GOF cell line, where an association with upregulated nodal-specific genes, like pacemaker 
channel Hcn4, and a downregulation of transcripts of the working myocardium was found to 
be the reason. In this study, IBP5 OE in the murine adult heart also led to the regulation of Hcn4 
(see chapter 4.2), suggesting a connection between Isl1 and Igfbp5 downstream gene regulation. 
Since Isl1 and Igfbp5 regulation seems to be tightly interconnected and there are several 
phenotypic similarities between the ISL1 GOF cell line [88] and the IGFBP5 GOF cell line, 
further investigations regarding the regulatory interaction need to be done. ISL as well as 
NKX2.5 were reported to transcriptionally target TNNT2 and by this, initiate differentiation. In 
this study it was shown that IGFBP5 can repress the TNNT2 promoter and even antagonize the 
NKX2.5-mediated TNNT2 promoter activation, further confirming IGFBP5s role in cardiac 
progenitor cells. Of note, MYOCD, which was found being an IGFBP5 target in this study, and 
which was also upregulated in differentiated IGFBP5 GOF cells, was found to be directly 
regulated by ISL1 [269] and NKX2.5 [271]. Several transcription factors in the cardiac 
regulatory hierarchy have both, activator and repressor functions sometimes even on the same 
target gene. Negative feedback regulation plays a major role in this context. Regarding this 
complex network, Prall et al. stated that “(…) the negative feedback pathway of NKX2.5 may 
be an example of how the number of progenitor cells (…) is controlled by the degree of 
differentiation – a paradigm that could apply to adult stem cells and organ regeneration. In this 
paradigm, NKX2.5 acts as both the sensor of differentiation, and as the arbiter of repression.” 
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[87]. Cardiogenesis is a dynamic process involving multiple phases of pattern formation to drive 
cell commitment (specification and determination) and finally differentiation of multipotent 
cardiac cells.  
Concluding, IGFBP5 seems to be involved in the tight regulatory network of developmental 
transcription factors, suggesting an important role during early cardiogenesis.  
 
 
Figure 5-1: Scheme of gene expression and interactions during cardiogenesis.  
Information about reported gene expression and regulatory interactions from published data is referred as “known” [87–
89, 259, 269–271], whereas confirmed and new interactions found in this study are referred as “new identified”. Black 
triangle shows differentiation from progenitor cells to cardiomyocytes, blue triangles show gene expression.  
 
5.7 Downregulation of Igfbp5 correlates with cardiomyocyte maturation 
and might be beneficial in the adult diseased heart 
5.7.1 Neonatal cell maturation is accompanied by Igfbp5 downregulation 
There is evidence that downregulation of Igfbp5 is important for cardiomyocyte differentiation 
and cardiac maturation as already mentioned above [87–89]. To investigate whether Igfbp5 
downregulation correlates with increased cardiomyocyte maturation, murine neonatal 
cardiomyocytes (MNCMs) served as a suitable model since they are not entirely matured [280]. 
To induce in vitro maturation, MNCMs were stimulated with Ang II or NE. Ang II, the 
principal circulating hormone of the renin-angiotensin system and mediator of cardiac 
hypertrophy in vivo [123], was shown to increase fetal cardiomyocyte maturation in sheep 
[124]. Also noradrenergic stimulation of neonatal cardiomyocytes is known to drive 
cardiomyocyte growth and differentiation and increases the amount and organization of 
myofibrils [281]. Furthermore, NE was reported to enhance sarcomere formation [102], 
increase the expression of alpha-actin as well as Cx43 [122]. Treatment of MNCMs with these 
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two hypertrophic mediators led to a downregulation of Igfbp5 with a concomitant decrease of 
the fetal sarcomere component Myh7, indicating cardiomyocyte maturation. During murine 
embryonic and fetal stages, expression of Myh7 predominates and decreases after birth, when 
myosin heavy chain alpha (Myh6) expression gets higher [17]. The switch from Myh7 to a 
predominant Myh6 expression distinguishes immature- from adult cardiomyocytes.  
A decreasing Igfbp5 expression during cardiogenesis is consistent with a downregulated 
expression upon NE or Ang II treatment in MNCMs in vitro, indicating a correlation between 
decreased Igfbp5 expression and increased cardiomyocyte maturation.  
5.7.2 Igfbp5 is downregulated during angiotensin II-induced hypertrophy in vivo 
Several studies have shown that Ang II infused mice develop hypertensive heart disease with 
cardiac hypertrophy and fibrosis, while heart function is often preserved [282]. To confirm 
previous findings that Igfbp5 is only upregulated consequent to HF, its expression was studied 
in this mild hypertrophy model. Chronic Ang II infusion for two weeks led to the upregulation 
of the early hypertrophy marker gene Nppa when compared to saline treated control mice, 
confirming hypertrophic remodelling. Interestingly, Igfbp5 was found downregulated 
comparing Ang II infused mice with saline treated control mice. This regulation was the 
opposite of what was observed in mice with pressure-overload induced HF in this study. A 
second experimental set up in which mice received a chronic Ang II infusion for two weeks but 
had two additional weeks after infusion without Ang II stimulation, was studied. In this set up, 
the progression of Igfbp5 expression was examined to investigate whether its downregulation 
is a direct Ang II-dependent effect or a consequence of the hypertrophic remodelling process. 
Interestingly, Igfbp5 was still downregulated in Ang II infused mice compared to control mice, 
while Nppa was not significantly regulated. Induction of Nppa is a conserved feature of 
ventricular hypertrophy [283] and it is known that its expression has a local anti-hypertrophic 
function as reviewed by Song et al. [284]. These findings suggest that the Ang II-induced 
hypertrophy is not progressive, and a remission might occur. Igfbp5 is not regulated upon TAC-
induced hypertrophic remodelling which inevitably leads to HF but is downregulated upon 
Ang II-induced hypertrophy which might be regressive. This observation might suggest a 
positive effect of downregulated Igfbp5 in the early hypertrophic phase. Trying to find a 
connection between Ang II and the concomitant downregulation of Igfbp5, another common 
involvement was observed in cardiac progenitor cells. There are reported effects of Ang II on 
stem cell and progenitor cell proliferation and differentiation as reviewed by Ahmadian et al. 
[285]. Ang II was shown to promote differentiation of Sca-1-positive progenitor cells [261] and 
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further, promotes differentiation of mouse c-kit-positive cardiac stem cells into pacemaker-like 
cells in vitro [286]. Regarding Igfbp5, its expression is highest in the undifferentiated Sca1-
positive progenitor cells of the adult heart (unpublished, see preliminary data chapter 2.2.3), 
whereas its downregulation could be correlated with increased progenitor differentiation [87, 
89].  
Collectively the data suggests a potential beneficial effect of Igfbp5 downregulation in Ang II-
induced hypertrophy in vivo, which needs further investigation.  
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6 Conclusion and outlook 
The transition from compensatory hypertrophy to HF is a multi-step process and the 
mechanisms driving this transition are not well understood. Since HF clinically manifests itself 
in the form of multiple symptoms, diagnosing its onset and determining an appropriate 
intervention can be difficult. Hence, it is essential to discover novel biomarkers that define HF 
transition. IGFBP5 could be such a novel biomarker since this study reveals conserved IGFBP5 
upregulation in the transition to HF in humans and mice, in addition to increased IGFBP5 serum 
levels in mice with HF. However, further investigations of human serum are needed to confirm 
the observations made in mice. On a cellular level, cardiomyocytes were shown to express and 
secrete IGFBP5 in the diseased heart, indicating that IGFBP5 might be a novel cardiokine with 
paracrine and endocrine-like features. In turn, cardiac fibroblasts were shown to uptake 
exogenous IGFBP5 in vitro, suggesting that IGFBP5 can mediate cardiomyocyte-fibroblast 
crosstalk. IBP5 OE in hCFBs altered cardiac gene expression including that of MYOCD and 
cardiovascular disease marker, GDF15. IBP5 OE in cardiomyocytes of the healthy adult murine 
heart resulted in reduced heart size. Transcriptome analysis revealed a decrease in extra-cellular 
matrix and sarcomeric gene expression as well as reduced junction and ion channel expression. 
These observations indicate altered cardiac cell integrity that may have detrimental effects on 
the healthy heart. On the contrary, key regulators of fibrotic processes like Mylk and Sox9 were 
downregulated upon cardiomyocyte specific IBP5 OE concomitant with upregulation of fatty 
acid metabolism indicating a potential favourable outcome for increased Igfbp5 expression. 
Further investigation of IBP5 OE and downregulation post-TAC are essential to better 
understand the effect of IGFBP5 on the diseased heart. In the healthy adult murine heart, Igfbp5 
expression was found very low in cardiomyocytes in contrast to a high expression in Sca1-
positive cardiac progenitor cells. Investigating a human embryonic stem cell line with an 
IGFBP5 GOF revealed arrested cardiomyocyte differentiation subsequent to progenitor 
specification. Taken together, the data indicates a role for IGFBP5 on stem cell commitment 
and progenitor cell homeostasis. Investigation of a knockout (or inducible knock-down) stem 
cell line would help to further reveal the effect of IGFBP5 expression on cardiomyocyte 
differentiation and maturation. Previous reports indicated that enhanced cardiomyocyte 
differentiation correlates with decreasing Igfbp5 expression, which is in agreement with the 
results of this study. The re-expression of IGFBP5 consequent to HF suggests a role for IGFBP5 
in the developmental gene re-activation program of the diseased heart. Mechanistically, 
IGFBP5 ChIP revealed an IGFBP5 occupancy on its own promoter and on the TNNT2 
promoter. Luciferase data showed that IGFBP5 repressed the TNNT2 promoter by antagonizing 
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the NKX2.5-mediated TNNT2 promoter activation, indicating that IGFBP5 functions as a 
transcriptional co-factor. However, other transcriptional co-factors involved in directing 
IGFBP5 mediated transcriptional regulation need to be identified. 
To summarize, IGFBP5 can play multiple roles as (i) an IGF-binding protein, (ii) a 
paracrine/endocrine-like mediator and (iii) a transcriptional co-factor depending on the cell 
type, its pattern of distribution and the disease state of the heart. Whether the observed IGFBP5 
mediated actions are IGF-dependent or independent has to be clarified. Further studies of 
IGFBP5 could contribute to our understanding of both cardiac regulatory networks driving 
cardiogenesis and cellular/molecular mechanisms mediating HF progression. These insights 
could help define novel pharmacological strategies that enhance the endogenous repair 
machinery of the adult heart to prevent HF.  
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Figure 6-1: Conclusion figure 
Top: Igfbp5 regulation during cardiogenesis and heart failure. Bottom: Possible cellular actions mediated by IGFBP5. 
Red: Cardiomyocyte, blue: fibroblasts, pink: cardiac progenitor cell, orange: secreted IGFBP5, dark blue: secreted 
IGFBP5 targets, question marks: hypnotized effects and unknown components.  
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8 Appendix 
8.1 Vector maps 
 
 
Figure 8-1: Vectors for lentivirus production 
(A) Lentiviral envelope plasmid pMD2.G vector by Addgene (Lab of Didié Trono). (B) Lentiviral packaging plasmid 
psPAX2 vector by Addgene (Lab of Didié Trono). (C) Commercial lentiviral vector pGIPZ with eGFP reporter from 
Thermo Scientifc Open Biosystems. (D) Modified pGIPZ vector with removed puromycin resistance cassette, IRES and 
eGFP and inserted CMV hIGFBP5 CDS with FLAG tag. 
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Figure 8-2: Vectors for AAV9 particle production 
(A) Self-complementary AAV vector genome plasmid, derived from pdsCMV-MLC0.26-EGFP with luciferase CDS 
under control of the human troponin T promoter for AAV9 particle production (from Prof O. Müller, Kiel). (B) Modified 
self-complementary AAV vector genome plasmid with FLAG tagged ms-Igfbp5 CDS. 
 
 
Figure 8-3: Overexpression vectors 
(A) Commercial pcDNA3.1 vector with CMV promoter. (B) Modified pcDNA3.1 with FLAG tagged hIGFBP5 CDS. 
(C) pEXPR-221 vector with EF1α promoter and eGFP reporter (From a. Roa, Goettingen). (D) pEXPR-221 vector with 
EF1α promoter and hNKX2.5 CDS (From a. Roa, Goettingen). 
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Figure 8-4: Luciferase reporter vectors 
(A) Commercial luciferase reporter vector (Promega). (B) Modified luciferase reporter vector with cloned potential 
hIGFBP5 promoter region and (C) hTNNT2 promoter region, identified by IGFBP5-ChIP. 
 
 
Figure 8-5: Cas9/gRNA vector 
Human CAS9 nickase OE vector with insertion side for designed gRNAs (from B. Greber, Münster). 
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